

```

; GENERAL INFORMATION:
;
; APPLICANT: Warren, Wesley C
; APPLICANT: Tao, Nengbing

```

APPLICANT: Bvatt, John C.  
TITLE OF INVENTION: NOCTIC ACID AND OTHER MOLECULES ASSOCIATED WITH LACTATION AND  
FILE REFERENCE: MUSCLE AND FAT DEPOSITION  
CURRENT APPLICATION NUMBER: US/09/960.352  
CURRENT FILING DATE: 2001-09-24  
NUMBER OF SEQ ID NOS: 15112  
SEQ ID NO 5863  
LENGTH: 424  
TYPE: DNA  
ORGANISM: Bos taurus  
OTHER INFORMATION: Clone ID: 25-LIB34-026-Q1-EL-G1  
US-09-960-352-5863

Query Match 54.08; Score 54; DB 10; Length 424;  
Best Local Similarity 76.78; Pred. No. 6e-09;  
Matches 66; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 14 CACAGGAGCTGTGACCTGGACACGAGGAGCTGTGACCACTTGTCCGACGAGACA 73  
b 11 CACCGCTGACATCTGCACCTGGACATGAGGCTGCGACCACTTGTGACGAGAGACG 70

QY 74 GAACCTGTGTGTGCTCTGCGCC 99  
Db 71 CAGCGAGGTGGGTGCTCTGCGCG 96

## RESULT 3

US-09-867-701-3188/c  
Sequence 3188, Application US/09867701  
Patent No. US20020132237A1  
GENERAL INFORMATION:  
APPLICANT: Ajiata, Paul A.  
APPLICANT: Jones, Robert  
APPLICANT: Harlocker, Susan L.  
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY  
FILE REFERENCE: 210121.497  
CURRENT APPLICATION NUMBER: US/09/867,701  
CURRENT FILING DATE: 2001-05-29  
NUMBER OF SEQ ID NOS: 10912  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 3188  
LENGTH: 295  
TYPE: DNA  
ORGANISM: Homo sapien  
US-09-867-701-3188

Query Match 30.88; Score 30.8; DB 10; Length 295;  
Best Local Similarity 63.58; Pred. No. 0.24;  
Matches 47; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 27 TGCAGCTGACACAGGAGGAGCTGTGACCACTTGTCCGACGAGACAAGACTGTGCTG 86  
Db 108 TGCAGCTGACACAGGAGGAGGAGCTGTGACCACTTGTCCGACGAGACAAGACTGTGCTG 86

QY 87 TGTCTGTGCGCCG 100  
Db 48 TGTCTGTGCGACAG 35

## RESULT 4

US-10-044-090-780  
Sequence 780, Application US/10044090  
Patent No. US20020137081A1  
GENERAL INFORMATION:  
APPLICANT: Olga Bandman  
TITLE OF INVENTION: GENES DIFFERENTIALLY EXPRESSED IN VASCULAR TISSUE ACTIVATION  
FILE REFERENCE: PA-0028 US  
CURRENT APPLICATION NUMBER: US/10/044,090  
CURRENT FILING DATE: 2002-01-09  
NUMBER OF SEQ ID NOS: 850

SOFTWARE: PERL Program  
SEQ ID NO 780  
LENGTH: 7132  
TYPE: DNA  
ORGANISM: Homo sapiens  
FEATURE:  
NAME/KEY: misc-feature  
OTHER INFORMATION: Incyte ID No. US20020137081A1 198499.13  
US-10-044-090-780

Query Match 29.68; Score 29.6; DB 12; Length 7132;  
Best Local Similarity 61.88; Pred. No. 1.4;  
Matches 47; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 20 GAACCTGTGACCTGGACACAGGAGGAGCTGTGACCACTTGTCCGACGAGACAAGACTG 79  
Db 78 GGAACATGCACTTGAACAAGGCTGTGCTGCTCCGACAGACTGCAAGATGTGCGGGCGC 137

QY 80 TGTGTGTGCTCTGC 95  
Db 138 AGTCACCTGTACTGC 153

## RESULT 5

US-10-001-189-40/c  
Sequence 40, Application US/10001189  
Patent No. US20020173634A1  
GENERAL INFORMATION:  
APPLICANT: FRASER JR., MALCOLM J.  
APPLICANT: LI, XU  
APPLICANT: BEAM, TERESA  
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TRANSPOSITION USING  
TITLE OF INVENTION: MINIMAL SEGMENTS OF THE EUKARYOTIC TRANSFORMATION  
FILE REFERENCE: 835910-92098  
CURRENT APPLICATION NUMBER: US/10/001,189  
CURRENT FILING DATE: 2001-10-30  
PRIOR APPLICATION NUMBER: 60/244,984  
PRIOR FILING DATE: 2000-11-01  
PRIOR APPLICATION NUMBER: 60/244,677  
PRIOR FILING DATE: 2000-10-31  
NUMBER OF SEQ ID NOS: 70  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 40  
LENGTH: 707  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: ITR Cartridge  
US-10-001-189-40

Query Match 28.28; Score 28.2; DB 9; Length 707;  
Best Local Similarity 61.68; Pred. No. 2.2;  
Matches 45; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 18 CGAAGCTCTGCAAGCTGTGACACAGGAGGAGCTGTGACCACTTGTCCGACGAGACAAGACTG 77  
Db 358 CTGATCGGCTTGGGCTGACCACTGCGAAGCTGTGCTCCGAAAAAGCGGACGACACTGTGA 299

QY 78 TGTGTGTGTGCT 90  
Db 298 TCCAGGTGGCT 286

## RESULT 6

US-10-001-189-41/c  
Sequence 41, Application US/10001189  
Patent No. US20020173634A1  
GENERAL INFORMATION:  
APPLICANT: FRASER JR., MALCOLM J.  
APPLICANT: LI, XU  
APPLICANT: BEAM, TERESA

;; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TRANSPOSITION USING  
;; TITLE OF INVENTION: MINIMAL SEGMENTS OF THE EUKARYOTIC TRANSFORMATION  
;; TITLE OF INVENTION: VECTOR PIGGYBAC  
;; FILE REFERENCE: 835910-92098  
;; CURRENT APPLICATION NUMBER: US/10/001,189  
;; CURRENT FILING DATE: 2001-10-30  
;; PRIOR APPLICATION NUMBER: 60/244,984  
;; PRIOR FILING DATE: 2000-11-01  
;; PRIOR APPLICATION NUMBER: 60/244,677  
;; PRIOR FILING DATE: 2000-10-31  
;; NUMBER OF SEQ ID NOS: 70  
;; SOFTWARE: PatentIn Ver. 2.1  
;; SEQ ID NO 41  
;; LENGTH: 3662  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Description of Artificial Sequence: pXL-Bac  
;; OTHER INFORMATION: sequence  
S-10-001-189-41

Query Match 28.2%; Score 28.2; DB 9; Length 3662;  
Best Local Similarity 61.6%; Pred. No. 3.5;  
Matches 45; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 18 CGGAAGCTCTGACGCTGAGACAGCGGAGCTGTGACCACTTCTCCACGAGGACAGAAC 77  
DB 1339 CTGATGCGCTTCGGCTGACCATCCGGAACGTGTCTCCGAAAGCCCGACGAACCTGTA 1280  
QY 78 TCTGTGCTGTGCT 90  
DB 1279 TCCGAGGTGGCT 1267

RESULT 7  
US-10-001-189-46/c  
;; Sequence 46, Application US/10001189  
;; Patent No. US20020173634A1  
;; GENERAL INFORMATION:  
;; APPLICANT: FRASER JR., MALCOLM J.  
;; APPLICANT: LI, XU  
;; APPLICANT: BEAM, TERESA  
;; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TRANSPOSITION USING  
;; TITLE OF INVENTION: MINIMAL SEGMENTS OF THE EUKARYOTIC TRANSFORMATION  
;; FILE REFERENCE: 835910-92098  
;; CURRENT APPLICATION NUMBER: US/10/001,189  
;; CURRENT FILING DATE: 2001-10-30  
;; PRIOR APPLICATION NUMBER: 60/244,984  
;; PRIOR FILING DATE: 2000-11-01  
;; PRIOR APPLICATION NUMBER: 60/244,677  
;; PRIOR FILING DATE: 2000-10-31  
;; NUMBER OF SEQ ID NOS: 70  
;; SOFTWARE: PatentIn Ver. 2.1  
;; SEQ ID NO 46  
;; LENGTH: 4613  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Description of Artificial Sequence: pCR11-ITR  
;; OTHER INFORMATION: sequence  
;; NAME/KEY: CDS  
;; LOCATION: (344)..(922)  
US-10-001-189-46

Query Match 28.2%; Score 28.2; DB 9; Length 4613;  
Best Local Similarity 61.6%; Pred. No. 3.7;  
Matches 45; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 18 CGGAAGCTCTGACGCTGAGACAGCGGAGCTGTGACCACTTCTCCACGAGGACAGAAC 77  
DB 651 CTGATGCGCTTCGGCTGACCATCCGGAACGTGTCTCCGAAAGCCCGACGAACCTGTA 592

QY 78 TCTGTGCTGTGCT 90  
DB 591 TCCGAGGTGGCT 579

RESULT 8  
US-10-001-189-53  
;; Sequence 53, Application US/10001189  
;; Patent No. US20020173634A1  
;; GENERAL INFORMATION:  
;; APPLICANT: FRASER JR., MALCOLM J.  
;; APPLICANT: LI, XU  
;; APPLICANT: BEAM, TERESA  
;; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TRANSPOSITION USING  
;; TITLE OF INVENTION: MINIMAL SEGMENTS OF THE EUKARYOTIC TRANSFORMATION  
;; FILE REFERENCE: 835910-92098  
;; CURRENT APPLICATION NUMBER: US/10/001,189  
;; CURRENT FILING DATE: 2001-10-30  
;; PRIOR APPLICATION NUMBER: 60/244,984  
;; PRIOR FILING DATE: 2000-11-01  
;; PRIOR APPLICATION NUMBER: 60/244,677  
;; PRIOR FILING DATE: 2000-10-31  
;; NUMBER OF SEQ ID NOS: 70  
;; SOFTWARE: PatentIn Ver. 2.1  
;; SEQ ID NO 53  
;; LENGTH: 4941  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Description of Artificial Sequence: pXL-Bac-ECFP  
US-10-001-189-53

Query Match 28.2%; Score 28.2; DB 9; Length 4941;  
Best Local Similarity 61.6%; Pred. No. 3.8;  
Matches 45; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 18 CGGAAGCTCTGACGCTGAGACAGCGGAGCTGTGACCACTTCTCCACGAGGACAGAAC 77  
DB 778 CTGATGCGCTTCGGCTGACCATCCGGAACGTGTCTCCGAAAGCCCGACGAACCTGTA 837  
QY 78 TCTGTGCTGTGCT 90  
DB 838 TCCGAGGTGGCT 850

RESULT 9  
US-10-001-189-54/c  
;; Sequence 54, Application US/10001189  
;; Patent No. US20020173634A1  
;; GENERAL INFORMATION:  
;; APPLICANT: FRASER JR., MALCOLM J.  
;; APPLICANT: LI, XU  
;; APPLICANT: BEAM, TERESA  
;; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TRANSPOSITION USING  
;; TITLE OF INVENTION: MINIMAL SEGMENTS OF THE EUKARYOTIC TRANSFORMATION  
;; FILE REFERENCE: 835910-92098  
;; CURRENT APPLICATION NUMBER: US/10/001,189  
;; CURRENT FILING DATE: 2001-10-30  
;; PRIOR APPLICATION NUMBER: 60/244,984  
;; PRIOR FILING DATE: 2000-11-01  
;; PRIOR APPLICATION NUMBER: 60/244,677  
;; PRIOR FILING DATE: 2000-10-31  
;; NUMBER OF SEQ ID NOS: 70  
;; SOFTWARE: PatentIn Ver. 2.1  
;; SEQ ID NO 54  
;; LENGTH: 4943  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: PBS-ITR-ECFP  
OTHER INFORMATION: sequence  
US-10-001-189-54

Query Match 28.2%; Score 28.2; DB 9; Length 4943;  
Best Local Similarity 61.6%; Pred. No. 3.8;  
Matches 45; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 18 CGGAAGCTCTGACCTTGACGACGAGGAGCTGTGACCACTTCTGCCACGACGACGAC 77  
DB 1076 CTGATGCGCTTGGGGCTGACCATCCGAACTGTCTCCGAAAACCCCGACGACGACGTA 1017  
QY 78 TCTGTGTGTGCT 90  
DB 1016 TCCAGGTGCGCT 1004

RESULT 10  
US-10-001-189-55/c  
Sequence 55, Application US/10001189  
Patent No. US20020173634A1  
GENERAL INFORMATION:  
APPLICANT: FRASER JR., MALCOLM J.  
APPLICANT: LI, XU  
APPLICANT: BEAM, TERESA  
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TRANSPOSITION USING  
TITLE OF INVENTION: MINIMAL SEGMENTS OF THE EUKARYOTIC TRANSFORMATION  
FILE REFERENCE: 835910-92098  
CURRENT APPLICATION NUMBER: US/10/001,189  
CURRENT FILING DATE: 2001-10-30  
PRIOR APPLICATION NUMBER: 60/244,984  
PRIOR FILING DATE: 2000-11-01  
PRIOR APPLICATION NUMBER: 60/244,677  
PRIOR FILING DATE: 2000-10-31  
NUMBER OF SEQ ID NOS: 70  
SOFTWARE: Patentlin Ver. 2.1  
SEQ ID NO 55  
LENGTH: 4944  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: PBS-ITR-EGFP  
US-10-001-189-55

Query Match 28.2%; Score 28.2; DB 9; Length 4944;  
Best Local Similarity 61.6%; Pred. No. 3.8;  
Matches 45; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 18 CGGAAGCTCTGACCTTGACGACGAGGAGCTGTGACCACTTCTGCCACGACGACGAC 77  
DB 1076 CTGATGCGCTTGGGGCTGACCATCCGAACTGTCTCCGAAAACCCCGACGACGACGTA 1017  
QY 78 TCTGTGTGTGCT 90  
DB 1016 TCCAGGTGCGCT 1004

RESULT 11  
US-10-001-189-56/c  
Sequence 56, Application US/10001189  
Patent No. US20020173634A1  
GENERAL INFORMATION:  
APPLICANT: FRASER JR., MALCOLM J.  
APPLICANT: LI, XU  
APPLICANT: BEAM, TERESA  
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TRANSPOSITION USING  
TITLE OF INVENTION: MINIMAL SEGMENTS OF THE EUKARYOTIC TRANSFORMATION  
FILE REFERENCE: 835910-92098  
CURRENT APPLICATION NUMBER: US/10/001,189  
CURRENT FILING DATE: 2001-10-30

PRIOR APPLICATION NUMBER: 60/244,984  
PRIOR FILING DATE: 2000-11-01  
PRIOR APPLICATION NUMBER: 60/244,677  
PRIOR FILING DATE: 2000-10-31  
NUMBER OF SEQ ID NOS: 70  
SOFTWARE: Patentlin Ver. 2.1  
SEQ ID NO 56  
LENGTH: 4944  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: PBS-ITR-EYFP  
US-10-001-189-56

Query Match 28.2%; Score 28.2; DB 9; Length 4944;  
Best Local Similarity 61.6%; Pred. No. 3.8;  
Matches 45; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 18 CGGAAGCTCTGACCTTGACGACGAGGAGCTGTGACCACTTCTGCCACGACGACGAC 77  
DB 1076 CTGATGCGCTTGGGGCTGACCATCCGAACTGTCTCCGAAAACCCCGACGACGACGTA 1017  
QY 78 TCTGTGTGTGCT 90  
DB 1016 TCCAGGTGCGCT 1004

RESULT 12  
US-10-001-189-51  
Sequence 51, Application US/10001189  
Patent No. US20020173634A1  
GENERAL INFORMATION:  
APPLICANT: FRASER JR., MALCOLM J.  
APPLICANT: LI, XU  
APPLICANT: BEAM, TERESA  
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TRANSPOSITION USING  
TITLE OF INVENTION: MINIMAL SEGMENTS OF THE EUKARYOTIC TRANSFORMATION  
FILE REFERENCE: 835910-92098  
CURRENT APPLICATION NUMBER: US/10/001,189  
CURRENT FILING DATE: 2001-10-30  
PRIOR APPLICATION NUMBER: 60/244,984  
PRIOR FILING DATE: 2000-11-01  
PRIOR APPLICATION NUMBER: 60/244,677  
PRIOR FILING DATE: 2000-10-31  
NUMBER OF SEQ ID NOS: 70  
SOFTWARE: Patentlin Ver. 2.1  
SEQ ID NO 51  
LENGTH: 4951  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: pXL-Bac-EYFP  
US-10-001-189-51

Query Match 28.2%; Score 28.2; DB 9; Length 4951;  
Best Local Similarity 61.6%; Pred. No. 3.8;  
Matches 45; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 18 CGGAAGCTCTGACCTTGACGACGAGGAGCTGTGACCACTTCTGCCACGACGACGAC 77  
DB 778 CTGATGCGCTTGGGGCTGACCATCCGAACTGTCTCCGAAAACCCCGACGACGACGTA 837  
QY 78 TCTGTGTGTGCT 90  
DB 838 TCCAGGTGCGCT 850

RESULT 13  
US-10-001-189-52  
Sequence 52, Application US/10001189



```
Patent No. US20020173634A1
GENERAL INFORMATION:
APPLICANT: FRASER JR., MALCOLM J.
APPLICANT: LI, XU
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TRANSPOSITION USING
TITLE OF INVENTION: MINIMAL SEGMENTS OF THE EUKARYOTIC TRANSFORMATION
FILE REFERENCE: 835910-92098
CURRENT APPLICATION NUMBER: US/10/001,189
PRIOR FILING DATE: 2001-10-30
PRIOR APPLICATION NUMBER: 60/244,984
PRIOR FILING DATE: 2000-11-01
PRIOR APPLICATION NUMBER: 60/244,677
PRIOR FILING DATE: 2000-10-31
NUMBER OF SEQ ID NOS: 70
SOFTWARE: Patentln Ver. 2.1
SEQ ID NO 52
LENGTH: 4952
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: pXL-Bac-Egfp
US-10-001-189-52

Query Match
Best Local Similarity 28.2%; Score 28.2; DB 9; Length 4952;
Matches 45; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 18 CGAAGCTCTGCAGCTGCAGCAACGGGAGCTGTGACCATCTTCCGCAAGCAAGAAC 77
DB 778 CTGATCGGCTCGGCTCGGACCATCCGGAAGTGTCCGAAAGCCGCGAAGTGTGTA 837
QY 78 TCTGTGTGTGCT 90
DB 838 TCCCAAGCTGGCCT 850

RESULT 14
US-10-001-189-48
Sequence 48, Application US/10001189
Patent No. US20020173634A1
GENERAL INFORMATION:
APPLICANT: FRASER JR., MALCOLM J.
APPLICANT: LI, XU
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TRANSPOSITION USING
TITLE OF INVENTION: MINIMAL SEGMENTS OF THE EUKARYOTIC TRANSFORMATION
FILE REFERENCE: 835910-92098
CURRENT APPLICATION NUMBER: US/10/001,189
PRIOR FILING DATE: 2001-10-30
PRIOR APPLICATION NUMBER: 60/244,984
PRIOR FILING DATE: 2000-11-01
PRIOR APPLICATION NUMBER: 60/244,677
PRIOR FILING DATE: 2000-10-31
NUMBER OF SEQ ID NOS: 70
SOFTWARE: Patentln Ver. 2.1
SEQ ID NO 48
LENGTH: 8999
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: p(PZ)-Bac-Eyfp
US-10-001-189-48

Query Match
Best Local Similarity 28.2%; Score 28.2; DB 9; Length 8999;
Matches 45; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 18 CGAAGCTCTGCAGCTGCAGCAACGGGAGCTGTGACCATCTTCCGCAAGCAAGAAC 77
```

```
DB 8593 CTGATCGGCTTCCGCTGCAGCATCCGGAAGTGTCCGAAAGCCGCGAAGTGTGTA 8652
QY 78 TCTGTGTGTGCT 90
DB 8653 TCCCAAGCTGGCCT 8665

RESULT 15
US-10-001-189-49
Sequence 49, Application US/10001189
Patent No. US20020173634A1
GENERAL INFORMATION:
APPLICANT: FRASER JR., MALCOLM J.
APPLICANT: LI, XU
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TRANSPOSITION USING
TITLE OF INVENTION: MINIMAL SEGMENTS OF THE EUKARYOTIC TRANSFORMATION
FILE REFERENCE: 835910-92098
CURRENT APPLICATION NUMBER: US/10/001,189
PRIOR FILING DATE: 2001-10-30
PRIOR APPLICATION NUMBER: 60/244,984
PRIOR FILING DATE: 2000-11-01
PRIOR APPLICATION NUMBER: 60/244,677
PRIOR FILING DATE: 2000-10-31
NUMBER OF SEQ ID NOS: 70
SOFTWARE: Patentln Ver. 2.1
SEQ ID NO 49
LENGTH: 9012
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: p(PZ)-Bac-EGFP
US-10-001-189-49

Query Match
Best Local Similarity 28.2%; Score 28.2; DB 9; Length 9012;
Matches 45; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 18 CGAAGCTCTGCAGCTGCAGCAACGGGAGCTGTGACCATCTTCCGCAAGCAAGAAC 77
DB 8606 CTGATCGGCTTCCGCTGCAGCATCCGGAAGTGTCCGAAAGCCGCGAAGTGTGTA 8665
QY 78 TCTGTGTGTGCT 90
DB 8666 TCCCAAGCTGGCCT 8678

Search completed: January 15, 2003, 22:32:21
Job time : 36.5 secs
```

GenCore version 5.1.3  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 15, 2003, 19:39:40 : Search time 1268 Seconds  
(without alignments)  
1277.247 Million cell updates/sec

Title: L00394\_COPY\_1\_100  
Perfect score: 100  
Sequence: 1 CTCCTTTGGCAGTCACACGCG.....GTGGTGTGCTCTGCGCCCG 100

Scoring table: IDENTITY\_NUC  
Gapop 10.0, Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues  
Total number of hits satisfying chosen parameters: 32308132

Minimum DB seq length: 0  
Maximum DB seq length: 200000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :  
1: em\_estba:\*  
2: em\_estlum:\*  
3: em\_estlin:\*  
4: em\_estnu:\*  
5: em\_estov:\*  
6: em\_estpl:\*  
7: em\_estro:\*  
8: em\_hic:\*  
9: gb\_est1:\*  
10: gb\_est2:\*  
11: gb\_hic:\*  
12: gb\_est3:\*  
13: gb\_est4:\*  
14: gb\_est5:\*  
15: em\_estfun:\*  
16: em\_estom:\*  
17: gb\_gss:\*  
18: em\_gss\_hum:\*  
19: em\_gss\_inv:\*  
20: em\_gss\_pln:\*  
21: em\_gss\_vit:\*  
22: em\_gss\_fun:\*  
23: em\_gss\_mam:\*  
24: em\_gss\_mus:\*  
25: em\_gss\_other:\*  
26: em\_gss\_pro:\*  
27: em\_gss\_rod:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	88.4	88.4	407	12	BE839155 RC6-FN013
2	88.4	88.4	716	13	B1757668 603028107
3	88.4	88.4	844	9	AL553470 AL553470
4	88.4	88.4	882	14	BQ882177 ACENCOURT
5	88.4	88.4	898	9	AL521984 AL521984
6	88.4	88.4	984	9	AL570383 AL570383

7	88.4	88.4	1049	13	BM546790
8	88.4	88.4	1211	14	BM926296
9	87.4	87.4	455	14	W21335
10	86.8	86.8	472	12	BE838990
11	65.4	65.4	552	9	AI255604
12	65.4	65.4	552	13	BI283861
13	65.4	65.4	758	13	BI257017
14	65.4	65.4	771	13	BF384882
15	65.4	65.4	744	12	BF532104
16	65.4	65.4	875	12	BF385197
17	62.8	62.8	790	12	BF335332
18	53.6	53.6	698	13	BI146007
19	39	39.0	598	12	BG641612
20	39	39.0	640	13	BG641885
21	39	39.0	640	12	BI468182
22	37.6	37.6	1061	17	CNS0339PM
23	36.4	36.4	618	10	AM133828
24	36.2	36.2	641	13	BM427276
25	35.6	35.6	900	13	BM438559
26	33	33.0	325	9	AA176034
27	33	33.0	433	10	BB796863
28	33	33.0	854	17	CNS028W1
29	32.2	32.2	285	9	AI449301
30	31.6	31.6	304	9	AI852041
31	31.4	31.4	349	10	BB798742
32	31.4	31.4	359	10	BB804261
33	31.4	31.4	385	10	BB806529
34	31.4	31.4	956	12	BG122154
35	31.4	31.4	206	12	BF912734
36	30.8	30.8	295	9	AA293295
37	30.8	30.8	543	12	BG710842
38	30.8	30.8	602	14	BM951218
39	30.8	30.8	679	14	BQ330929
40	30.8	30.8	720	13	BI552439
41	30.8	30.8	724	13	BI547738
42	30.8	30.8	749	13	BM050541
43	30.8	30.8	776	13	BI833415
44	30.8	30.8	848	13	BI752594
45	30.8	30.8			

## ALIGNMENTS

RESULT 1  
BE839155/c 407 bp mRNA linear EST 22-SEP-2000  
LOCUS RC6-FN0138-110800-012-E07 FN0138 Homo sapiens CDNA, mRNA sequence.  
DEFINITION BE839155  
ACCESSION BE839155.1 GI:10271442  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
human.

REFERENCE  
AUTHORS  
Dias Neto, E., Garcia Correa, R., Verjovski-Almeida, S., Brites, M.R., Nagai, M.A., da Silva, W. Jr., Zaglo, M.A., Bordin, S., Costa, R.F., Goldman, G.H., Carvalho, A.F., Matsukuma, A., Bata, G.S., Simpson, D.H., Brunstein, A., deOliveira, P.S., Bucher, P., Jongeneel, C.V., O'Hare, M.J., Soares, F., Brentani, R.R., Reis, L.F., de Souza, S.J. and Simpson, A.J.

TITLE  
Shotgun sequencing of the human transcriptome with ORF expressed  
sequence tags  
JOURNAL  
MEDLINE  
COMMENT  
Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)  
Contact: Simpson A.J.G.  
Laboratory of Cancer Genetics  
Ludwig Institute for Cancer Research  
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,  
Brazil  
Tel: +55-11-2704922  
Fax: +55-11-2707001

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_image="5188760"
/clone_11p="NTH MGC_114"
/lab_host="DH10B"
/notes="Organ: brain; Vector: pCMV-Sport6; Site_1: NotI;
Site_2: EcoRV (destroyed); RNA source anonymous pool of 6

```

		88.4%;	Score	88.4;	DB	9;	Length	844;	
Query Match		Similarity	98.9%;	Pred.	No.	7e-16;			
Best local									
Matches	89;	Conservative	0;	Mismatches	1;	Indels	0;	Gaps	0;
OY	11	AQTCACAGGAACTCTCAGCTGTGAACAAGGGAGCTGTACCAGTTCGCCACGAGGA	70						
Db	398	ATTCCACGGGAAGCTCTCAGCTCGAGGAAACAAGGGAGACTGTACCAAGTTCTGCCACGAGA	457						
OY	71	ACGAAACTCTGCCTGCTGCTCTCTCTGCCCCG	100						



BASE COUNT	274 a	289 c	316 g	169 t	1 others
ORIGIN					

```

SOURCE
1. 1211
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:5764698"
/clone_lib="NIH_MGC_114"
/1cd_host="DH10B"
/note="Organ: brain; Vector: pCMV-Sport6; Site:1: NotI;
Site:2: EcoRV (destroyed): RNA source anonymous pool of 6
male brains, age range 23-27 yo. Library is oligo-dT
primed and directionally cloned (EcoRV site is destroyed
upon cloning). Average insert size 1.5 kb, insert size
range 1-3 kb. Library is normalized and enriched for
full-length clones and was constructed by C. Gruber
(Livtrogen). Research Genetics tracking code 019. Note
this is a NIH_MGC Library."
296 a 351 c 351 g 211 t 2 others
BASE COUNT
ORIGIN

```

	Query Match	88.4%	Score 88.4;	DB 14;	Length 1211;
	Best Local Similarity	98.9%;	Pred. No. 8,3e-16;		
	Matches	89; Conservative	0; Mismatches	1; Indels	0; Gaps
QY	11 AGTCACAGCGAAGCTCTGCAGCCTGGACAACGCGGACTGTGCCAGTTCGTCACGAGA	70			
Dd	392 ATTCACAGCGAAGCTCTGCAGCCTGGACAACGCGGACTGTGCCAGTTCGTCACGAGA	451			
QY	71 ACAGAACTCTGTGTGTCTCTCTCGCGCCG	100			
Dd	452 ACAGAACTCTGTGTGTCTCTCTCGCGCCG	481			

RESULT 9  
W21335  
LOCUS W21335 455 bp mRNA linear EST 20-AUG-1996  
DEFINITION 2b55f03.r1 Soares\_fetal\_lung\_NBHL19W Homo sapiens CDNA clone  
IMAGE:307517 5' similar to gb:M57285 COAGULATION FACTOR X PRECURSOR  
(HUMAN);, mRNA sequence.  
ACCESSION W21335  
VERSION W21335.1 GI:1298387  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
1 (bases 1 to 435)  
AUTHORS Hillier, L., Lennon, G., Becker, M., Bonaldo, M.F., Chiapelli, B.,  
Chissoe, S., Dietrich, N., Dubuque, T., Favello, A., Gish, W., Hawkins,  
B., Hultman, M., Kucaba, T., Lacey, M., Le, M., Le, N., Mardis, E., Moore,  
M., Morris, M., Parsons, J., Prange, C., Rifkin, L., Rohlfing, T.,  
Schellenberg, K., Soares, M.B., Tan, F., Thierry-Mieg, J., Trevisan, E.,  
Underwood, K., Woldmann, P., Waterston, R., Wilson, R., and Mair, M.  
Generation and analysis of 280,000 human expressed sequence tags  
Genome Res. 6 (9), 807-828 (1996)  
97044478  
TITLE JOURNAL MEDLINE  
COMMENT Contact: Wilson RK  
Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: estewatson.wustl.edu  
This clone is available royalty-free through LNL; contact the  
IMAGE Consortium (info@image.lnl.gov) for further information.  
Insert Length: 1028 Std Error: 0.00  
Seq primer: mob.RBG+ET  
High quality sequence stop: 424.  
Location/Qualifiers  
1. 435  
/organism="Homo sapiens"  
/db\_xref="GDB:1250929"  
/db\_xref="taxon:9606"  
/clone\_1fb="IMAGE:307517"  
/clone\_1fb="Soares\_fetal\_lung\_NBHL19W"  
/dev\_stage="19 weeks"  
/lab\_host="DH10B (ampicillin resistant)"  
/note="Organ: lung; Vector: pTR73D (Pharmacia) with a  
modified polylinker; Site\_1: Not I; Site\_2: Eco RI; 1st  
strand cDNA was primed with a Not I - 01190(dT) primer  
15'-TGTTACCAATCTGAAGTGGAGCGCGCAATTTTCTTTTCTTTT-3',  
double-stranded cDNA was size selected, ligated to Eco RI  
adapters (Pharmacia), digested with Not I and cloned into  
the Not I and Eco RI sites of a modified pTR73 vector  
(Pharmacia). Library went through one round of  
normalization to a Cot = 5. Library constructed by Bento  
Soares and M.Patima Bonaldo. This library was constructed  
from the same fetus as the fetal heart library, Soares  
fetal heart NBHL19W."  
BASE COUNT 116 a 135 c 131 g 69 t 4 others  
ORIGIN  
Query Match 87.4%; Score 87.4; DB 14; Length 455;  
Best Local Similarity 98.9%; Pred. No. 1e-15;  
Matches 88; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

LOCUS BE838990 472 bp mRNA linear EST 22-SEP-2000  
DEFINITION RC6-FN0138-260700-011-G08 FN0138 Homo sapiens CDNA, mRNA sequence.  
ACCESSION BE838990  
VERSION BE838990.1 GI:10271368  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
1 (bases 1 to 472)  
AUTHORS Dias Neto, E., Garcia Correa, R., Verjovski-Almeida, S., Brites, M.R.,  
Nagai, M.A., da Silva, M. Jr., Zago, M.A., Bordin, S., Costa, F.F.,  
Goldman, G.H., Carvalho, A.F., Matsukuma, A., Bala, G.S., Simpson, D.H.,  
Brunstein, A., deoliveira, P.S., Bucher, P., Jongeneel, C.V., O'Hare,  
M.J., Soares, F., Brentani, R.R., Reis, L.F., de Souza, S.J. and  
Simpson, A.J.  
Shotgun sequencing of the human transcriptome with ORF expressed  
sequence tags  
Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)  
20202663  
TITLE JOURNAL MEDLINE  
COMMENT Contact: Simpson A.J.G.  
Laboratory of Cancer Genetics  
Rue Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,  
Brazil  
Tel: +55-11-2704922  
Fax: +55-11-2707001  
Email: asimpson@ludwig.org.br  
This sequence was derived from the FAPESP/LICR Human Cancer Genome  
Project. This entry can be seen in the following URL  
(http://www.ludwig.org.br/scripts/gethtml2.pl?l=RC6-FN0138-260  
700-011-G08&l3=2000-07-26&l4=1)  
Seq primer: puc 18 forward  
High quality sequence start: 9  
High quality sequence stop: 307.  
Location/Qualifiers  
1. 472  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone\_1fb="FN0138"  
/dev\_stage="Adult"  
/note="Organ: prostate; normal; Vector: puc18; Site\_1: SmaI  
; Site\_2: SmaI; A mini-library was made by cloning  
products derived from ORESTES PCR (U.S. Letters Patent  
Application No. 196,716 - Ludwig Institute for Cancer  
Research) profiles into the puc 18 vector. Reverse  
transcription of tissue mRNA and cDNA amplification were  
performed under low stringency conditions."  
BASE COUNT 105 a 144 c 106 g 117 t  
ORIGIN  
Query Match 86.8%; Score 86.8; DB 12; Length 472;  
Best Local Similarity 97.8%; Pred. No. 1.6e-15;  
Matches 88; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

LOCUS A1255604 552 bp mRNA linear EST 12-NOV-1998  
DEFINITION u156a05.y1 Sugano mouse liver mila mus musculus CDNA clone  
IMAGE:1886384 5' similar to gb:M57285 COAGULATION FACTOR X  
PRECURSOR (HUMAN);, mRNA sequence.  
ACCESSION A1255604  
VERSION A1255604.1 GI:3863129  
KEYWORDS EST.



FEATURES  
source

Location/Qualifiers  
1..758  
/organism="Mus musculus"  
/strain="FVB/N"  
/db\_xref="taxon:10090"  
/clone\_image="5123607"  
/clone\_lib="NCI\_CGAP\_L19"  
/lab\_host="DH10B (TI phage-resistant)"  
/note="Organ: Liver; Vector: pCMV-SPORT6; Site: 1: NotI;  
Site: 2: SalI; Cloned unidirectionally. Primer: Oligo dt.  
Average insert size 1.9 kb. Constructed by Life  
Technologies. Note: this is a NCI\_CGAP library."  
BASE COUNT 200 a 171 c 223 g 164 t  
ORIGIN

Query Match 65.4%; Score 65.4; DB 13; Length 758;  
Best Local Similarity 86.7%; Pred. No. 4.3e-09;  
Matches 72; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Y 18 CGGAAGCTCTGAGCGCTGACACAGCGGAGCTGACCACTTCTGCCACGAGACAGAAC 77  
0 378 CGGAAGCTCTGAGCGCTGACACAGCGGAGCTGACCACTTCTGCCACGAGACAGAAC 437  
DB 78 TCTGTGCTGCTCTCTCTGCGCCCG 100  
438 TCAGTGTGCTCTCTCTGCGCCGAG 460

RESULT 14  
LOCUS BF384882 771 bp mRNA linear EST 27-NOV-2000  
DEFINITION 602046381P1 NCI\_CGAP\_L19 Mus musculus cDNA clone IMAGE:419508 5',  
mRNA sequence.  
ACCESSION BF384882  
VERSION BF384882.1 GI:11366187  
KEYWORDS EST.  
SOURCE house mouse.  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1 (bases 1 to 771)  
NIH-MGC http://mgi.nci.nih.gov/  
National Institutes of Health, Mammalian Gene Collection (MGC)  
Unpublished (1999)  
Contact: Robert Strausberg, Ph.D.  
Email: cgaabrs@mail.nih.gov  
Tissue Procurement: Jeffrey E. Green, M.D.  
cDNA Library Preparation: Life Technologies, Inc.  
DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be  
found through the I.M.A.G.E. Consortium/LLNL at:  
http://image.llnl.gov  
Plate: LAM9531 row: b column: 21  
High quality sequence stop: 690.  
Location/Qualifiers

1..771  
/organism="Mus musculus"  
/strain="FVB/N"  
/db\_xref="taxon:10090"  
/clone\_image="419508"  
/clone\_lib="NCI\_CGAP\_L19"  
/lab\_host="DH10B (TI phage-resistant)"  
/note="Organ: Liver; Vector: pCMV-SPORT6; Site: 1: NotI;  
Site: 2: SalI; Cloned unidirectionally. Primer: Oligo dt.  
Average insert size 1.9 kb. Constructed by Life  
Technologies. Note: this is a NCI\_CGAP library."  
BASE COUNT 204 a 184 c 231 g 152 t  
ORIGIN

Query Match 65.4%; Score 65.4; DB 12; Length 771;  
Best Local Similarity 86.7%; Pred. No. 4.4e-09;  
Matches 72; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

OY 18 CGGAAGCTCTGAGCGCTGACACAGCGGAGCTGACCACTTCTGCCACGAGACAGAAC 77  
DB 381 CGGAAGCTCTGAGCGCTGACACAGCGGAGCTGACCACTTCTGCCACGAGACAGAAC 440  
OY 78 TCTGTGCTGCTCTCTCTGCGCCCG 100  
DB 441 TCAGTGTGCTCTCTCTGCGCCGAG 463

RESULT 15  
LOCUS BF532104 784 bp mRNA linear EST 11-DEC-2000  
DEFINITION 602073227P1 NCI\_CGAP\_L19 Mus musculus cDNA clone IMAGE:4210183 5',  
mRNA sequence.  
ACCESSION BF532104  
VERSION BF532104.1 GI:11619570  
KEYWORDS EST.  
SOURCE house mouse.  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1 (bases 1 to 784)  
NIH-MGC http://mgi.nci.nih.gov/  
National Institutes of Health, Mammalian Gene Collection (MGC)  
Unpublished (1999)  
Contact: Robert Strausberg, Ph.D.  
Email: cgaabrs@mail.nih.gov  
Tissue Procurement: Jeffrey E. Green, M.D.  
cDNA Library Preparation: Life Technologies, Inc.  
DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be  
found through the I.M.A.G.E. Consortium/LLNL at:  
http://image.llnl.gov  
Plate: LAM9777 row: f column: 08  
High quality sequence stop: 722.  
Location/Qualifiers

1..784  
/organism="Mus musculus"  
/strain="FVB/N"  
/db\_xref="taxon:10090"  
/clone\_image="4210183"  
/clone\_lib="NCI\_CGAP\_L19"  
/lab\_host="DH10B (TI phage-resistant)"  
/note="Organ: Liver; Vector: pCMV-SPORT6; Site: 1: NotI;  
Site: 2: SalI; Cloned unidirectionally. Primer: Oligo dt.  
Average insert size 1.9 kb. Constructed by Life  
Technologies. Note: this is a NCI\_CGAP library."  
BASE COUNT 202 a 186 c 231 g 165 t  
ORIGIN

Query Match 65.4%; Score 65.4; DB 12; Length 784;  
Best Local Similarity 86.7%; Pred. No. 4.4e-09;  
Matches 72; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

OY 18 CGGAAGCTCTGAGCGCTGACACAGCGGAGCTGACCACTTCTGCCACGAGACAGAAC 77  
DB 383 CGGAAGCTCTGAGCGCTGACACAGCGGAGCTGACCACTTCTGCCACGAGACAGAAC 442  
OY 78 TCTGTGCTGCTCTCTCTGCGCCCG 100  
DB 443 TCAGTGTGCTCTCTCTGCGCCGAG 465

Search completed: January 15, 2003, 21:18:47  
Job time : 1273 secs



GenCore version 5.1.3  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 15, 2003, 17:50:20 ; Search time 151 Seconds  
(without alignments)  
1491.390 Million cell updates/sec

Title: 100394\_COPY\_1\_100

Perfect score: 1 CTCCTTGGCAGTCACACG.....GTGTGTGCTCTGCGCCG 100

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : N\_Geneseq\_101002.\*  
1: /SID2/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.\*  
2: /SID2/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.\*  
3: /SID2/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.\*  
4: /SID2/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.\*  
5: /SID2/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.\*  
6: /SID2/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.\*  
7: /SID2/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.\*  
8: /SID2/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.\*  
9: /SID2/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.\*  
10: /SID2/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.\*  
11: /SID2/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.\*  
12: /SID2/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.\*  
13: /SID2/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.\*  
14: /SID2/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.\*  
15: /SID2/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.\*  
16: /SID2/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.\*  
17: /SID2/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.\*  
18: /SID2/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.\*  
19: /SID2/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.\*  
20: /SID2/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.\*  
21: /SID2/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.\*  
22: /SID2/gcgdata/geneseq/geneseq-emb1/NA2001.DAT.\*  
23: /SID2/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.\*  
24: /SID2/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	100	100.0	367	21	AAC70860
2	99.6	99.6	367	21	AAC70878
3	99.6	99.6	367	21	AAC70884
4	88.4	88.4	788	12	AAQ12776
5	88.4	88.4	1126	20	AAK15427
6	88.4	88.4	1126	21	AAK89786
7	88.4	88.4	1126	21	AAK12970
8	88.4	88.4	1126	21	AAZ55120
9	88.4	88.4	1404	19	AAV10462

10	88.4	88.4	1467	19	AAV56776	Human Factor X gen
11	88.4	88.4	1467	19	AAV56821	Human Factor X gen
12	88.4	88.4	1467	19	AAV59409	Human Factor X nuc
13	88.4	88.4	1507	21	AAA54031	Human factor X cod
14	88.4	88.4	1887	21	AAH57469	Human liver cell s
15	85.4	85.4	300	22	AAH57261	Human liver specif
16	82.8	82.8	1560	22	AAE24735	Nucleotide sequenc
17	82.8	82.8	1660	22	AAE24738	Nucleotide sequenc
18	52.4	52.4	1554	15	AAQ71243	Serine protease fo
19	31.8	31.8	13923	23	ABL05109	Drosophila melanog
20	31.8	31.8	17902	23	ABL05108	Drosophila melanog
21	30.8	30.8	295	24	ABL80210	Human ovarian can
22	30.8	30.8	2461	17	AAE41544	Human yag6-encodin
23	29.6	29.6	4790	22	AAE45254	Human haematopoiet
24	29.6	29.6	7037	22	AAE45066	Human haematopoiet
25	29.4	29.4	4181	22	AAE06778	DNA encoding nove
26	29.4	29.4	4801	22	AAE06781	DNA encoding nove
27	29.2	29.2	1743	23	AAE85732	DNA encoding nove
28	29.2	29.2	2196	23	AAE85734	DNA encoding nove
29	29.2	29.2	2196	23	AAE85733	DNA encoding nove
30	29.2	29.2	2196	23	AAE85733	DNA encoding nove
31	29.2	29.2	2309	23	AAE85733	DNA encoding nove
32	29.2	29.2	3747	23	AAE73293	DNA encoding nove
33	29.2	29.2	3810	23	AAE73044	DNA encoding nove
34	29.2	29.2	3810	23	AAE82533	DNA encoding nove
35	29.2	29.2	4901	23	AAE93853	DNA encoding nove
36	29.2	29.2	6813	23	AAE85740	DNA encoding nove
37	29.2	29.2	1241	23	AAE77139	DNA encoding nove
38	29.2	29.2	2013	22	AAE03051	Human reproductive
39	29.2	29.2	2013	22	AAE03051	Human reproductive
40	29.2	29.2	2565	24	ABL97387	Human testicular a
41	29.2	29.2	2565	24	ABL92075	Human testicular a
42	28.6	28.6	405	22	ABL01005	Human testicular a
43	28.6	28.6	405	22	ABL96473	Human testicular a
44	28.6	28.6	719	23	ABL05065	Drosophila melanog
45	28.6	28.6	1875	23	AAE85741	DNA encoding nove

#### ALIGNMENTS

RESULT 1	AAC70860	Standard; DNA; 367 BP.
ID	AAC70860	
AC	AAC70860	
XX		
DT	09-FEB-2001	(first entry)
XX		
DE	Single nucleotide polymorphism containing sequence #230.	
XX		
KW	Single nucleotide polymorphism; SNP; human; genetic disease;	
KW	disease susceptibility; cardiovascular system; endocrine system;	
KW	neurological system; forensic testing; paternity testing; ds.	
XX		
OS	Homo sapiens.	
XX		
PN	WO200058519-A2.	
XX		
PD	05-OCT-2000.	
XX		
PF	30-MAR-2000; 2000WO-US08440.	
PR	31-MAR-1999; 99US-0127248.	
XX		
PA	(WHED) WHITEHEAD INST BIOMEDICAL RES.	
PA	(AFY-) AFFYMETRIX INC.	
XX		
PI	Altshuler D, Cargill M, Daley GO, Ireland JS, Lander ES;	
PI	Lipshutz RJ, Patil N, Sklar P;	
XX		
DR	WPI; 2000-611722/58.	
XX		

The present invention is concerned with a number of human single nucleotide polymorphisms (SNPs) which the inventors identified in human genes. These SNPs can be used in disease diagnosis and prediction of an individual's susceptibility to disease, in forensic and paternity testing and in genetic mapping. In particular, the SNPs of the invention can be

PS Disclosure: Page 12-14; 17pp; English.  
 CC The protein is used as a blood coagulation inhibitor in mammals. It  
 CC is believed to mimic the Xa/LACI complex in binding to and  
 CC inhibiting VIIa/tissue factor. LACI inhibits via a novel feedback  
 CC mechanism requiring generation of Xa (a prod. of VIIa/TF activity);  
 CC XIcIACIKI inhibits VIIa/TF activity directly.  
 CC The DNA allows prodn. of XIcIACIKI by introduction of the gene into  
 CC cells suitable for expression, e.g. E. coli or CHO cells.  
 SQ Sequence 788 BP; 230 A; 187 C; 209 G; 162 T; 0 other;  
 Query Match 88.4%; Score 88.4; DB 12; Length 788;  
 Best Local Similarity 98.9%; Pred. No. 1.7e-18;  
 Matches 89; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 11 AGTCACACGGAAGCTCTGCAGCCTTGACACAGCGGAGCATGTTCGCACGAGA 70  
 DB 390 ATTCAACACGGAAGCTCTGCAGCCTTGACACAGCGGAGCATGTTCGCACGAGA 449  
 QY 71 ACAGAACTGTGTGTGCTCTCTCGCGCCG 100  
 DB 450 ACAGAACTGTGTGTGCTCTCTCGCGCCG 479  
 RESULT 5  
 AAX15427  
 ID AAX15427 standard; DNA: 1126 BP.  
 XX AAX15427;  
 AC  
 XX  
 DT 05-MAY-1999 (first entry)  
 XX  
 DE DNA encoding coagulation factor X/Xa.  
 KW Truncated tissue factor; tissue factor binding ligand; coagulation;  
 KW disease-associated vasculature; tumour; benign prostatic hyperplasia;  
 KW diabetic-retinopathy; vascular restenosis; arteriovenous malformation;  
 KW AVM; meningioma; hemangioma; neurovascular glaucoma; psoriasis; synovitis;  
 KW dermatitis; endometriosis; angiolipoma; Rheumatoid arthritis;  
 KW atherosclerotic plaque; corneal graft neovascularisation;  
 KW haemophilic joint; hypertrophic scar; Osler-Weber syndrome;  
 KW pyogenic granuloma; retrolental fibroplasia; scleroderma; trachoma;  
 KW vascular adhesion; coagulation factor; factor X/Xa; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 US5877289-A.  
 XX  
 PD 02-MAR-1999.  
 XX  
 PF 07-JUN-1995; 95US-0479733.  
 XX  
 PR 07-JUN-1995; 95US-0479733.  
 PR 05-MAR-1992; 92US-0846349.  
 PR 02-MAR-1994; 94US-0205330.  
 PR 11-JUL-1994; 94US-0273567.  
 PA (SCRI ) SCRIPPS RES INST.  
 PA (TEXA ) UNIV TEXAS SYSTEM.  
 XX  
 Edgington TS, Thorpe PE;  
 WP1: 1999-189722/16.  
 XX  
 Tissue factor binding ligands - comprising first binding region  
 PT which binds to vasculature, particularly of tumours, and tissue  
 PT factor construct  
 XX  
 Example 9; Columns 129-132; 83pp; English.  
 The present sequence encodes a coagulation factor whe





OS	Homo sapiens.
XX	
FH	Key
FT	CDS
FT	Location/Qualifiers
FT	1..1404
FT	/lag= a
FT	/product= Factor X
FT	/note= "partial coding sequence"
PX	
PN	
PN	W09747737-A1.
PD	
PD	18-DEC-1997.
XX	
XX	11-JUN-1997; 97MO-EP03027.
XX	
PR	06-JUL-1996; 96EP-0110959.
PR	11-JUN-1996; 96EP-0109288.
PR	22-JUN-1996; 96EP-0110109.
PA	(BOE ) BOEHRINGER MANNHEIM GMBH.
PA	
X	
X	Hopfner K, Kopetzki E;
DR	WPI: 1998-052304/05.
DR	P-PSTDB: AAW40283.
PT	
PT	Non-glycosylated, truncated forms of factor IX family protein with
PT	serine protease activity - used to screen for specific modulators
PT	and to assay factor IXa
XX	
PS	
PS	Disclosure; Fig 3; 49pp; German.
CC	
CC	This sequence encodes a human factor X protease. This protein is used
CC	in the construction of a novel non-glycosylated protein and truncated
CC	and zymogen forms of this protein, which have serine protease activity.
CC	The protein is composed of various domains from a factor IX family
CC	protein, namely a catalytic domain (CD) N-terminally bound to a
CC	zymogen-activating domain (ZAD), N-terminally bound to a
CC	EGF2 domain (EGF + epidermal growth factor-like domain). Such proteins
CC	are used to identify activators/inhibitors of factor IX family proteins
CC	(potentially useful as regulators of coagulation, fibrinolysis and
CC	homostasis). The protein in zymogen form is also useful in assays for
CC	detecting factor IXa activity in aqueous solution (specifically in body
CC	fluids). The protein can be used to produce co-crystals with protease
CC	variants or inhibitors for x-ray structural analysis and drug modelling
CC	and as restriction proteases in biotechnology. These truncated proteins
CC	have the same specificity as factor IX family proteases and can be
CC	produced in prokaryotes in a form that allows production of active enzyme
CC	by conversion to native form and enzymatic cleavage.
CC	
Sequence	1404 BP; 356 A; 404 C; 423 G; 221 T; 0 other;
Query Match	88.4%; Score 88.4; DB 19; Length 1404;
Best Local Similarity	98.9%; Pred. No. 2e-18;
Matches	89; Conservative 0; Mismatches 1; Indels 0; Gaps 0
OY	11 ACTGCACGCGAGCTCTGCAGCCTGGACAACGGGGACTGTGACCAGTCTGCCACGAGGA 70   Db 315 ATTTCACGCGAAGCTCTGCAAGCTGGACAACGGGGAGCTGTGACCAGTCTGCCACGAGGA 374
OY	71 ACAGAACTCTGTGTGTGCTCTCTGCGCCG 100   Db 375 ACAGAAGCTCTGTGTGTGCTCTCTGCGCCG 404
RESULT 10	
AAV56776	
ID	AAV56776 standard; DNA; 1467 BP.
XX	
AC	AAV56776;
XX	
DT	27-NOV-1998 (first entry)
XX	
DE	Human Factor X genomic DNA.

ID	AAV56821 standard; DNA; 1467 BP.
XX	AAV56821;
AC	AAV56821;
XX	27-NOV-1998 (first entry)
DT	27-NOV-1998 (first entry)
XX	Human Factor X genomic DNA.
DE	Human Factor X genomic DNA.
XX	Factor X; analogue; activation cleavage site; protease; bleeding; human;
KM	Factor IX; Factor VII; Factor VIII; haemophilia; gene therapy; ss.
XX	Factor IX; Factor VII; Factor VIII; haemophilia; gene therapy; ss.
OS	Homo sapiens.
XX	Homo sapiens.
FH	Key
FT	CDS
FT	Location/Qualifiers
FT	1..1467
FT	/*tag= a
FT	1..120
FT	/*tag= b
FT	121..1464
FT	/*tag= C
FT	/product= "Factor X"
..X	
PN	MO9838318-A1.
XX	03-SEP-1998.
PD	03-SEP-1998.
XX	27-FEB-1998; 98WO-AT00046.
FF	27-FEB-1998; 98WO-AT00046.
XX	27-FEB-1997; 97AT-0000336.
PR	27-FEB-1997; 97AT-0000336.
XX	(IMMO ) IMMUNO AG.
PA	(IMMO ) IMMUNO AG.
XX	Dorner F, Elbl J, Falkner F, Himmelsbach M, Pfeleiderer M;
PI	Schlokat U;
PI	Schlokat U;
DR	WP1: 1998-481212/41.
DR	P-PSDB: AAW76218.
XX	New factor 10 deletion mutants lacking the natural protease
PT	processing site - but having a non-natural site inserted, and
PT	related DNA, particularly for in vitro activation to products used
PT	to treat blood coagulation disorders
XX	
PS	Claim 3; Fig 1; 82pp; German.
XX	
CC	This sequence encodes the human Factor X protein which is used in a
CC	method resulting in the production of novel human Factor X (F10)
CC	analogues. Such analogues have in the region of the natural F10a
CC	activation cleavage site, a modification that creates a processing site
CC	for a protease that does not naturally cleave F10 in this region. The
CC	proteins are used to generate, in vivo or in vitro, F10a analogues that
CC	can be used to control bleeding and for treating defects of factors IX,
CC	VII or VIII, e.g. in haemophiliacs who have developed antibodies to
CC	factors VIII and/or IX. The encoding nucleic acid can be used in gene
CC	therapy of the same conditions. The analogues have high stability and can
CC	be activated without use of animal enzymes such as trypsin. Only
CC	activation is affected, their activity is the same as the natural factor.
CC	The analogues can be isolated as a pure single-chain pro-protein (not
CC	usually possible because of rapid processing of the native precursor) and
CC	this converted to two-chain form by subsequent activation. Activated
CC	analogues have good stability and structural integrity and are
CC	practically free of inactive intermediates and autolytic
CC	decomposition products.
XX	
SO	Sequence 1467 BP; 363 A; 424 C; 444 G; 236 T; 0 other;
QY	Query Match 88.4%; Score 88.4; DB 19; Length 1467;
	Best Local Similarity 98.9%; Pred. No. 2e-18;
Matches	89; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
11	AGTACACGGAGGACCTGACGCTG6ACAAAGGGGACGTGACCACTTCTGCACAGGAGA 70
369	ATTTCACAGGAGGACCTGACGCTG6ACAAAGGGGACGTGACCACTTCTGCACAGGAGA 428

OY	71	ACAGAACTGTGTCCTCCTGGCCCG	100
Db	429	ACAGAACTGTGTCCTCCTGGCCCG	458
 RESULT_12			
ID	AAF59409	AAF59409 standard; cDNA: 1467 BP.	
XX	AC	AAF59409;	
XX	AT	02-MAY-2001 (first entry)	
XX	DE	Human factor X nucleotide sequence SEQ ID NO:1.	
XX	KM	Human; factor X; mutant; haemostatic; gene therapy; haemophilia;	
XX	KW	blood coagulation disorder; haemophiliac; ss.	
OS		Homo sapiens.	
XX	BN	WO200110896-A2.	
PD	PD	15-FEB-2001.	
PF	PF	07-AUG-2000; 2000WO-EPO7631.	
XX	PR	10-AUG-1999; 99AT-0001377.	
PA	PA	(BAXT ) BAXTER AG.	
P1	P1	Himmelsbach M, Schlokat U;	
DR	DR	WPI: 2001-191516/19.	
DR	DR	P-PSDB; AAB70411.	
PT	PT	Novel factor X analog useful for producing drug which is useful for	
PT	PT	treatment of blood coagulation disorders, such as hemophilia, contains	
XX	XX	modification between amino acids Glu226 and Ile235 -	
BS	BS	Disclosure; Fig 1; 50pp; English.	
XX	XX	The present invention describes a factor X analogue (I) which contains	
CC	CC	a modification between Glu226 and Ile235, relative to the 488 residue	
CC	CC	amino acid sequence given in AAB70411. (I) has haemostatic activity and	
CC	CC	can be used in gene therapy. (II) encoding polynucleotide (II) can be	
CC	CC	used to produce a drug, which is useful for treatment of patients with	
CC	CC	blood coagulation disorders, such as patients suffering from haemophilia,	
CC	CC	or haemophilias with inhibitory antibodies. Preparations containing a	
CC	CC	polypeptide with factor X/Xa activity are more readily activated by	
CC	CC	factor XIIa or its derivative, which has high stability, without having	
CC	CC	to use one of the proteases used in prior art to activate the natural	
CC	CC	factor X, particularly one of animal origins, such as Russell's viper	
CC	CC	venom (RVV) or trypsin. The present sequence encodes human factor X,	
CC	CC	which is given in the exemplification of the present invention.	
SQ	SQ	Sequence 1467 BP: 363 A: 424 C: 444 G: 236 T: 0 other:	
 Query Match 88.4%; Score 88.4; DB 22; Length 1467;			
Best Local Similarity 98.9%; Pred. No. 2e-18;			
Matches 89; Conservative 0; Mismatches 1; Indels 0; Gaps 0;			
OY	11	AGTCACAGGAAGCTCTGCAGCTGGACAAGGGGACTGTGACCAGTTCTGCCACGAGA 70	
Db	369	ATTCAACAGGAAGCTCTGCAGCTGGACAAGGGGACTGTGACCAGTTCTGCCACGAGA 428	
OY	71	ACAGAACTGTGTCCTCCTGGCCCG 100	
Db	429	ACAGAACTGTGTCCTCCTGGCCCG 458	
 RESULT_13			
AAAS4031			

ID	AA54031	standard: DNA; 1507 BP.
XX	AA54031:	
AC	08-FEB-2001	(first entry)
XX	Human factor X coding sequence.	
XX	Vitamin K dependent protein; VKDP; gamma-carboxylation; chimeric	
KM	protein; fusion protein; coagulation factor: Factor X; Factor VII;	
KW	protein S; protein IX; Protein C; prothrombin; blood clotting;	
KM	haemophilia; human; ds.	
XX	Homo sapiens.	
OS	MO200054787-Al.	
PN	21-SEP-2000.	
XX	16-MAR-2000; 2000WO-US06934.	
PD	16-MAR-1999; 99US-0124609.	
PP	(CHIL-) CHILDRENS HOSPITAL PHILADELPHIA.	
XX	(UYNC-) UNIV NORTH CAROLINA.	
XX	High KA, Camlire RM, Larson PJ, Stafford DW;	
PI	WPI: 2000-638152/61.	
DR	Chimeric DNA for optimizing gamma carboxylation of vitamin K-dependent	
XX	protein useful for treating diseases associated with the protein,	
PT	comprises sequence encoding propeptide fused to sequence encoding the	
PT	protein	
XX	Disclosure; Fig 6a; 60pp; English.	
PS		
XX		
CC	Efficient processing and release of mature two-chain factor X into	
CC	the circulation requires: removal of the signal sequence; formation	
CC	of disulfide bonds; modification of amino terminal glutamic acid	
CC	residues, to gamma-carboxyglutamic acid; modification of one	
CC	aspartic acid in the first epidermal growth factor (EGF) domain to	
CC	Beta-hydroxyaspartic acid; addition of N- and O-linked	
CC	oligosaccharides to the activation peptide; removal of an internal	
CC	tripeptide to yield two-chain factor X and removal of the	
CC	propeptide just prior to secretion. While some of these modifications	
CC	do not appear essential for factor X function the removal of the	
CC	signal sequence, propeptide, internal tripeptide and full	
CC	gamma-carboxylation are all steps which are important requisites for	
CC	the production of biologically active factor X/FXa. Isolated chimeric	
CC	polynucleotides are described which encode a propeptide fused to a	
CC	nucleic acid sequence encoding a vitamin K-dependent protein (VKDP).	
CC	The fusion proteins encoded are vitamin K-dependent protein	
CC	gamma-carboxylation enhancers and are useful for optimizing the	
CC	gamma-carboxylation of a VKDP to produce a fully gamma-carboxylated	
CC	VKDP. The fusion proteins and recombinant cells expressing them are	
CC	useful for alleviating a VKDP associated disease. The fusion	
CC	constructs result in the production of fully gamma-carboxylated	
CC	mature VKDPs which are biologically active. The invention	
CC	encompasses all combinations of propeptide sequences (modified or	
CC	not) and VKDP's. This sequence encodes the signal, propeptide and	
CC	mature protein sequence of human Factor X.	
CC		
XX		
XX	Sequence 1507 BP; 394 A; 429 C; 446 G; 238 T; 0 other;	
SQ		
	Query Match	88.4%; Score 88.4; DB 21; Length 1507;
	Best Local Similarity	98.9%; Pred. No. 2e-18; 1; Indels 0; Gaps 0;
	Matches	89; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy	11 AGTCACAGGAAGCTCTGAGCGCTGGACAACGGGAGACTGTGACGATCTGCACGAGA 70	
	1	
Db	369 ATTCAACAGGAAGCTCTGAGCGCTGGACAACGGGAGACTGTGACGATCTGCACGAGA 428	

Y	71	ACAGAACTCTGTGGTGTCTCTCTGCGCCG	100
Db	429	ACAGAACTCTGTGTGTCTCTCTGCGCCG	458
RESULT 14			
AAH57469			
ID	AAH57469	standard; cDNA: 1887 BP.	
XX	AAH57469;		
XX	10-SEP-2001	(first entry)	
XX			
DE	Human liver cell specific cDNA sequence SEQ ID NO:309.		
XX			
KW	Human; tissue specific; diagnosis; brain; heart; skeletal muscle;		
KW	lung; liver; uterus; ovary; stomach; intestine; kidney; pancreas; ss;		
KW	metabolic disease; developmental disease; cytostatic; immunomodulatory;		
KW	neuroprotective; gene therapy; cancer; immunopathology; neuropathology.		
XX			
OS	Homo sapiens.		
XX			
XX	MO200132927-A2.		
XX	10-MAY-2001.		
XX	02-NOV-2000; 2000MO-US30396.		
XX	04-NOV-1999; 99US-0163508.		
XX	(INCYTE GENOMICS INC.		
PA			
XX	Sornasse J., Sellhammer JJ, Watson GA;		
PI			
XX	WPI: 2001-291057/30.		
DR			
XX			
PT	New cell and tissue specific polynucleotides useful for diagnosis,		
PT	prognosis or monitoring of treatments for disorders where the gene is		
PT	associated with a cancer, immunopathology or neuropathology -		
XX			
PS	Claim 1; Page 233; 327pp; English.		
XX			
CC	AAH57161 to AAH57576 represent cell and tissue specific polynucleotide		
CC	sequences (I). (I) can have cytosstatic, immunomodulatory and		
CC	neuroprotective activities, and can be used in gene therapy. (I) and		
CC	proteins (II) encoded by them are used in high throughput screening		
CC	assays to select DNA molecules, RNA molecules, peptide nucleic acids,		
CC	mimetics, peptides, proteins, agonists, antagonists, antibodies or		
CC	their fragments, immunoglobulins, inhibitors, drug compounds and		
CC	pharmaceutical agents. Expression of (I) in a sample indicates the		
CC	differentiation of embryonic stem cells into a tissue selected from		
CC	brain, heart, kidney, liver, lung, skeletal muscle or pancreatic		
CC	tissues. (I) and (II) are used to produce an expression profile that		
CC	describes a metabolic or developmental process, treatment, condition,		
CC	disease or disorder. The gene profile can be used for diagnosis,		
CC	prognosis or monitoring of treatments and for investigating a		
CC	predisposition to a disorder where the gene is associated with a		
CC	cancer, immunopathology or neuropathology.		
XX			
XX			
SO	Sequence 1887 BP; 467 A; 549 C; 544 G; 327 T; 0 other;		
Query Match	88.4%; Score 88.4; DB 22; Length 1887;		
Best Local Similarity	98.9%; Pred. No. 2,1e-18;		
Matches	89; Conservative 0; Mismatches 1; Indels 0; Gaps 0;		
Y	11	ACTCACACGGAAGCTCTCTGACGCTTGACAAACGGGAGCTGTGACCAAGTTCTGCCACGAGA	70
Db	424	ATTTCACACGGAAGCTCTCTGACGCTTGACAAACGGGAGCTGTGACCAAGTTCTGCCACGAGA	483
Y	71	ACAGAACTCTGTGGTGTCTCTCTGCGCCG	100
Db	484	ACAGAACTCTGTGTGTCTCTCTGCGCCG	513



## RESULT 15

AAH57261 standard; cDNA: 300 BP.

AAH57261;

10-SEP-2001 (first entry)

Human liver specific cDNA sequence SEQ ID NO:101.

Human: tissue specific; diagnosis; brain; heart; skeletal muscle; lung; liver; uterus; ovary; stomach; intestine; kidney; pancreas; ss; metabolic disease; developmental disease; cytostatic; immunomodulatory; neuroprotective; gene therapy; cancer; immunopathology; neuropathology.

Homo sapiens.

W0200132927-A2.

10-MAY-2001.

02-NOV-2000; 2000WO-US30396.

04-NOV-1999; 99US-0163508.

(INCYTE) INCYTE GENOMICS INC.

Sornasse T, Sellhamer JJ, Watson GA;

WPI; 2001-291057/30.

New cell and tissue specific polynucleotides useful for diagnosis, prognosis or monitoring of treatments for disorders where the gene is associated with a cancer, immunopathology or neuropathology -

Claim 1; Page 107; 327pp; English.

AAH57161 to AAH57576 represent cell and tissue specific polynucleotide sequences (I). (I) can have cytostatic, immunomodulatory and neuroprotective activities, and can be used in gene therapy. (I) and proteins (II) encoded by then are used in high throughput screening assays to select DNA molecules, RNA molecules, peptide nucleic acids, mimetics, peptides, proteins, agonists, antagonists, antibodies or their fragments, immunoglobulins, inhibitors, drug compounds and pharmaceutical agents. Expression of (I) in a sample indicates the differentiation of embryonic stem cells into a tissue selected from brain, heart, kidney, liver, lung, skeletal muscle or pancreatic tissues. (I) and (II) are used to produce an expression profile that defines a metabolic or developmental process, treatment, condition, disease or disorder. The gene profile can be used for diagnosis, prognosis or monitoring of treatments and for investigating a predisposition to a disorder where the gene is associated with a cancer, immunopathology or neuropathology.

Sequence 300 BP; 73 A; 81 C; 88 G; 44 T; 14 other;

Query Match 85.4%; Score 85.4; DB 22; Length 300;

Best Local Similarity 95.6%; Pred. No. 1,2e-17; Matches 86; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 11 AGTCACACGGAAGCTCTGCAGCTGACACAGGAGCTGTGACAGTTCTGCCAGAGGA 70  
 Db 16 ATTANANCGGAAGCTCTGNAGCTGACACAGGAGCTGTGACAGTTCTGCCAGAGGA 75  
 OY 71 ACAGAACTCTGTGTGGTGGCTGCTCCGCCCGC 100  
 Db 76 ACAGAACTCTGTGTGGTGGCTGCTCCGCCCGC 105

Search completed: January 15, 2003, 19:50:15  
 Job time : 154 secs

GenCore version 5.1.3  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 15, 2003, 17:56:05 ; Search time 1334 Seconds

(without alignments)  
2181.620 Million cell updates/sec

Title: L00394\_COPY\_1\_100

Perfect score: 100

Sequence: 1 CTCCTTGGCAGTACACGCG.....GTGCTGTGCTCCTGCGCCCG 100

Scoring table: IDENTITY\_NTC

Gapop 10.0, Gapext 1.0

Searched: 2034640 seqs, 14551402878 residues

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database:

Listing first 45 summaries

GenBank: 1: gb\_da: 2: gb\_da: 3: gb\_da: 4: gb\_da: 5: gb\_da: 6: gb\_da: 7: gb\_da: 8: gb\_da: 9: gb\_da: 10: gb\_da: 11: gb\_da: 12: gb\_da: 13: gb\_da: 14: gb\_da: 15: gb\_da: 16: gb\_da: 17: gb\_da: 18: gb\_da: 19: gb\_da: 20: gb\_da: 21: gb\_da: 22: gb\_da: 23: gb\_da: 24: gb\_da: 25: gb\_da: 26: gb\_da: 27: gb\_da: 28: gb\_da: 29: gb\_da: 30: gb\_da: 31: gb\_da: 32: gb\_da: 33: gb\_da: 34: gb\_da: 35: gb\_da: 36: gb\_da: 37: gb\_da: 38: gb\_da: 39: gb\_da: 40: gb\_da: 41: gb\_da:

score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	100	100.0	156	9	HUMFX5
2	93.8	93.8	29488	9	AF503510
3	93.8	93.8	132933	9	AL137002
4	92	92.0	1350	9	AB005892
5	88.4	88.4	1126	6	AR095306
6	88.4	88.4	1126	6	AR095306
7	88.4	88.4	1126	6	AR095306
8	88.4	88.4	1126	6	AR095306
9	88.4	88.4	1126	6	AR095306
10	88.4	88.4	1126	6	AR095306
11	88.4	88.4	1126	6	AR095306
12	88.4	88.4	1126	6	AR095306
13	88.4	88.4	1126	6	AR095306
14	88.4	88.4	1126	6	AR095306
15	88.4	88.4	1126	6	AR095306
16	88.4	88.4	1126	6	AR095306
17	88.4	88.4	1126	6	AR095306
18	88.4	88.4	1126	6	AR095306
19	88.4	88.4	1126	6	AR095306
20	88.4	88.4	1126	6	AR095306
21	88.4	88.4	1126	6	AR095306
22	88.4	88.4	1126	6	AR095306
23	88.4	88.4	1126	6	AR095306
24	88.4	88.4	1126	6	AR095306
25	88.4	88.4	1126	6	AR095306
26	88.4	88.4	1126	6	AR095306
27	88.4	88.4	1126	6	AR095306
28	88.4	88.4	1126	6	AR095306
29	88.4	88.4	1126	6	AR095306
30	88.4	88.4	1126	6	AR095306
31	88.4	88.4	1126	6	AR095306
32	88.4	88.4	1126	6	AR095306
33	88.4	88.4	1126	6	AR095306
34	88.4	88.4	1126	6	AR095306
35	88.4	88.4	1126	6	AR095306
36	88.4	88.4	1126	6	AR095306
37	88.4	88.4	1126	6	AR095306
38	88.4	88.4	1126	6	AR095306
39	88.4	88.4	1126	6	AR095306
40	88.4	88.4	1126	6	AR095306
41	88.4	88.4	1126	6	AR095306
42	88.4	88.4	1126	6	AR095306
43	88.4	88.4	1126	6	AR095306
44	88.4	88.4	1126	6	AR095306
45	88.4	88.4	1126	6	AR095306

## ALIGNMENTS

RESULT 1  
LOCUS HUMFX5  
DEFINITION Human factor X (blood coagulation factor) gene, exon 5.  
ACCESSION L00394.M14327  
VERSION L00394.1 GI:162826  
KEYWORDS Stuart factor; blood coagulation factor; factor X; glycoprotein; serine protease.  
SEGMENT 5 of 8  
SOURCE Homo sapiens (tissue library: of lawn et al., and Yoshitake et al.)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
REFERENCE 1 (bases 1 to 156)

Pred. No. is the number of results predicted by chance to have a

[illegible]



was generated from part of bacterial clone contigs of human chromosome 13, constructed by the Sanger Centre Chromosome 13 Mapping Group. Further information can be found at

<http://www.sanger.ac.uk/HGP/Chr13>  
 Rpl1-98F14 is from the library RPl1-11.1 constructed by the group of Pieter de Jong. For further details see  
<http://www.chori.org/bacpac/home.htm>  
 VECTOR: pBACe1.6

IMPORTANT: This sequence is not the entire insert of clone Rpl1-98F14. It may be shorter because we sequence overlapping sections only once, except for a 100 base overlap.

The true left end of clone Rpl1-98F14 is at 1 in this sequence. The true left end of clone Rpl1-391H12 is at 122834 in this sequence. The true right end of clone Rpl1-265C7 is at 123923 in this sequence.

# FEATURES

```

source          1..132933
                /organism="Homo sapiens"
                /db_xref="taxon:9606"
                /chromosome="13"
                /map="q22.1-31.1"
                /clone="Rpl1-98F14"
                /clone_1fb="RPl1-11.1"
                41..277
repeat_region   /note="AluJo repeat: matches 1..229 of consensus"
                377..472
repeat_region   /note="3 copies 32 mer 93% conserved"
                901..1207
repeat_region   /note="AluSq repeat: matches 1..307 of consensus"
                1483..1912
misc_feature    /note="Cpg island"
                /evidence="not_experimental"
                1999..2164
repeat_region   /note="MER58A repeat: matches 19..167 of consensus"
                2703..2861
repeat_region   /note="L1M3e repeat: matches -118..34 of consensus"
                4371..4978
repeat_region   /note="38 copies 16 mer 78% conserved"
                4374..4981
repeat_region   /note="19 copies 32 mer 87% conserved"
                6373..6448
repeat_region   /note="2 copies 38 mer 93% conserved"
                6411..6563
repeat_region   /note="3 copies 51 mer 93% conserved"
                6565..6669
repeat_region   /note="3 copies 35 mer 85% conserved"
                6612..6687
repeat_region   /note="2 copies 38 mer 98% conserved"
                6672..6773
repeat_region   /note="2 copies 51 mer 93% conserved"
                8852..8923
repeat_region   /note="4 copies 18 mer 81% conserved"
                8854..8988
repeat_region   /note="15 copies 9 mer cccgaacc 63% conserved"
                8860..8943
repeat_region   /note="3 copies 28 mer 83% conserved"
                8920..9059
repeat_region   /note="4 copies 35 mer 75% conserved"
                8927..9056
repeat_region   /note="5 copies 26 mer 69% conserved"
                8935..9002
repeat_region   /note="4 copies 17 mer 95% conserved"
                8984..9037
repeat_region   /note="3 copies 18 mer 90% conserved"
                9427..9530
repeat_region   /note="4 copies 26 mer 92% conserved"
                10204..10602
repeat_region   /note="7 copies 57 mer 87% conserved"
                11050..11091
repeat_region   /note="2 copies 21 mer 100% conserved"
                11469..11823
repeat_region   /note="L1MCl repeat: matches 5862..6231 of consensus"
                13157..13200

```

```

repeat_region   /note="L1R5 repeat: matches 690..733 of consensus"
                13006..14155
misc_feature    /note="5 copies 70 mer 82% conserved"
                15491..15973
                /note="Cpg island"
                /evidence="not_experimental"
                16278..16371
repeat_region   /note="2 copies 47 mer 87% conserved"
                16956..17159
repeat_region   /note="4 copies 51 mer 95% conserved"
                19411..19587
repeat_region   /note="3 copies 59 mer 79% conserved"
                20202..20342
repeat_region   /note="3 copies 47 mer 96% conserved"
                20473..20564
misc_feature    /note="L2 repeat: matches 2602..2693 of consensus"
                20816..21894
                /note="Cpg island"
                /evidence="not_experimental"
                24570..24680
repeat_region   /note="L1M4 repeat: matches 3584..3686 of consensus"
                24681..24999
repeat_region   /note="AluJo repeat: matches 1..311 of consensus"
                25000..25306
repeat_region   /note="L1M4 repeat: matches 3686..4029 of consensus"
                25311..25620
misc_feature    /note="AluY repeat: matches 1..311 of consensus"
                25345..25989
                /note="Cpg island"
                /evidence="not_experimental"
                25755..26053
repeat_region   /note="AluSq repeat: matches 1..304 of consensus"
                27585..27688
repeat_region   /note="4 copies 26 mer 74% conserved"
                27733..27981
repeat_region   /note="AluJo repeat: matches 9..282 of consensus"
                29431..29498
repeat_region   /note="MER81 repeat: matches 4..72 of consensus"
                29553..29870
repeat_region   /note="AluX repeat: matches 1..309 of consensus"
                30907..31396
repeat_region   /note="7 copies 70 mer 64% conserved"
                30908..31432
repeat_region   /note="15 copies 35 mer 61% conserved"
                30911..31412
repeat_region   /note="251 copies 2 mer 99 61% conserved"
                30938..31413
repeat_region   /note="17 copies 28 mer 61% conserved"
                30973..31420
repeat_region   /note="14 copies 32 mer 61% conserved"
                30987..31385
misc_feature    /note="7 copies 57 mer 64% conserved"
                31000..31080
                /note="Sequence from uni-directional dGTP big dye
                terminator reads only."
                31043..31413
repeat_region   /note="7 copies 53 mer 63% conserved"
                31078..31415
repeat_region   /note="13 copies 26 mer 62% conserved"
                31136..31417
repeat_region   /note="6 copies 47 mer 66% conserved"
                31152..31421
repeat_region   /note="9 copies 30 mer 61% conserved"
                31153..31267
misc_feature    /note="Single clone region. Sequence from reads from a
                short insert library derived from a single pUC clone.
                Restriction digest data confirm the assembly."
                31175..31426
repeat_region   /note="12 copies 21 mer 61% conserved"
                31268..31411
repeat_region   /note="9 copies 16 mer 64% conserved"
                31268
                /note="Random repeat. Forced join. Gap size estimated to

```

Query Match	Best Local Similarity	Score	DB	Length
Matches 92; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	92.0%;	100.0%;	Pred. No. 3.5e-17;	350;
LOCUS	AR095306	1126 bp	DNA	linear
DEFINITION	sequence 27 from patent US 6004555.			PAT 08-SEP-2000
ACCESSION	U095306			
VERSION	U095306.1	GI:10023064		
KEYWORDS	Unknown.			
SOURCE	Unknown.			
ORGANISM	Unknown.			
REFERENCE	1 (bases 1 to 1126)			
AUTHORS	Thorppe,P.E. and Edgington,T.S.			
TITLE	Methods for the specific coagulation of vasculature			
JOURNAL	Patent: US 6004555-A 27 21-DEC-1999;			
FEATURES	Location/Qualifiers			
source	1..1126			
BASE COUNT	269 a 341 c 342 g 174 t			
ORIGIN	/organism="unknown"			
Query Match	Best Local Similarity	Score	DB	Length
Matches 89; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	88.4%;	98.9%;	Pred. No. 3.9e-16;	1126;
LOCUS	AR103990	1126 bp	DNA	linear
DEFINITION	Sequence 27 from patent US 6093399.			PAT 14-FEB-2001
ACCESSION	AR103990			
VERSION	AR103990.1	GI:12816698		
KEYWORDS	Unknown.			
SOURCE	Unknown.			
ORGANISM	Unknown.			
Unclassified.				

REFERENCE 1 (bases 1 to 1126)  
 AUTHORS Thorpe,P.E. and Edgington,T.S.  
 TITLE Methods and compositions for the specific coagulation of vasculature  
 JOURNAL Patent: US 6093399-A 27 25-JUL-2000;  
 FEATURES Location/Qualifiers  
 source 1..1126 /organism="unknown"  
 BASE COUNT 269 a 341 c 342 g 174 t  
 ORIGIN  
 Query Match 88.4%; Score 88.4; DB 6; Length 1126;  
 Best Local Similarity 98.9%; Pred. No. 3.9e-16;  
 Matches 89; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Oy 11 AGTCACAGCGAAGCTCTGACCTGAGACAGCGAGCTGTGACAGCTTCTGCCAGAGGA 70  
 Db 27 ATTACACAGGAGAGCTCTGACCTGAGACAGCGAGCTGTGACAGCTTCTGCCAGAGGA 86  
 Oy 71 ACAGAACTCTGTGTGTCTCTGCGCCG 100  
 Db 87 ACAGAACTCTGTGTGTCTCTGCGCCG 116  
 RESULT 7  
 LOCUS HUMFX 1126 bp mRNA linear PRI 08-NOV-1994  
 DEFINITION Human factor X mRNA.  
 ACCESSION K01886.1 GI:182820  
 VERSION K01886.1  
 KEYWORDS Stuart factor; factor X; serine protease.  
 SOURCE Human liver, cDNA to mRNA, clone lambda-X-1137.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE 1 (bases 1 to 1126)  
 AUTHORS Leytus,S.P., Chung,D.W., Kiesel,W., Kurachi,K. and Davie,E.W.  
 TITLE Characterization of a cDNA coding for human factor X  
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 81 (12), 3699-3702 (1984)  
 MEDLINE 84322026  
 PUBMED 6587384  
 COMMENT In processing, factor X (Stuart factor) is converted to Xa by cleavage of a glycopeptide from the amino-terminal end of the heavy chain. It then acts as a serine protease in converting prothrombin to thrombin.  
 FEATURES  
 source location/Qualifiers  
 1..1126 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /map="13q34"  
 1..1126 /gene="F10"  
 <1..1126 /gene="F10"  
 /product="factor X mRNA"  
 <1..1116 /gene="F10"  
 /note="factor X precursor peptide"  
 /codon\_start=1  
 /protein\_id="AA552486.1"  
 /db\_xref="GI:182821"  
 /db\_xref="GDB:600-119-890"  
 /translation="GFEGRNCELFTFKLCSLNDGDDDFCHEONSYSVCARGYTLA DNGKACIPGPPYPCGKQLERKRSVAQNTSSSGEAPDSITWKPDAADLDPTENPFD LLDFOOTPERGDDNLTRIVGGECKDEGCPWQALINEENGFCGGTILSEFYILTA AHVIAOKREFGDDNTEOREGEAVHEVYVYKHNRTETETDPIINVRKTPITER MNVAPACIEPERMAESTLMTOKTGTISGCGRTHEGROSTRLKMLEPVYVDNSCKLS SFITLONFCAGTIDKQDADCGDSGPHVTRFKDTYFVTGIVSWGECARCKRYGI YTKVTAFLKMWIDRSMKTRGLPRAKSHAPVITSSPLK"  
 <1..195 /gene="F10"  
 /product="factor X light chain"  
 205..1113 mat\_peptide

/gene="F10"  
 /product="factor X heavy chain"  
 361..1113 mat\_peptide  
 /gene="F10"  
 /product="factor Xa heavy chain"  
 BASE COUNT 269 a 341 c 342 g 174 t  
 ORIGIN 5 bp upstream of TaqI site.  
 Query Match 88.4%; Score 88.4; DB 9; Length 1126;  
 Best Local Similarity 98.9%; Pred. No. 3.9e-16;  
 Matches 89; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Oy 11 AGTCACAGGAGAGCTCTGACCTGAGACAGCGGAGCTGTGACAGCTTCTGCCAGAGGA 70  
 Db 27 ATTACACAGGAGAGCTCTGACCTGAGACAGCGGAGCTGTGACAGCTTCTGCCAGAGGA 86  
 Oy 71 ACAGAACTCTGTGTGTCTCTGCGCCG 100  
 Db 87 ACAGAACTCTGTGTGTCTCTGCGCCG 116  
 RESULT 8  
 LOCUS A93124 1404 bp DNA linear PAT 22-JAN-2000  
 DEFINITION Sequence 15 from Patent WO9747737.  
 ACCESSION A93124  
 VERSION A93124.1 GI:6741514  
 KEYWORDS  
 SOURCE unidentified.  
 ORGANISM unidentified.  
 REFERENCE 1 (bases 1 to 1404)  
 AUTHORS Kopeitzki,E. and Hopfner,K.  
 TITLE RECOMBINANT BLOOD-COAGULATION PROTEASES  
 JOURNAL Patent: WO 9747737-A 15 18-DEC-1997;  
 KOPETZKI ERHARD (DE); BOEHRIINGER MANNHEIM GMBH (DE)  
 FEATURES  
 source location/Qualifiers  
 1..1404 /organism="unidentified"  
 /db\_xref="taxon:32644"  
 BASE COUNT 356 a 402 c 425 g 221 t  
 ORIGIN  
 Query Match 88.4%; Score 88.4; DB 6; Length 1404;  
 Best Local Similarity 98.9%; Pred. No. 3.8e-16;  
 Matches 89; Conservative 0; Mismatches 1; Indels 0; Gaps 0  
 Oy 11 AGTCACAGGAGAGCTCTGACCTGAGACAGCGGAGCTGTGACAGCTTCTGCCAGAGGA 70  
 Db 315 ATTACACAGGAGAGCTCTGACCTGAGACAGCGGAGCTGTGACAGCTTCTGCCAGAGGA 374  
 Oy 71 ACAGAACTCTGTGTGTCTCTGCGCCG 100  
 Db 375 ACAGAACTCTGTGTGTCTCTGCGCCG 404  
 RESULT 9  
 LOCUS HUMCFX 1414 bp mRNA linear PRI 01-NOV-1994  
 DEFINITION Human blood-coagulation factor X mRNA, complete cds.  
 ACCESSION M22613  
 VERSION M22613.1 GI:180935  
 KEYWORDS coagulation factor X.  
 SOURCE Human liver, cDNA to mRNA, clone pKT218.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE 1 (bases 1 to 1414)  
 AUTHORS Kaul,R.K., Hildebrand,B., Roberts,S. and Jagadeeswaran,P.  
 TITLE Isolation and characterization of human blood-coagulation factor X cDNA  
 JOURNAL Gene 41 (2-3), 311-314 (1986)  
 MEDLINE 86221713

blood coagulation factor X  
Proc. Natl. Acad. Sci. U.S.A. 82 (11), 3591-3595 (1985)  
85216545

During conversion of factor X to factor X-a a glycopeptide of 5 amino acids (encoded by positions 513-568 in this sequence) is released.

A polyadenylation signal is located at position 1424-1429. This sequence was kindly submitted over electronic mail by R.T.A. McGillivray (23-SPP-1985).

Location/Qualifiers

1-1443

```

gene
  /db_xref="taxon:9606"
  /map="13q34"
  1..143
  /gene="F10"
  <1..143
  /gene="F10"
  /product="X mRNA"
  1..143
  /partial
  /gene="F10"
  /note="factor X prepeptide"
  /codon_start=3
  /protein_id="AAA52490.1"
  /db_xref="GI:182841"
  /db_xref="GDR:GDR-600-110-800"
CDS

```

[illegible]

sig_peptide	<1..86 /gen-"F10" /note-"factor X signal peptide"
mat_peptide	87..503 /gene="F10" /product-"factor X light chain"
mat_peptide	513..1440 /gene="F10"

variation	/product= factor X heavy chain*
1117	/gene="F10"
	/note="a in pCHX8; t in pCHX5"
BASE COUNT	361 a 416 c 435 g 231 t
ORIGIN	24 bp upstream of Aval site.
Query Match	88.48% 20.4

QY	11	AGTCAACGGAAGCTCTGACCTGTGACAAAGGGAGCTGTGACCACTTGTGCACAGAGA	70
b	335	ATTCAACAGGAGCTCTGTCTACCTGTGACAAAGGGAGCTGTGACCACTTGTGCACAGAGA	...
		Matches 89; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
		Best local match: 90.4%; score 88.4; DB 9; Length 1443;	
		Best local similarity 98.9%; Pred. No. 3.8e-16;	

**OY**      73 ACAGAACTCTGTGTTGCTGCTCCTCGGCCG 100  
         |||||  
**Db**      395 ACAGAACTCTGTGTTGCTGCTCCTCGGCCG 424

RESULT 11			
LOCUS	AB6859		
DEFINITION	Sequence 43 from Patent WO983818.	1467 bp	DNA
ACCESSION	AB6859		linear
VERSION	AB6859.1	GI:6735650	PAT 22-JAN-2000
KEYWORDS	unidentified.		
SOURCE			



BASE COUNT	363 a	424 c	444 g	236 t	ITYKTAFLKMWIDRSMTKGLPKAKSHAPEVITSSPLK*
ORIGIN					
Query Match		88.4%;	Score 88.4;	DB 6;	Length 1467;
Best Local Similarity		98.9%;	Pred. No. 3.8e-16;		
Matches 89;	Conservative	0;	Mismatches 1;	Indels	0;
OY	11	AGTCACACGGAACCTCTGGACGCTGGACACACAGGGGAGCTGTGACCACTTCTGCCACAGAGA	70		
Db	369	ATTTCACACGGAAGCTCTGGACGCTGGACACAGGGGAGCTGTGACCACTTCTGCCACAGAGA	428		
OY	71	ACAGAACTCTGTGTGCTGTGCTCTGCGCCCG	100		
Db	429	ACAGAACTCTGTGTGCTGTGCTCTGCGCCCG	458		
RESULT 13					
AX082959					
LOCUS	AX082959	1467 bp	DNA	linear	PAT 28-FEB-2001
DEFINITION	Sequence 1 from Patent WO0110896.				
ACCESSION	AX082959				
VERSION	AX082959.1	GI:13184880			
KEYWORDS					
SOURCE	human.				
ORGANISM	Homo sapiens				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.				
TITLE	1 (bases 1 to 1467)				
JOURNAL	Himmelspach,M. and Schlokat,U.				
FEATURES	Factor x analog with an improved ability to be activated				
source	Patent: WO 0110896-A 1 15-FEB-2001;				
	Bakter Aktiengesellschaft (AT)				
	Location/Qualifiers				
	1..1467				
	/organism="Homo sapiens"				
	/db_xref="taxon:9606"				
BASE COUNT	363 a	424 c	444 g	236 t	
ORIGIN					
Query Match		8.4%;	Score 88.4;	DB 6;	Length 1467;
Best Local Similarity		>8.9%;	Pred. No. 3.8e-16;		
Matches 89;	Conservative	0;	Mismatches 1;	Indels	0;
OY	11	AGTCACACGGAAGCTCTGGACCTGTGGACACGGGAGCTGTGACCACTTCTGCCACAGAGA	70		
Db	369	ATTTCACACGGAAGCTCTGGACCTGTGGACACGGGAGCTGTGACCACTTCTGCCACAGAGA	428		
OY	71	ACAGAACTCTGTGTGCTGTGCTCTGCGCCCG	100		
Db	429	ACAGAACTCTGTGTGCTGTGCTCTGCGCCCG	458		
RESULT 14					
LOCUS	AR024194	1500 bp	DNA	linear	PAT 05-DEC-1998
DEFINITION	Sequence 4 from patent US 5795863.				
ACCESSION	AR024194				
VERSION	AR024194.1	GI:3977488			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 1500)				
TITLE	Wolf,D.				
JOURNAL	Recombinant agents affecting thrombosis				
FEATURES	Patent: US 5795863-A 4 18-AUG-1998;				
source	Location/Qualifiers				
	1..1500				
	/organism="unknown"				
BASE COUNT	390 a	425 c	441 g	244 t	
ORIGIN					

Query Match 88.4%; Score 88.4; DB 6; Length 1500;  
Best Local Similarity 98.9%; Pred. No. 3.8e-16;  
Matches 89; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 11 AGTCACAGGAGCTCTGACCTGACACGAGGAGCTGTGACCATTTCTCCACGAGA 70  
|||||  
Db 401 ATTACACAGGAGCTCTGACCTGACACGAGGAGCTGTGACCATTTCTCCACGAGA 460  
|||||

QY 71 ACAGAACTCTGTGTGTGCTCTGCGCCCG 100  
|||||  
Db 461 ACAGAACTCTGTGTGTGCTCTGCGCCCG 490  
|||||

## RESULT 15

## LOCUS

HUMFACX 1507 bp mRNA linear PRI 08-NOV-1994  
DEFINITION Human coagulation factor X (F10) mRNA, complete cds.

ACCESSION M57285  
VERSION M57285.1 GI:182389

KEYWORDS coagulation factor X.  
coagulation factor X.

## SOURCE

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Human, cDNA to mRNA.

Db 429 ACAGAACTCTGTGTGTGCTCTGCGCCCG 458  
Search completed: January 15, 2003, 20:35:16  
Job time: 1355 secs

## FEATURES

1..1507  
Location/Qualifiers

/organism="Homo sapiens"

/db\_xref="taxon:9606"

/map="13q34"

/tissue\_type="liver"

1..1507

/gene="F10"

1..1467

/gene="F10"

/EC\_number="3.4.21.6"

/codon\_start=1

/product="coagulation factor X"

/protein\_id="AA52421.1"

/db\_xref="GI:182390"

/db\_xref="GDB:600-119-890"

/translation="MORPLHVLASLAGLLLGESLPIRREQANNILAVTRANSF

LEEMKGLHERCEMETCSYEAREVEFEDSDKTNEFWNKYKDQCEPSCNOGCK

DIAGEYTCLEGFEGKNCLEFTRKLCISDNGCDQPCHEBONSVCSCARGYTLADN

GRACIPTGPGCKQTLERRKRSVAQATSSSEAPDSITWKPYDAADLPDENPDL

DENOTOPERGDNNLFRIVGGGCKDECPQWALLINENEGFCGTTLSSEYITLAAH

CLYQAKRFKRVVDRNTBOEGEGDAHVEFYIKHNRFTKREYDDIATRLKPTTF

BNVAPACLPEDMAESTIMTKGTIGVSGFTHRGROSTRKMLLEVYVDNSCKL

SSSFITQMFACGIDTKQEDACQDSGGPHTRRKDYFVTGIVSWEGCARKKYG

IYTKVTAFLKWIIDRSMTKTRGLPKAKSHAPEVITSSPLK"

1004..1060

/gene="F10"

/note="putative VECTOR sequence Bacteriophage lambda

(J02459); putative"

BASE COUNT 394 a 429 c 446 g 238 t

ORIGIN

Query Match 88.4%; Score 88.4; DB 9; Length 1507;

Best Local Similarity 98.9%; Pred. No. 3.8e-16;

Matches 89; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 11 AGTCACAGGAGCTCTGACCTGACACGAGGAGCTGTGACCATTTCTCCACGAGA 70  
|||||

Db 369 ATTACACAGGAGCTCTGACCTGACACGAGGAGCTGTGACCATTTCTCCACGAGA 428  
|||||

QY 71 ACAGAACTCTGTGTGTGCTCTGCGCCCG 100  
|||||

GenCore version 5.1.  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OW nucleic - nucleic search, using sw model

Run on: January 15, 2003, 17:58:10 : Search time 31 Seconds

(without alignments)  
989.280 Million cell updates/sec

Title: L00394\_COPY\_1\_100

Sequence: 1 CTCCTTGGCAGTCACACG.....GTGGTGGCTCTGCGCCG 100

Scoring table: IDENTITY NUC

Gapop 10.0, Gapext 1.0

Searched: 441362 seqs, 15338381 residues

Total number of hits satisfying chosen parameters: 882724

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued\_Patents\_MN:\*  
1: /cgn2\_6/ptodata/2/1na/5a.COMB.seq:\*  
2: /cgn2\_6/ptodata/2/1na/5b.COMB.seq:\*  
3: /cgn2\_6/ptodata/2/1na/5a.COMB.seq:\*  
4: /cgn2\_6/ptodata/2/1na/5b.COMB.seq:\*  
5: /cgn2\_6/ptodata/2/1na/5a.COMB.seq:\*  
6: /cgn2\_6/ptodata/2/1na/5b.COMB.seq:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	88.4	88.4	1126	2	US-08-479-733A-27 Sequence 27, Appl
2	88.4	88.4	1126	3	US-08-487-427-27 Sequence 27, Appl
3	88.4	88.4	1126	3	US-08-479-727A-27 Sequence 27, Appl
4	88.4	88.4	1126	3	US-08-482-369A-27 Sequence 27, Appl
5	88.4	88.4	1126	5	PCT-US95-07439-27 Sequence 27, Appl
6	88.4	88.4	1404	4	US-09-202-101-15 Sequence 15, Appl
7	88.4	88.4	1500	1	US-08-487-037-1 Sequence 4, Appl
8	52.4	52.4	1554	2	US-08-469-486-1 Sequence 1, Appl
9	52.4	52.4	1554	2	US-08-469-658-1 Sequence 1, Appl
10	30.8	30.8	2461	1	US-08-282-141-1 Sequence 1, Appl
11	28.2	28.2	22306	4	US-09-453-702B-251 Sequence 251, Appl
12	28.2	28.2	46819	4	US-09-453-702B-72 Sequence 72, Appl
13	26.8	26.8	4403765	4	US-09-103-840A-2 Sequence 2, Appl
14	26.8	26.8	4411529	4	US-09-103-840A-1 Sequence 1, Appl
15	26.4	26.4	3156	4	US-09-284-819-8 Sequence 8, Appl
16	25.8	25.8	10095	3	US-08-822-586-45 Sequence 45, Appl
17	25.4	25.4	286	2	US-08-675-508-21 Sequence 21, Appl
18	25.4	25.4	1409	4	US-09-338-907-72 Sequence 72, Appl
19	25.4	25.4	1409	4	US-09-338-907-72 Sequence 72, Appl
20	25.4	25.4	1409	4	US-09-338-907-72 Sequence 72, Appl
21	25.4	25.4	1409	4	US-09-338-907-72 Sequence 72, Appl
22	25.4	25.4	4550	4	US-09-218-207-182 Sequence 182, Appl
23	25.4	25.4	4550	4	US-09-218-207-182 Sequence 182, Appl
24	25.2	25.2	1866	4	US-09-615-192A-103 Sequence 103, Appl
25	25.2	25.2	2013	4	US-09-615-192A-103 Sequence 103, Appl
26	25.2	25.2	6677	4	US-08-939-366-27 Sequence 27, Appl
27	25.2	25.2	6677	4	US-08-939-366-27 Sequence 27, Appl

28	25.2	25.2	10079	2	US-08-476-866-20 Sequence 20, Appl
29	25	25.0	1386	2	US-08-756-506-3 Sequence 3, Appl
30	25	25.0	1387	6	5270178-1 Patent No. 5270178
31	25	25.0	1755	6	5225537-1 Patent No. 5225537
32	25	25.0	2373	4	US-08-980-080-1 Sequence 1, Appl
33	25	25.0	3003	1	US-08-434-730-15 Sequence 15, Appl
34	25	25.0	4493	4	US-09-417-822-6 Sequence 6, Appl
35	25	25.0	4534	4	US-09-417-822-7 Sequence 7, Appl
36	25	25.0	4535	4	US-09-417-822-8 Sequence 8, Appl
37	25	25.0	8838	4	US-09-417-822-1 Sequence 1, Appl
38	25	25.0	11725	2	US-08-756-506-1 Sequence 1, Appl
39	24.8	24.8	288	2	US-08-675-508-23 Sequence 23, Appl
40	24.8	24.8	494	2	US-08-675-508-4 Sequence 4, Appl
41	24.8	24.8	998	4	US-09-203-939-1 Sequence 1, Appl
42	24.8	24.8	998	4	US-09-251-835-1 Sequence 1, Appl
43	24.8	24.8	998	4	US-09-318-503-1 Sequence 1, Appl
44	24.8	24.8	998	4	US-09-318-503-1 Sequence 1, Appl
45	24.8	24.8	1485	4	US-09-088-435-2 Sequence 2, Appl

## ALIGNMENTS

RESULT 1  
US-08-479-733A-27  
Sequence 27, Application US/08479733A  
Patent No. 5877289  
GENERAL INFORMATION:  
APPLICANT: Thorpe, Philip E.  
APPLICANT: Edgington, Thomas S.  
TITLE OF INVENTION: Methods and Compositions for the  
TITLE OF INVENTION: Specific Coagulation of Vasculature  
NUMBER OF SEQUENCES: 32  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Arnold, White & Durkee  
STREET: P.O. Box 4433  
CITY: Houston  
STATE: Texas  
COUNTRY: US  
ZIP: 77210  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/479,733A  
FILING DATE: 07-JUN-1995  
CLASSIFICATION: 424  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: US 08/273,567  
FILING DATE: 11-JUL-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Parker, David L.  
REGISTRATION NUMBER: 32,165  
REFERENCE/DOCKET NUMBER: UTSD:459/PAR  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 512/418-3000  
TELEFAX: 512/474-7577  
TELEX: N/A  
INFORMATION FOR SEQ ID NO: 27:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1126 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-479-733A-27  
Query Match 88.4% Score 88.4: DB 2: Length 1126:  
Best Local Similarity 98.9% Pred. No. 1e-19:  
Matches 89: Conservative 0: Mismatches 1: Indels 0: Gaps 0:  
QY 11 AGTCACGAGGAGCTGCGACGCTGACACGCGGACGTCGTGACGAGTTCTGCGACGAGGA 70

Db 27 ATTACACGGAACTCTGCAGCCTGSAACAAGGGAACTGTACAGATTCTGCCAGAGA 85  
|||||  
Oy 71 ACAGAACTGTGTGTGTGTCTCTGTGCGCCG 100  
|||||  
Db 87 ACAGAACTGTGTGTGTGTCTCTGTGCGCCG 116  
|||||

RESULT 2  
US-08-487-427-27

GENERAL INFORMATION:

COMPUTER READABLE FORM:

```

: INFORMATION FOR SEQ ID NO: 27:
:
: SEQUENCE CHARACTERISTICS:
:     LENGTH: 1126 base pairs
:     TYPE: nucleic acid
:     STRANDEDNESS: single
:     TOPOLOGY: linear
:
: OS=08-487-427-27

```

RESULT 3  
US-08-479-727A-27  
: Sequence 27, Application US/08479727A  
: Patent No. 6036955  
: GENERAL INFORMATION:  
: APPLICANT: THORPE, Philip E.  
: TITLE OF INVENTION: Methods and Compositions for the

```

1      TITLE OF INVENTION:  Specific Coagulation of Vasculature
2
3      NUMBER OF SEQUENCES:  32
4
5      CORRESPONDENCE ADDRESS:
6
7      ADDRESSEE:  Arnold, White & Durkee
8
9      STREET:  P. O. Box 4433
10
11     CITY:  Houston
12

```

COMPUTER READABLE FORM:

```

? INFORMATION FOR SEQ. ID NO: 27
?
? SEQUENCE CHARACTERISTICS:
?
? LENGTH: 1126 base pairs
?
? TYPE: nucleic acid
?
? STRANDEDNESS: single
?
? TOPOLOGY: linear
?
US-08-479-727A-27

```

1  
 2  
 3  
 4  
 5  
 6  
 7  
 8  
 9  
 10  
 11  
 12  
 13  
 14  
 15  
 16  
 17  
 18  
 19  
 20  
 21  
 22  
 23  
 24  
 25  
 26  
 27  
 28  
 29  
 30  
 31  
 32  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60  
 61  
 62  
 63  
 64  
 65  
 66  
 67  
 68  
 69  
 70  
 71  
 72  
 73  
 74  
 75  
 76  
 77  
 78  
 79  
 80  
 81  
 82  
 83  
 84  
 85  
 86  
 87  
 88  
 89  
 90  
 91  
 92  
 93  
 94  
 95  
 96  
 97  
 98  
 99  
 100  
 101  
 102  
 103  
 104  
 105  
 106  
 107  
 108  
 109  
 110  
 111  
 112  
 113  
 114  
 115  
 116  
 117  
 118  
 119  
 120  
 121  
 122  
 123  
 124  
 125  
 126  
 127  
 128  
 129  
 130  
 131  
 132  
 133  
 134  
 135  
 136  
 137  
 138  
 139  
 140  
 141  
 142  
 143  
 144  
 145  
 146  
 147  
 148  
 149  
 150  
 151  
 152  
 153  
 154  
 155  
 156  
 157  
 158  
 159  
 160  
 161  
 162  
 163  
 164  
 165  
 166  
 167  
 168  
 169  
 170  
 171  
 172  
 173  
 174  
 175  
 176  
 177  
 178  
 179  
 180  
 181  
 182  
 183  
 184  
 185  
 186  
 187  
 188  
 189  
 190  
 191  
 192  
 193  
 194  
 195  
 196  
 197  
 198  
 199  
 200  
 201  
 202  
 203  
 204  
 205  
 206  
 207  
 208  
 209  
 210  
 211  
 212  
 213  
 214  
 215  
 216  
 217  
 218  
 219  
 220  
 221  
 222  
 223  
 224  
 225  
 226  
 227  
 228  
 229  
 230  
 231  
 232  
 233  
 234  
 235  
 236  
 237  
 238  
 239  
 240  
 241  
 242  
 243  
 244  
 245  
 246  
 247  
 248  
 249  
 250  
 251  
 252  
 253  
 254  
 255  
 256  
 257  
 258  
 259  
 260  
 261  
 262  
 263  
 264  
 265  
 266  
 267  
 268  
 269  
 270  
 271  
 272  
 273  
 274  
 275  
 276  
 277  
 278  
 279  
 280  
 281  
 282  
 283  
 284  
 285  
 286  
 287  
 288  
 289  
 290  
 291  
 292  
 293  
 294  
 295  
 296  
 297  
 298  
 299  
 300  
 301  
 302  
 303  
 304  
 305  
 306  
 307  
 308  
 309  
 310  
 311  
 312  
 313  
 314  
 315  
 316  
 317  
 318  
 319  
 320  
 321  
 322  
 323  
 324  
 325  
 326  
 327  
 328  
 329  
 330  
 331  
 332  
 333  
 334  
 335  
 336  
 337  
 338  
 339  
 340  
 341  
 342  
 343  
 344  
 345  
 346  
 347  
 348  
 349  
 350  
 351  
 352  
 353  
 354  
 355  
 356  
 357  
 358  
 359  
 360  
 361  
 362  
 363  
 364  
 365  
 366  
 367  
 368  
 369  
 370  
 371  
 372  
 373  
 374  
 375  
 376  
 377  
 378  
 379  
 380  
 381  
 382  
 383  
 384  
 385  
 386  
 387  
 388  
 389  
 390  
 391  
 392  
 393  
 394  
 395  
 396  
 397  
 398  
 399  
 400  
 401  
 402  
 403  
 404  
 405  
 406  
 407  
 408  
 409  
 410  
 411  
 412  
 413  
 414  
 415  
 416  
 417  
 418  
 419  
 420  
 421  
 422  
 423  
 424  
 425  
 426  
 427  
 428  
 429  
 430  
 431  
 432  
 433  
 434  
 435  
 436  
 437  
 438  
 439  
 440  
 441  
 442  
 443  
 444  
 445  
 446  
 447  
 448  
 449  
 450  
 451  
 452  
 453  
 454  
 455  
 456  
 457  
 458  
 459  
 460  
 461  
 462  
 463  
 464  
 465  
 466  
 467  
 468  
 469  
 470  
 471  
 472  
 473  
 474  
 475  
 476  
 477  
 478  
 479  
 480  
 481  
 482  
 483  
 484  
 485  
 486  
 487  
 488  
 489  
 490  
 491  
 492  
 493  
 494  
 495  
 496  
 497  
 498  
 499  
 500  
 501  
 502  
 503  
 504  
 505  
 506  
 507  
 508  
 509  
 510  
 511  
 512  
 513  
 514  
 515  
 516  
 517  
 518  
 519  
 520  
 521  
 522  
 523  
 524  
 525

RESULT 7  
US-08-487-037-4

RESULT 9  
US-08-469-658-1  
; Sequence 1, Application US/08469658  
; Patent No. 5917018  
; GENERAL INFORMATION:  
; APPLICANT: Th egeresen, Hans Christian  
; APPLICANT: Hollet, Thor las  
; APPLICANT: Etzerodt, Michael  
; TITLE OF INVENTION: IMPROVED METHOD FOR THE REPRODING OF  
; TITLE OF INVENTION: PROTEINS  
; NUMBER OF SEQUENCES: 58  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version  
; #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/469,658  
; FILING DATE: June 5, 1995



Db 16880 CTGATCGCTTGGGCTGACCATCCGAACTGTCTCCGGAACATCGAGGAGCGGTA 16939  
QY 78 TCTGTGTGTGCT 90  
Db 16940 TCCAGAGTGCCCT 16952

RESULT 12  
US-09-453-702B-72/c  
Sequence 72, Application US/09453702B  
Patent No. 6365723  
GENERAL INFORMATION:  
APPLICANT: Blattner, Frederick R.  
Burland, Nicole T.  
Perna, Nicole T.  
Plunkett, Guy  
Weich, Rod

TITLE OF INVENTION: No. 6365723el Sequences of E. coli O157  
NUMBER OF SEQUENCES: 265  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Quarles & Brady  
STREET: 1 South Plinckney Street  
CITY: Madison  
STATE: WI  
COUNTRY: US  
ZIP: 53701-2113

COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3.50 inch, 1.44mb storage  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Word Perfect 8.0

CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/453,702B  
FILING DATE: 03-Dec-1999  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/110,955  
FILING DATE: 04-DEC-1998

ATTORNEY/AGENT INFORMATION:  
NAME: Seay, Nicholas J.  
REGISTRATION NUMBER: 27386  
REFERENCE/DOCKET NUMBER: 960296.95017  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (608) 251-5000  
TELEFAX: (608) 251-9166

INFORMATION FOR SEQ ID NO: 72:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 46819  
TYPE: nucleic acid  
STRANDEDNESS: double  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
SEQUENCE DESCRIPTION: SEQ ID NO: 72:

US-09-453-702B-72  
Query Match 28.2%; Score 28.2; DB 4; Length 46819;  
Best Local Similarity 61.6%; Pred. No. 6.3;  
Matches 45; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 18 CGGAAGCTCTGAGCCTGACACAGGGAGCTGTGACCACTTCTGCCAGAGAGACAGAAC 77  
Db 15108 CTGATGCGCTTGGGCTGACATCCGAACTGTCTCCGGAACATCGAGAGAGCGGTA 15049  
QY 78 TCTGTGTGTGCT 90  
Db 15048 TCCAGAGTGCCCT 15036

RESULT 13  
US-09-103-840A-2/c  
Sequence 2, Application US/09103840A  
Patent No. 6294328  
GENERAL INFORMATION:

APPLICANT: FLEISCHMAN, Robert D.  
APPLICANT: WHITE, Owen R.  
APPLICANT: FRASER, Claire M.  
APPLICANT: VENTER, John C.  
TITLE OF INVENTION: DNA SEQUENCES FOR STRAIN ANALYSIS IN MYCOBACTERIUM  
FILE REFERENCE: 24366-20007.00  
CURRENT APPLICATION NUMBER: US/09/103,840A  
NUMBER OF SEQ ID NOS: 2  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 2  
LENGTH: 4403765  
TYPE: DNA  
ORGANISM: Mycobacterium tuberculosis  
FEATURE:  
OTHER INFORMATION: CDC 1551  
OTHER INFORMATION: "n" bases at various positions throughout the sequence  
US-09-103-840A-2

Query Match 26.8%; Score 26.8; DB 4; Length 4403765;  
Best Local Similarity 68.5%; Pred. No. 38;  
Matches 37; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 6 TTGGCAGTCAACAGGAGCTGTGACCTGTGACACAGGGAGCTGTGACCACTTC 59  
Db 3915983 TTGGGAATCGCACCGGATATCTTGACCTGTGACGACGAGGACTATGCGGTGCTC 3915930

RESULT 14  
US-09-103-840A-1/c  
Sequence 1, Application US/09103840A  
Patent No. 6294328  
GENERAL INFORMATION:

APPLICANT: FLEISCHMAN, Robert D.  
APPLICANT: WHITE, Owen R.  
APPLICANT: FRASER, Claire M.  
APPLICANT: VENTER, John C.  
TITLE OF INVENTION: DNA SEQUENCES FOR STRAIN ANALYSIS IN MYCOBACTERIUM  
FILE REFERENCE: 24366-20007.00  
CURRENT APPLICATION NUMBER: US/09/103,840A  
CURRENT FILING DATE: 1998-06-24  
NUMBER OF SEQ ID NOS: 2  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 1  
LENGTH: 4411529  
TYPE: DNA  
ORGANISM: Mycobacterium tuberculosis  
OTHER INFORMATION: H37RV  
US-09-103-840A-1

Query Match 26.8%; Score 26.8; DB 4; Length 4411529;  
Best Local Similarity 68.5%; Pred. No. 38;  
Matches 37; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 6 TTGGCAGTCAACAGGAGCTGTGACCTGTGACACAGGGAGCTGTGACCACTTC 59  
Db 3922204 TTGGGAATCGCACCGGATATCTTGACCTGTGACGACGAGGACTATGCGGTGCTC 3922151

RESULT 15  
US-09-284-819-8/c  
Sequence 8, Application US/09284819  
Patent No. 6365712  
GENERAL INFORMATION:  
APPLICANT: Kelly, Kathleen  
APPLICANT: The Government of the United States of America  
APPLICANT: as represented by The Secretary of the  
Department of Health and Human Services  
TITLE OF INVENTION: Methods and Compositions for Inhibiting Inflammation  
and Angiogenesis Comprising a Mammalian CD97 Alpha





```

Db      267 TCCTACCGTGCCCACTGCTTCT 290
          |||| | | ||||| | |

```

## RESULT 4

Best Local Similarity	34.28;	Score
Matched	64.68;	Pred.

Best Local Similarity	34.28;	Score
Matched	64.68;	Pred.

OY 21 CATCAATGAGGAAACAGAGGTTCTGTGTGAACCATCTTGAGCGAGTTTACATCCT 80  
Db 857 CATCCAGACAGCAAAACAGCAGCTGTGTGAGGAGCATCCTGACCCCACTGGGTCT 916  
OY 81 AAGCGAGCCCACTGTCTC 99  
Db 917 CACGGCAGCCCACTGTCTC 935

RESULT 6  
US-10-006-867-111  
Sequence 111, Application US/10006867  
Patent No. US20020119130A1  
GENERAL INFORMATION:  
APPLICANT: Eaton, Dan L.  
APPLICANT: Filvaroff, Ellen  
APPLICANT: Geriltsen, Mary E.  
APPLICANT: Goddard, Audrey  
APPLICANT: Godowski, Paul J.  
APPLICANT: Grimaldi, Christopher J.  
APPLICANT: Gurney, Austin L.  
APPLICANT: Matanabe, Colin K.  
APPLICANT: Wood, William I.  
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
FILE REFERENCE: P3230R1C1  
CURRENT APPLICATION NUMBER: US/10/006,867  
PRIOR FILING DATE: 2001-12-06  
PRIOR APPLICATION NUMBER: 60/063435  
PRIOR FILING DATE: 1997-10-29  
PRIOR APPLICATION NUMBER: 60/064215  
PRIOR FILING DATE: 1997-10-29  
PRIOR APPLICATION NUMBER: 60/082797  
PRIOR FILING DATE: 1998-04-22  
PRIOR APPLICATION NUMBER: 60/083495  
PRIOR FILING DATE: 1998-04-29  
PRIOR APPLICATION NUMBER: 60/085579  
PRIOR FILING DATE: 1998-05-15  
PRIOR APPLICATION NUMBER: 60/087759  
PRIOR FILING DATE: 1998-06-02  
PRIOR APPLICATION NUMBER: 60/088021  
PRIOR FILING DATE: 1998-06-04  
PRIOR APPLICATION NUMBER: 60/088029  
PRIOR FILING DATE: 1998-06-04  
PRIOR APPLICATION NUMBER: 60/088030  
PRIOR FILING DATE: 1998-06-04  
PRIOR APPLICATION NUMBER: 60/088734  
PRIOR FILING DATE: 1998-06-10  
PRIOR APPLICATION NUMBER: 60/088740  
PRIOR FILING DATE: 1998-06-10  
PRIOR APPLICATION NUMBER: 60/088811  
PRIOR FILING DATE: 1998-06-10  
PRIOR APPLICATION NUMBER: 60/088824  
PRIOR FILING DATE: 1998-06-10  
PRIOR APPLICATION NUMBER: 60/088825  
PRIOR FILING DATE: 1998-06-10  
PRIOR APPLICATION NUMBER: 60/088863  
PRIOR FILING DATE: 1998-06-11  
PRIOR APPLICATION NUMBER: 60/089105  
PRIOR FILING DATE: 1998-06-12  
PRIOR APPLICATION NUMBER: 60/089514  
PRIOR FILING DATE: 1998-06-16  
PRIOR APPLICATION NUMBER: 60/089653  
PRIOR FILING DATE: 1998-06-17  
PRIOR APPLICATION NUMBER: 60/089952  
PRIOR FILING DATE: 1998-06-19  
PRIOR APPLICATION NUMBER: 60/090246  
PRIOR FILING DATE: 1998-06-22  
PRIOR APPLICATION NUMBER: 60/090444  
PRIOR FILING DATE: 1998-06-24  
PRIOR APPLICATION NUMBER: 60/090688  
PRIOR FILING DATE: 1998-06-25

PRIOR APPLICATION NUMBER: 60/090696  
PRIOR FILING DATE: 1998-06-25  
PRIOR APPLICATION NUMBER: 60/090862  
PRIOR FILING DATE: 1998-06-26  
PRIOR APPLICATION NUMBER: 60/091628  
PRIOR FILING DATE: 1998-07-02  
PRIOR APPLICATION NUMBER: 60/096012  
PRIOR FILING DATE: 1998-08-10  
PRIOR APPLICATION NUMBER: 60/096757  
PRIOR FILING DATE: 1998-08-17  
PRIOR APPLICATION NUMBER: 60/096949  
PRIOR FILING DATE: 1998-08-18  
PRIOR APPLICATION NUMBER: 60/096959  
PRIOR FILING DATE: 1998-08-18  
PRIOR APPLICATION NUMBER: 60/097954  
PRIOR FILING DATE: 1998-08-26  
PRIOR APPLICATION NUMBER: 60/097971  
PRIOR FILING DATE: 1998-08-26  
PRIOR APPLICATION NUMBER: 60/097979  
PRIOR FILING DATE: 1998-09-26  
PRIOR APPLICATION NUMBER: 60/098749  
PRIOR FILING DATE: 1998-09-01  
PRIOR APPLICATION NUMBER: 60/099741  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/099763  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/099792  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/099812  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/099815  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/100627  
PRIOR FILING DATE: 1998-09-16  
PRIOR APPLICATION NUMBER: 60/100662  
PRIOR FILING DATE: 1998-09-16  
PRIOR APPLICATION NUMBER: 60/100683  
PRIOR FILING DATE: 1998-09-17  
PRIOR APPLICATION NUMBER: 60/100684  
PRIOR FILING DATE: 1998-09-17  
PRIOR APPLICATION NUMBER: 60/100930  
PRIOR FILING DATE: 1998-09-17  
PRIOR APPLICATION NUMBER: 60/101279  
PRIOR FILING DATE: 1998-09-22  
PRIOR APPLICATION NUMBER: 60/101475  
PRIOR FILING DATE: 1998-09-23  
PRIOR APPLICATION NUMBER: 60/101738  
PRIOR FILING DATE: 1998-09-24  
PRIOR APPLICATION NUMBER: 60/101743  
PRIOR FILING DATE: 1998-09-24  
PRIOR APPLICATION NUMBER: 60/101916  
PRIOR FILING DATE: 1998-09-24  
PRIOR APPLICATION NUMBER: 60/102570  
PRIOR FILING DATE: 1998-09-30  
PRIOR APPLICATION NUMBER: 60/103449  
PRIOR FILING DATE: 1998-10-06  
PRIOR APPLICATION NUMBER: 60/103678  
PRIOR FILING DATE: 1998-10-08  
PRIOR APPLICATION NUMBER: 60/103679  
PRIOR FILING DATE: 1998-10-08  
PRIOR APPLICATION NUMBER: 60/103711  
PRIOR FILING DATE: 1998-10-08  
PRIOR APPLICATION NUMBER: 60/105000  
PRIOR FILING DATE: 1998-10-20  
PRIOR APPLICATION NUMBER: 60/105002  
PRIOR FILING DATE: 1998-10-20  
PRIOR APPLICATION NUMBER: 60/105881  
PRIOR FILING DATE: 1998-10-27  
PRIOR APPLICATION NUMBER: 60/106030  
PRIOR FILING DATE: 1998-10-28  
PRIOR APPLICATION NUMBER: 60/106464  
PRIOR FILING DATE: 1998-10-30  
PRIOR APPLICATION NUMBER: 60/106856



PRIOR FILING DATE: 1998-03-11  
PRIOR APPLICATION NUMBER: 60/077649  
PRIOR FILING DATE: 1998-03-11  
PRIOR APPLICATION NUMBER: 60/078886  
PRIOR FILING DATE: 1998-03-20  
PRIOR APPLICATION NUMBER: 60/078939  
PRIOR FILING DATE: 1998-03-20  
PRIOR APPLICATION NUMBER: 60/079664  
PRIOR FILING DATE: 1998-03-27  
PRIOR APPLICATION NUMBER: 60/079786  
PRIOR FILING DATE: 1998-03-27  
PRIOR APPLICATION NUMBER: 60/080107  
PRIOR FILING DATE: 1998-03-31  
PRIOR APPLICATION NUMBER: 60/080194  
PRIOR FILING DATE: 1998-03-31  
PRIOR APPLICATION NUMBER: 60/080327  
PRIOR FILING DATE: 1998-04-01  
PRIOR APPLICATION NUMBER: 60/080333  
PRIOR FILING DATE: 1998-04-01  
PRIOR APPLICATION NUMBER: 60/081049  
PRIOR FILING DATE: 1998-04-08  
PRIOR APPLICATION NUMBER: 60/081070  
PRIOR FILING DATE: 1998-04-08  
PRIOR APPLICATION NUMBER: 60/081195  
PRIOR FILING DATE: 1998-04-09  
PRIOR APPLICATION NUMBER: 60/081838  
PRIOR FILING DATE: 1998-04-15  
PRIOR APPLICATION NUMBER: 60/082568  
PRIOR FILING DATE: 1998-04-21  
PRIOR APPLICATION NUMBER: 60/082569  
PRIOR FILING DATE: 1998-04-21  
PRIOR APPLICATION NUMBER: 60/082704  
PRIOR FILING DATE: 1998-04-22  
PRIOR APPLICATION NUMBER: 60/082797  
PRIOR FILING DATE: 1998-04-22  
PRIOR APPLICATION NUMBER: 60/083322  
PRIOR FILING DATE: 1998-04-28  
PRIOR APPLICATION NUMBER: 60/083495  
PRIOR FILING DATE: 1998-04-29  
PRIOR APPLICATION NUMBER: 60/083496  
PRIOR FILING DATE: 1998-04-29  
PRIOR APPLICATION NUMBER: 60/083499  
PRIOR FILING DATE: 1998-04-29  
PRIOR APPLICATION NUMBER: 60/083559  
PRIOR FILING DATE: 1998-04-29  
PRIOR APPLICATION NUMBER: 60/084366  
PRIOR FILING DATE: 1998-05-05  
PRIOR APPLICATION NUMBER: 60/084414  
PRIOR FILING DATE: 1998-05-06  
PRIOR APPLICATION NUMBER: 60/084639  
PRIOR FILING DATE: 1998-05-07  
PRIOR APPLICATION NUMBER: 60/084640  
PRIOR FILING DATE: 1998-05-07  
PRIOR APPLICATION NUMBER: 60/084643  
PRIOR FILING DATE: 1998-05-07  
PRIOR APPLICATION NUMBER: 60/085573  
PRIOR FILING DATE: 1998-05-15  
PRIOR APPLICATION NUMBER: 60/085579  
PRIOR FILING DATE: 1998-05-15  
PRIOR APPLICATION NUMBER: 60/085580  
PRIOR FILING DATE: 1998-05-15  
PRIOR APPLICATION NUMBER: 60/085582  
PRIOR FILING DATE: 1998-05-15  
PRIOR APPLICATION NUMBER: 60/085700  
PRIOR FILING DATE: 1998-05-15  
PRIOR APPLICATION NUMBER: 60/086023  
PRIOR FILING DATE: 1998-05-18  
PRIOR APPLICATION NUMBER: 60/086392  
PRIOR FILING DATE: 1998-05-22  
PRIOR APPLICATION NUMBER: 60/086486  
PRIOR FILING DATE: 1998-05-22  
PRIOR APPLICATION NUMBER: 60/087098  
PRIOR FILING DATE: 1998-05-28

PRIOR APPLICATION NUMBER: 60/087208  
PRIOR FILING DATE: 1998-05-28  
PRIOR APPLICATION NUMBER: 60/087609  
PRIOR FILING DATE: 1998-06-02  
PRIOR APPLICATION NUMBER: 60/087759  
PRIOR FILING DATE: 1998-06-02  
PRIOR APPLICATION NUMBER: 60/087827  
PRIOR FILING DATE: 1998-06-03  
PRIOR APPLICATION NUMBER: 60/088025  
PRIOR FILING DATE: 1998-06-04  
PRIOR APPLICATION NUMBER: 60/088028  
PRIOR FILING DATE: 1998-06-04  
PRIOR APPLICATION NUMBER: 60/088029  
PRIOR FILING DATE: 1998-06-04  
PRIOR APPLICATION NUMBER: 60/088033  
PRIOR FILING DATE: 1998-06-04  
PRIOR APPLICATION NUMBER: 60/088167  
PRIOR FILING DATE: 1998-06-05  
PRIOR APPLICATION NUMBER: 60/088202  
PRIOR FILING DATE: 1998-06-05  
PRIOR APPLICATION NUMBER: 60/088212  
PRIOR FILING DATE: 1998-06-05  
PRIOR APPLICATION NUMBER: 60/088217  
PRIOR FILING DATE: 1998-06-05  
PRIOR APPLICATION NUMBER: 60/088326  
PRIOR FILING DATE: 1998-06-04  
PRIOR APPLICATION NUMBER: 60/088655  
PRIOR FILING DATE: 1998-06-09  
PRIOR APPLICATION NUMBER: 60/088722  
PRIOR FILING DATE: 1998-06-10  
PRIOR APPLICATION NUMBER: 60/088738  
PRIOR FILING DATE: 1998-06-10  
PRIOR APPLICATION NUMBER: 60/088740  
PRIOR FILING DATE: 1998-06-10  
PRIOR APPLICATION NUMBER: 60/088811  
PRIOR FILING DATE: 1998-06-10  
PRIOR APPLICATION NUMBER: 60/088824  
PRIOR FILING DATE: 1998-06-10  
PRIOR APPLICATION NUMBER: 60/088825  
PRIOR FILING DATE: 1998-06-10  
PRIOR APPLICATION NUMBER: 60/088826  
PRIOR FILING DATE: 1998-06-10  
PRIOR APPLICATION NUMBER: 60/088861  
PRIOR FILING DATE: 1998-06-11  
PRIOR APPLICATION NUMBER: 60/088863  
PRIOR FILING DATE: 1998-06-11  
PRIOR APPLICATION NUMBER: 60/088876  
PRIOR FILING DATE: 1998-06-11  
PRIOR APPLICATION NUMBER: 60/089090  
PRIOR FILING DATE: 1998-06-12  
PRIOR APPLICATION NUMBER: 60/089105  
PRIOR FILING DATE: 1998-06-12  
PRIOR APPLICATION NUMBER: 60/089512  
PRIOR FILING DATE: 1998-06-16  
PRIOR APPLICATION NUMBER: 60/089514  
PRIOR FILING DATE: 1998-06-16  
PRIOR APPLICATION NUMBER: 60/089538  
PRIOR FILING DATE: 1998-06-17  
PRIOR APPLICATION NUMBER: 60/089598  
PRIOR FILING DATE: 1998-06-17  
PRIOR APPLICATION NUMBER: 60/089653  
PRIOR FILING DATE: 1998-06-17  
PRIOR APPLICATION NUMBER: 60/089908

Query Match 34.2% Score 34.2; DB 12; Length 2063;  
Best Local Similarity 64.6%; Pred. No. 0.0034;  
Matches 51; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 21 CATCATGAGAAACGAGCGTTCTGCTGGAACCATTCGAGCGAGTCTACATCCT 80  
DB 857 CATCCAGTAGCAACAAACAGCAGCTGTGTGAGGAGCATCTCGACCCCACTGGTCTCT 916  
QY 81 AACGCGAGCCCACTGTCTC 99

Db 917 CACGGCAGCCCACTGCTTC 935

RESULT 8  
US-09-851-588-5

Sequence 5, Application US/09851588  
Patent No. US20020042067A1

GENERAL INFORMATION:

APPLICANT: Mack, David

APPLICANT: Gish, Kurt C.

APPLICANT: Wilson, Keith E.

TITLE OF INVENTION: NOVEL METHODS OF DIAGNOSING COLORECTAL CANCER, COMPOSITIONS, AND

FILE REFERENCE: A-68829-1/DJB/JJD/AMS

CURRENT APPLICATION NUMBER: US/09/851,588

PRIOR FILING DATE: 2001-09-24

PRIOR APPLICATION NUMBER: US 09/642,252

PRIOR FILING DATE: 2000-08-17

PRIOR APPLICATION NUMBER: US 09/656,002

PRIOR FILING DATE: 2000-09-06

NUMBER OF SEQ ID NOS: 9

SOFTWARE: Patent version 3.1

SEQ ID NO 5

LENGTH: 2079

TYPE: DNA

ORGANISM: Homo sapiens

US-09-851-588-5

Query Match

Best Local Similarity 34.2%; Score 34.2; DB 10; Length 2079;

Matches 51; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

Db 871 CATCATGAGGAAACAGGGTTCTGTGTGAGAACCATCTGTGAGATCTTACATCT 80

Db 871 CATCATGAGGAAACAGGGTTCTGTGTGAGAACCATCTGTGAGATCTTACATCT 80

Db 871 CACGGCAGCCCACTGCTTC 949

Db 931 CACGGCAGCCCACTGCTTC 949

RESULT 9

US-09-851-588-7

Sequence 7, Application US/09851588

Patent No. US20020042067A1

GENERAL INFORMATION:

APPLICANT: Mack, David

APPLICANT: Gish, Kurt C.

APPLICANT: Wilson, Keith E.

TITLE OF INVENTION: NOVEL METHODS OF DIAGNOSING COLORECTAL CANCER, COMPOSITIONS, AND

FILE REFERENCE: A-68829-1/DJB/JJD/AMS

CURRENT APPLICATION NUMBER: US/09/851,588

PRIOR FILING DATE: 2001-09-24

PRIOR APPLICATION NUMBER: US 09/642,252

PRIOR FILING DATE: 2000-08-17

PRIOR APPLICATION NUMBER: US 09/656,002

PRIOR FILING DATE: 2000-09-06

NUMBER OF SEQ ID NOS: 9

SOFTWARE: Patent version 3.1

SEQ ID NO 7

LENGTH: 2081

TYPE: DNA

ORGANISM: Homo sapiens

FEATURE:

NAME/KEY: CDS

LOCATION: (215)..(1528)

OTHER INFORMATION:

US-09-851-588-7

Query Match

Best Local Similarity 34.2%; Score 34.2; DB 10; Length 2081;

Matches 51; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

Matches 51; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

Db 21 CATCATGAGGAAACAGGGTTCTGTGTGAGAACCATCTGTGAGATCTTACATCT 80

Db 877 CATCATGAGGAAACAGGGTTCTGTGTGAGAACCATCTGTGAGATCTTACATCT 80

Db 877 CACGGCAGCCCACTGCTTC 936

Db 81 AACGGCAGCCCACTGCTTC 99

Db 937 CACGGCAGCCCACTGCTTC 955

RESULT 10  
US-09-960-352-10052

Sequence 10052, Application US/09960352  
Patent No. US20020137139A1

GENERAL INFORMATION:

APPLICANT: Warren, Wesley C.

APPLICANT: Tao, Nengbing

APPLICANT: Byatt, John C.

APPLICANT: Mathalaagan, Nagappan

TITLE OF INVENTION: MUSCLE AND FAT DEPOSITION

FILE REFERENCE: 16511.006/37-21(102987C)

CURRENT APPLICATION NUMBER: US/09/960,352

PRIOR FILING DATE: 2001-09-24

NUMBER OF SEQ ID NOS: 15112

SEQ ID NO 10052

LENGTH: 396

TYPE: DNA

ORGANISM: Bos taurus

OTHER INFORMATION: Clone ID: 43-LIB34-017-01-EI-C4

US-09-960-352-10052

Query Match

Best Local Similarity 30.2%; Score 30.2; DB 10; Length 396;

Matches 50; Conservative 0; Mismatches 33; Indels 0; Gaps 0;

Db 17 TGCATCATGAGGAAACAGGGTTCTGTGTGAGAACCATCTGTGAGATCTTACATCT 76

Db 60 TCCATTCATGAGGAAACAGGGTTCTGTGTGAGAACCATCTGTGAGATCTTACATCT 76

Db 77 TCCATTCATGAGGAAACAGGGTTCTGTGTGAGAACCATCTGTGAGATCTTACATCT 76

Db 120 TCCATTCATGAGGAAACAGGGTTCTGTGTGAGAACCATCTGTGAGATCTTACATCT 76

RESULT 11

US-09-960-352-6361

Sequence 6361, Application US/09960352

Patent No. US20020137139A1

GENERAL INFORMATION:

APPLICANT: Warren, Wesley C.

APPLICANT: Tao, Nengbing

APPLICANT: Byatt, John C.

APPLICANT: Mathalaagan, Nagappan

TITLE OF INVENTION: MUSCLE AND FAT DEPOSITION

FILE REFERENCE: 16511.006/37-21(102987C)

CURRENT APPLICATION NUMBER: US/09/960,352

PRIOR FILING DATE: 2001-09-24

NUMBER OF SEQ ID NOS: 15112

SEQ ID NO 6361

LENGTH: 420

TYPE: DNA

ORGANISM: Bos taurus

OTHER INFORMATION: Clone ID: 27-LIB34-043-01-EI-G3

US-09-960-352-6361

Query Match

Best Local Similarity 30.2%; Score 30.2; DB 10; Length 420;

Matches 50; Conservative 0; Mismatches 33; Indels 0; Gaps 0;

Db 17 TGCATCATGAGGAAACAGGGTTCTGTGTGAGAACCATCTGTGAGATCTTACATCT 76

Db 29 TCCTTTGCAATGGGAATTCGATCTGTGGAGGTTCCATGCTTAATGAAAAATGG 88  
OY 77 TCCTAACGGAGCCCACTGCTC 99  
Db 89 TTGTAAGTGCAGCCCACTGCATC 111

RESULT 12  
US-09-738-626-1340/C

Sequence 1340, Application US/09738626  
Publication No. US20020197605A1  
GENERAL INFORMATION:  
APPLICANT: MAKAGAWA, SATOSHI  
APPLICANT: MIZOGUCHI, HIROSHI  
APPLICANT: ANDO, SEIKO  
APPLICANT: HAYASHI, MIKIRO  
APPLICANT: OCHIAI, KEIKO  
APPLICANT: YOKOI, HARUHIKO  
APPLICANT: TATEISHI, NAOKO  
APPLICANT: SENOH, AKIHIRO  
APPLICANT: IKEDA, MASATO  
APPLICANT: OZAKI, AKIO  
TITLE OF INVENTION: NOVEL POLYNUCLEOTIDES  
FILE REFERENCE: 249-125  
CURRENT APPLICATION NUMBER: US/09/738,626  
CURRENT FILING DATE: 2000-12-18  
PRIOR APPLICATION NUMBER: JP 99/377484  
PRIOR FILING DATE: 1999-12-16  
PRIOR APPLICATION NUMBER: JP 00/159162  
PRIOR FILING DATE: 2000-04-07  
PRIOR APPLICATION NUMBER: JP 00/280988  
PRIOR FILING DATE: 2000-08-03  
NUMBER OF SEQ ID NOS: 7059  
SOFTWARE: PatentIn ver. 3.0  
SEQ ID NO 1340  
LENGTH: 1674  
TYPE: DNA  
ORGANISM: Corynebacterium glutamicum  
US-09-738-626-1340

Query Match 29.8%; Score 29.8; DB 9; Length 1674;  
Best Local Similarity 66.2%; Pred. No. 0.14;  
Matches 43; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

OY 13 GCGCTGCTATCAATGAGAAACGAGGTTCTGTGAGAACCTTCTGAGCGAGTTC 72  
Db 714 GCGCTGCTCTCTCGAGGCTCTTACGCGAGGCTGCATGTTGAGCCCTCTGACCGATTC 655  
73 TACAT 77  
Db 654 GACGT 650

RESULT 13  
US-09-888-615-36

Sequence 36, Application US/09888615  
Patent No. US20020064856A1  
GENERAL INFORMATION:  
APPLICANT: PLOWMAN, GREGORY  
APPLICANT: WHITE, DAVID  
APPLICANT: CAENEPEL, SEAN  
APPLICANT: CHARYDCZAK, GLEN  
APPLICANT: MANNING, GERARD  
APPLICANT: SUDARSANAM, SUCHA  
TITLE OF INVENTION: NOVEL PROTEASES  
FILE REFERENCE: 038602/1214  
CURRENT APPLICATION NUMBER: US/09/888,615  
CURRENT FILING DATE: 2001-06-26  
PRIOR APPLICATION NUMBER: 60/214,047  
PRIOR FILING DATE: 2000-06-26  
NUMBER OF SEQ ID NOS: 150  
SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 36  
LENGTH: 1059  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-888-615-36

Query Match 29.6%; Score 29.6; DB 10; Length 1059;  
Best Local Similarity 64.7%; Pred. No. 0.14;  
Matches 44; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

OY 33 AAACGAGGTTCTGTGCGAATTCGAGCGAGTTCATCCTTAACGCGAGCCCA 92  
Db 264 AAGTGAACCTTCTGTGCGGCTCCTCAACAGTGTGATTCCTCATCTGCGCTCA 323  
OY 93 CTGCTCTCT 100  
Db 324 CTGCTTAT 331

RESULT 14  
US-09-755-016-5

Sequence 5, Application US/09755016  
Patent No. US20010034437A1  
GENERAL INFORMATION:  
APPLICANT: WAIKE, D. Wade  
APPLICANT: WILGANSKI, Nathaniel L.  
APPLICANT: Donoho, Gregory  
TITLE OF INVENTION: No. US20010034437A1 Human Proteases and Polynucleotides Enc  
FILE REFERENCE: LEX-0114-USA  
CURRENT APPLICATION NUMBER: US/09/755,016  
CURRENT FILING DATE: 2001-06-01  
PRIOR APPLICATION NUMBER: 60/174,686  
PRIOR FILING DATE: 2000-01-06  
NUMBER OF SEQ ID NOS: 7  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 5  
LENGTH: 867  
TYPE: DNA  
ORGANISM: Homo sapien  
US-09-755-016-5

Query Match 28.4%; Score 28.4; DB 10; Length 867;  
Best Local Similarity 70.4%; Pred. No. 0.36;  
Matches 38; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

OY 42 TTTCTGTGCGAATTCGAGCGAGTTCATCCTTAACGCGAGCCCACTG 95  
Db 135 TGTATGTGGGGAACCCCTAGTAGAGAGAGTGGTCCCTCAGACGCTGCCACTG 188

RESULT 15  
US-09-755-016-3

Sequence 3, Application US/09755016  
Patent No. US20010034437A1  
GENERAL INFORMATION:  
APPLICANT: WAIKE, D. Wade  
APPLICANT: WILGANSKI, Nathaniel L.  
APPLICANT: Donoho, Gregory  
TITLE OF INVENTION: No. US20010034437A1 Human Proteases and Polynucleotides Enc  
FILE REFERENCE: LEX-0114-USA  
CURRENT APPLICATION NUMBER: US/09/755,016  
CURRENT FILING DATE: 2001-06-01  
PRIOR APPLICATION NUMBER: 60/174,686  
PRIOR FILING DATE: 2000-01-06  
NUMBER OF SEQ ID NOS: 7  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 3  
LENGTH: 1047  
TYPE: DNA  
ORGANISM: Homo sapien  
US-09-755-016-3







enriched, double-stranded cDNA was digested with Not I and cloned into the Not I and Eco RV sites of the pCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies. Contact : Feng Liang Life Technologies, a division of Invitrogen 9800 Medical Center Drive Rockville, Maryland 20850, USA Fax : (1) 301 610 8371 Email : fliang@lifestech.com URL : http://fulllength.invitrogen.com

BASE COUNT 129 a 263 c 250 g 210 t 3 others

Query Match 92.6%; Score 92.6; DB 9; Length 855;  
Best Local Similarity 96.0%; Pred. No. 3.7e-22;  
Matches 95; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2 GTCGTACAGCCCTGCTCATCATGAGAAACGAGGTTCTGTGGGACCACTTC 61  
DB 672 GTCCCTGACAGCCCTGCTCATCATGAGAAACGAGGTTCTGTGGGACCACTTC 613  
QY 62 TGAGCGAGTTCTACATCTTAACGCGACCCACTGTCTCT 100  
612 TGAGCGAGTTCTACATCTTAACGCGACCCACTGTCTCT 574

RESULT 2  
AL576464/c 806 bp mRNA linear EST 16-FEB-2001  
LOCUS AL576464 LTI\_NFL006\_PL2 Homo sapiens cDNA clone CSDDI076YA10 3  
DEFINITION AL576464 prime, mRNA sequence.  
ACCESSION AL576464  
VERSION AL576464.1 GI:12938633  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1 (bases 1 to 806)  
Li, W.B., Gruber, C., Jesse, J. and Polyes, D.  
Full-length cDNA libraries and normalization  
Unpublished (2001)  
COMMENT Contact: Genoscope  
Genoscope - Centre National de Sequencage  
BP 191 91006 Evry cedex - France  
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr.

FEATURES  
source  
Location/Qualifiers  
1..806  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone="CSDDI076YA10"  
/clone\_lib="LTI\_NFL006\_PL2"  
/tissue\_type="Placenta"  
/note="Vector: pCMVSPORT 6; Site\_1: NotI; 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-stranded cDNA was digested with Not I and cloned into the Not I and Eco RV sites of the pCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies. Contact : Feng Liang Life Technologies, a division of Invitrogen 9800 Medical Center Drive Rockville, Maryland 20850, USA Fax : (1) 301 610 8371 Email : fliang@lifestech.com URL : http://fulllength.invitrogen.com"

BASE COUNT 124 a 251 c 239 g 188 t 4 others

Query Match 92.2%; Score 92.2; DB 9; Length 806;  
Best Local Similarity 94.9%; Pred. No. 4.9e-22;  
Matches 94; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 2 GTCGTACAGCCCTGCTCATCATGAGAAACGAGGTTCTGTGGGACCACTTC 61  
DB 692 GTCCCTGACAGCCCTGCTCATCATGAGAAACGAGGTTCTGTGGGACCACTTC 633  
QY 62 TGAGCGAGTTCTACATCTTAACGCGACCCACTGTCTCT 100

DB 632 TGAGCGAGTTCTACATCTTAACGCGACCCACTGTCTCT 594

RESULT 3  
LOCUS BE766639 246 bp mRNA linear EST 19-SEP-2000  
DEFINITION IL3-NT0105-200700-220-A03 NT0105 Homo sapiens cDNA, mRNA sequence.  
ACCESSION BE766639  
VERSION BE766639.1 GI:10196563  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1 (bases 1 to 246)  
Dias Neto, E., Garcia Correa, R., Verjovski-Almeida, S., Brlones, M.R., Nagai, M.A., da Silva, M. Jr., Zago, M.A., Bordin, S., Costa, F.F., Goldman, G.H., Carvalho, A.F., Matsukuma, A., Bala, G.S., Simpson, D.H., Brunstein, A., deoliveira, P.S., Bucher, P., Jongeneel, C.V., O'Hare, M.J., Soares, F., Brentani, R.R., Reis, L.F., de Souza, S.J. and Simpson, A.J.  
Shotgun sequencing of the human transcriptome with ORF expressed sequence tags  
Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)

TITLE  
JOURNAL  
MEDLINE  
COMMENT Contact: Simpson A.J.G.  
Laboratory of Cancer Genetics  
Ludwig Institute for Cancer Research  
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP, Brazil  
Tel: +55-11-2704922  
Fax: +55-11-2707001  
Email: asimpson@ludwig.org.br  
This sequence was derived from the FAPESP/LICR Human Cancer Genome Project. This entry can be found in the following URL  
(http://www.ludwig.org.br/scripts/gethtml2.pl?tl=IL3-NT0105-200700-220-A03&f3=2000-07-20&f4=1)  
Seq primer: puc 18 forward  
High quality seq. nce stop: 246.  
Location/Qualifiers  
1..246  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone\_lib="NT0105"  
/dev\_stage="Adult"

FEATURES  
source  
Location/Qualifiers  
1..246  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone\_lib="NT0105"  
/dev\_stage="Adult"

/note="Organ: nervous-tumor; Vector: puc18; Site\_1: SmaI; Site\_2: SmaI; A mini-library was made by cloning products derived from ORFESTS PCR (U.S. Letters Patent application No. 196,716 - Ludwig Institute for Cancer Research) profiles into the pUC 18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions."

BASE COUNT 59 a 70 c 73 g 44 t

Query Match 91.0%; Score 91; DB 12; Length 246;  
Best Local Similarity 94.9%; Pred. No. 6.8e-22;  
Matches 94; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 2 GTCGTACAGCCCTGCTCATCATGAGAAACGAGGTTCTGTGGGACCACTTC 61  
DB 116 GTCCCTGACAGCCCTGCTCATCATGAGAAACGAGGTTCTGTGGGACCACTTC 175  
QY 62 TGAGCGAGTTCTACATCTTAACGCGACCCACTGTCTCT 100  
DB 176 TGAGCGAGTTCTACATCTTAACGCGACCCACTGTCTCT 214

RESULT 4  
LOCUS R02602 329 bp mRNA linear EST 31-MAR-1995  
DEFINITION ye76a02.r1 Soares fetal liver spleen INFIS Homo sapiens cDNA clone

1

http://image.1hnl.gov	row: 9	column: 15
plate: WAM12711	row: 9	column: 15

```

/organism="Homo sapiens"
/db_xref="GDB:3794720"
/db_xref="taxon:9606"
/clone="IMAGE:245474"

```

269 c	300 g	160 t	3 others
81.6%, 95.0%, 0;	Score 81.6; Pred. No. 3.4e-16; Mismatches 4;	DB 9; Length 984; Indels 1;	Caps 1;

email: smith@email.marc.usda.gov  
Single pass sequencing. Bases called and alt.trimmed with phred  
v0.980904.e. Vector identified by cross\_match with the -mnscore 18  
and -mismatch 12 options.



0Y 14 CCGTGCATCATATGAGAAAAAGAGGGTTCTGTGGTGAACCATTTCTAGCGAGTTCT 73  
 1 CTTGGCTCATTAACGAAGACATGAAAGGTTCTGTGGGGGACCATCTTGAAATGAATTCT 60  
 0Y 74 ACATCCCAAGGAGCCCACTGTCTC 99



Thu Jan 16 09:32:18 2003

100396\_copy\_1\_100.rst

Page 8

Db 61 ACAFCCCTCACTGCTGCCCACTGCTC 86

Search completed: January 15, 2003, 21:18:51  
Job time : 1272 secs

## SUMMARIES

2181.620 Million cell updates/sec

Scoring table: IDENTITY\_NUC

Total number of hits satisfying chosen parameters: 4109280

```
Minimum DB seq length: 0
Maximum DB seq length: 2000000000
```

Post-processing:	Minimum Match	08
------------------	---------------	----

Listing first 45 summaries

Database

```

1:  genitor: *
2:  gb_da: *
3:  gb_hlg: *
4:  gb_in: *
5:  gb_om: *
6:  gb_ov: *
7:  gb_pat: *
8:  gb_ph: *
9:  gb_pl: *
10: gb_pro: *
11: gb_srs: *
12: gb_sys: *
13: gb_un: *
14: gb_vl: *
15: em_da: *
16: em_fun: *
17: em_hum: *
18: em_in: *
19: em_in: *
20: em_om: *
21: em_or: *
22: em_ov: *
23: em_pat: *
24: em_ph: *
25: em_pl: *
26: em_pro: *
27: em_srs: *
28: em_un: *
29: em_vl: *
30: em_hlg_hum: *
31: em_hlg_inv: *
32: em_hlg_other: *
33: em_hlg_oms: *
34: em_hlg_pln: *
35: em_hlg_rod: *
36: em_hlg_mam: *
37: em_hlg_vrt: *
38: em_sy: *
39: em_hlgo_hum: *
40: em_hlgo_oms: *
41: em_hlgo_other: *

```

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

## SUMMARIES

No.	Result	Score	Query Match	Length	DB	ID	Description
1	100	100.0	142	9	HMMEX7	L00396 Human facto	
2	100	100.0	132933	9	AL1337002	AL1337002 Human DNA	
3	98.4	98.4	29488	9	AF503510	AF503510 Homo sapi	
4	92.6	92.6	725	6	AR121387	AR121387 Sequence	
5	92.6	92.6	725	6	AR124119	AR124119 Sequence	
6	92.6	92.6	725	6	AX022601	AX022601 Sequence	
7	92.6	92.6	725	6	E36142	E36142 Chimeric se	
8	92.6	92.6	1126	6	AR095306	AR095306 Sequence	
9	92.6	92.6	1126	6	AR103990	AR103990 Sequence	
10	92.6	92.6	1126	6	HMMFX	K01866 Human facto	
11	92.6	92.6	1404	6	A93124	A93124 Sequence 15	
12	92.6	92.6	1414	9	HMMCFX	M22613 Human blood	
13	91.0	91.0	1443	9	HMMFXM	K03194 Human facto	
14	91.0	91.0	1447	6	A86859	A86859 Sequence 43	
15	91.0	91.0	1467	6	A86886	A86886 Sequence 26	
16	91.0	91.0	1467	6	AX082959	AX082959 Sequence	
17	91.0	91.0	1500	6	AR024194	AR024194 Sequence	
18	91.0	91.0	1507	9	HMMFACX	M57285 Human coagu	
19	66.8	66.8	20130	10	AE211347	AE211347 Mus muscu	
20	66.8	66.8	293880	2	AC127308	AC127308 Mus muscu	
21	64.4	64.4	1486	10	AE087644	AE087644 Mus muscu	
22	63.4	63.4	1491	10	MCMOACGULX	AJ226677 Mus muscu	
23	63.4	63.4	1537	4	BTCXXI	X00673 Bovine mRNA	
24	63.4	63.4	1554	6	A73583	A73583 Sequence 1	
25	63.4	63.4	1554	6	AR001423	AR001423 Sequence	
26	62.8	62.8	1925	10	BC003677	BC003677 Mus muscu	
27	61.8	61.8	1500	4	AF003200	AF003200 Oryctolag	
28	55.8	55.8	20947	5	AE519546	AE519546 Dario rer	
29	48.8	48.8	1497	5	CHNXPAT	X79807 R.nortvegicr	
30	42.8	42.8	2246	5	RRKAPR	D00844 Gallus gall	
31	42.6	42.6	1599	4	AE275654	AE275654 Ornithorh	
32	37.4	37.4	164533	2	AC129680	AC129680 Rattus no	
33	37.4	37.4	192453	2	AC129457	AC129457 Rattus no	
34	37.2	37.2	855	10	GPFFIXA	M6237 Guinea pig	
35	36.0	36.0	846	10	RAFFIXA	M6247 Rat factor	
36	36.0	36.0	852	6	MUSFIXA	M6256 Mouse facto	
37	36.0	36.0	1047	6	AX250084	AX250084 Sequence	
38	36.0	36.0	2637	10	MUSFIX	M23109 Mouse coagu	
39	36.0	36.0	219448	2	AL671984	AL671984 Mus muscu	
40	35.2	35.2	111516	5	AL672083	AL672083 Zebrafish	
41	34.4	34.4	1360	3	AY118979	AY118979 Drosophil	
42	34.4	34.4	95613	2	AC020389	AC020389 Drosophil	
43	34.4	34.4	155840	2	AC006495	AC006495 Drosophil	
44	34.4	34.4	139044	3	AC009394	AC009394 Drosophil	
45	34.4	34.4	224896	3	AE003721	AE003721 Drosophil	

## ALIGNMENTS

LOCUS	DEFINITION	ACCESSION	VERSION	KEYWORDS	SEGMENT	SOURCE	ORGANISM	REFERENCE
HUMEX7	HUMEX7	142 bp	DNA	linear	PRI 09-NOV-1996			
	Human factor X (blood coagulation factor) gene, exon 7.	L00396	M14327					
	L00396.1 GI:182828							
	Stuart factor; blood coagulation factor; factor X; glycoprotein; serine protease.							
	7 of 8							
	Homo sapiens (tissue library:: of Lawn et al., and Yoshitake et al.)							
	DNA.							
	Homo sapiens							
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;							
	Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.							
	1 (bases 1 to 142)							

AUTHORS Leytus, S. P., Foster, D. C., Kurachi, K. and Davie, E. M.  
 TITLE Gene for human factor X: a blood coagulation factor whose gene  
 organization is essentially identical with that of factor IX and  
 protein C  
 JOURNAL Biochemistry 25 (18), 5098-5102 (1986)  
 MEDLINE 87026600  
 PUBMED 3768336  
 COMMENT map + 13 + 130 factor Xa heavy chain.  
 FEATURES  
 source  
 1. 142  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /map="13q34"  
 /tissue="liver" of Law et al., and Yoshitake et al.  
 join(L00390.1:1..95,L00391.1:1..185,L00392.1:1..49,  
 L00393.1:1..138,L00394.1:1..156,L00395.1:1..269,1..130)  
 /gene="F10"  
 <1..12  
 /gene="F10"  
 /note="FX intron F"  
 13..130  
 /gene="F10"  
 /note="G00-119-890"  
 /number="7  
 131..>142  
 /note="FX intron G"  
 intron  
 38 a 35 c 38 g 31 t  
 BASE COUNT About 3.4 kb after segment 6; chromosome 13q34.  
 ORIGIN  
 Query Match 100.0%; Score 100; DB 9; Length 142;  
 Best Local Similarity 100.0%; Pred. No. 2,2e-24;  
 Matches 100; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 CGTCGTACAGAGCCCTCATCATCAATGAGAAACGAGGCTTCTGTGCGTGAACATT 60  
 Db 1 CGTCGTACAGAGCCCTCATCATCAATGAGAAACGAGGCTTCTGTGCGTGAACATT 60  
 Oy 61 CTGAGCAGATTCTACATCTTACAGCAGCCACCTGTCTCT 100  
 Db 61 CTGAGCAGATTCTACATCTTACAGCAGCCACCTGTCTCT 100

RESULT 2  
 AL137002 132933 bp DNA linear PRI 04-MAY-2001  
 LOCUS Human DNA sequence from clone RP11-98F14 on chromosome  
 AL137002 13q22.1-31.1, complete sequence.  
 ACCESSION AL137002.19 GI:13990998  
 VERSION  
 YNORDS  
 SOURCE human.  
 ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 TITLE 1 (bases 1 to 132933)  
 JOURNAL Bates, K.  
 COMMENT Direct Submission  
 Submitted (04-MAY-2001) Sanger Centre, Hinxton, Cambridgeshire,  
 CB10 1SA, UK. E-mail enquiries: humquerry@sanger.ac.uk  
 On May 8, 2001 this sequence was replaced by:13274222.  
 During sequence assembly data is compared from overlapping clones.  
 Where differences are found these are annotated as variations  
 together with a note of the overlapping clone name. Note that the  
 variation annotation may not be found in the sequence submission  
 corresponding to the overlapping clone, as we submit sequences with  
 only a small overlap as described above.  
 This sequence was finished as follows unless otherwise noted: all  
 regions were either double-stranded or sequenced with an alternate  
 chemistry or covered by high quality data (i.e., phred quality >= 30);  
 an attempt was made to resolve all sequencing problems, such  
 as compressions and repeats; all regions were covered by at least  
 one plasmid subclone or more than one X13 subclone; and the

assembly was confirmed by restriction digest. The following  
 abbreviations are used to associate primary accession numbers given  
 in the feature table with their source databases: Em, EMBL; Sw, SWISSPROT; Tr, TrEMBL; Wp, WORMPEP; Information on the WORMPEP  
 database can be found at  
<http://www.sanger.ac.uk/Projects/C.elegans/wormpep> This sequence  
 was generated from part of bacterial clone contigs of human  
 chromosome 13, constructed by the Sanger Centre Chromosome 13  
 Mapping Group. Further information can be found at  
<http://www.sanger.ac.uk/MGP/Chr13>  
 RP11-98F14 is from the library RP11-11.1 constructed by the group  
 of Pieter de Jong. For further details see  
<http://www.chori.org/bacpac/home.htm>  
 VECTOR: pBACE3.6  
 IMPORTANT: This sequence is not the entire insert of clone  
 RP11-98F14. It may be shorter because we sequence overlapping  
 sections only once, except for a 100 base overlap.  
 The true left end of clone RP11-98F14 is at 1 in this sequence. The  
 true left end of clone RP11-39H12 is at 132834 in this sequence.  
 The true right end of clone RP11-265C7 is at 123923 in this  
 sequence.

FEATURES  
 source  
 1..132933  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /chromosome="13"  
 /map="q22.1-31.1"  
 /clone="RP11-98F14"  
 /clone\_lib="RP11-11.1"  
 41..277  
 /note="Alu repeat: matches 1..229 of consensus"  
 377..472  
 /note="3 copies 32 mer 93% conserved"  
 901..1207  
 /note="AluSg repeat: matches 1..307 of consensus"  
 1483..1912  
 /note="CpG island"  
 /evidence="not-experimental"  
 1399..2164  
 /note="MER58A repeat: matches 19..167 of consensus"  
 2703..2861  
 /note="LIM3 repeat: matches 118..34 of consensus"  
 4371..4978  
 /note="38 copies 16 mer 78% conserved"  
 4374..4981  
 /note="19 copies 32 mer 87% conserved"  
 6373..6448  
 /note="2 copies 38 mer 93% conserved"  
 6411..6563  
 /note="3 copies 51 mer 93% conserved"  
 6565..6669  
 /note="3 copies 35 mer 85% conserved"  
 6612..6687  
 /note="2 copies 38 mer 98% conserved"  
 6672..6773  
 /note="2 copies 51 mer 93% conserved"  
 8852..8923  
 /note="4 copies 18 mer 81% conserved"  
 8854..8988  
 /note="15 copies 9 mer cccgagacc 63% conserved"  
 8860..8943  
 /note="3 copies 28 mer 83% conserved"  
 8920..9059  
 /note="4 copies 35 mer 75% conserved"  
 8927..9056  
 /note="5 copies 26 mer 69% conserved"  
 8935..9002  
 /note="4 copies 17 mer 95% conserved"  
 8984..9037  
 /note="3 copies 18 mer 90% conserved"  
 9427..9530  
 /note="4 copies 26 mer 92% conserved"  
 10204..10602

```

repeat_region /note="7 copies 57 mer 87% conserved"
11050. .11091
repeat_region /note="2 copies 21 mer 100% conserved"
11469. .11823
repeat_region /note="LMC1 repeat: matches 5862. .6231 of consensus"
1157. .13200
repeat_region /note="LMR5 repeat: matches 690. .733 of consensus"
13806. .14155
repeat_region /note="5 copies 70 mer 82% conserved"
15491. .15973
misc_feature /note="CpG island"
/evidence=not_experimental
repeat_region /note="2 copies 47 mer 87% conserved"
16278. .16371
repeat_region /note="2 copies 47 mer 87% conserved"
16956. .17159
repeat_region /note="4 copies 51 mer 95% conserved"
19411. .19587
repeat_region /note="3 copies 59 mer 79% conserved"
20202. .20342
repeat_region /note="3 copies 47 mer 96% conserved"
20473. .20564
repeat_region /note="L2 repeat: matches 2602. .2693 of consensus"
20816. .21894
misc_feature /note="CpG island"
/evidence=not_experimental
repeat_region /note="LM4 repeat: matches 3584. .3686 of consensus"
24570. .24680
repeat_region /note="LM4 repeat: matches 1. .311 of consensus"
24681. .24999
repeat_region /note="LM4 repeat: matches 3686. .4029 of consensus"
25000. .25306
repeat_region /note="LM4 repeat: matches 3686. .4029 of consensus"
25311. .25620
repeat_region /note="LM4 repeat: matches 1. .311 of consensus"
25345. .25989
misc_feature /note="CpG island"
/evidence=not_experimental
repeat_region /note="LM4 repeat: matches 3584. .3686 of consensus"
25755. .26053
repeat_region /note="LM4 repeat: matches 1. .304 of consensus"
27585. .27688
repeat_region /note="4 copies 26 mer 74% conserved"
27733. .27981
repeat_region /note="LM4 repeat: matches 9. .282 of consensus"
29431. .29498
repeat_region /note="MER81 repeat: matches 4. .72 of consensus"
29553. .29870
repeat_region /note="LM4 repeat: matches 1. .309 of consensus"
30907. .31396
repeat_region /note="7 copies 70 mer 64% conserved"
30908. .31432
repeat_region /note="15 copies 35 mer 61% conserved"
30911. .31412
repeat_region /note="251 copies 2 mer 99 61% conserved"
30938. .31413
repeat_region /note="17 copies 28 mer 61% conserved"
30973. .31420
repeat_region /note="14 copies 32 mer 61% conserved"
30987. .31385
repeat_region /note="7 copies 57 mer 64% conserved"
31000. .31080
misc_feature /note="Sequence from uni-directional dGMP big dye
terminator reads only."
31043. .31413
repeat_region /note="7 copies 53 mer 63% conserved"
31078. .31415
repeat_region /note="13 copies 26 mer 62% conserved"
31136. .31417
repeat_region /note="6 copies 47 mer 66% conserved"
31152. .31421
repeat_region /note="9 copies 30 mer 61% conserved"
31153. .31267
misc_feature /note="Single clone region. Sequence from reads from a
short insert library derived from a single pUC clone.
Restriction digest data confirm the assembly."
31175. .31426
repeat_region /note="12 copies 21 mer 61% conserved"
31268. .31411
repeat_region /note="9 copies 16 mer 64% conserved"
31268
misc_feature /note="Tandem repeat. Forced join. Gap size estimated to
be approximately 350bp by restriction digest data."
31882. .32952
repeat_region /note="21 copies 51 mer 89% conserved"
31884. .32937
repeat_region /note="62 copies 17 mer 89% conserved"
31896. .35863
misc_feature /note="CpG island"
/evidence=not_experimental
repeat_region /note="28 copies 70 mer 54% conserved"
31982. .33941
repeat_region /note="28 copies 70 mer 54% conserved"
32243. .32434
repeat_region /note="6 copies 32 mer 64% conserved"
32271. .32535
repeat_region /note="5 copies 53 mer 64% conserved"
32883. .32952
repeat_region /note="2 copies 35 mer 92% conserved"
33336. .33475
repeat_region /note="4 copies 35 mer 70% conserved"
33367. .33893
Query Match 100.0%; Score 100; DB 9; Length 132933;
Best Local Similarity 100.0%; Pred. No. 3.5e-24;
Matches 100; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CGTCTGTACAGAGCCCTGTCTATCATCATGAGGAAACAGAGGTTCTGTGTGACCATTT 60
Db 72010 CGTCTGTACAGAGCCCTGTCTATCATCATGAGGAAACAGAGGTTCTGTGTGACCATTT 72069
Qy 61 CTGAGCGAGTTTCTATCATCTACGCGAGCCCATCTGTCT 100
Db 72070 CTGAGCGAGTTTCTATCATCTACGCGAGCCCATCTGTCT 72109
RESULT 3
AF503510 29488 bp DNA linear PRI 22-MAY-2002
LOCUS Homo sapiens coagulation factor X (F10) gene, complete cds.
DEFINITION AF503510
ACCESSION AF503510
VERSION AF503510.1 GI:20336662
KEYWORDS
SOURCE Homo sapiens.
ORGANISM Homo sapiens
Chordata; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 29488)
REFERENCE
1 Rieder, M.J., Armel, T.Z., Carrington, D.P., Chung, M.-W., Lee, K.L.,
Ozuna, M., Peil, C.L., Tsch, E.J., Yi, Q. and Nickerson, D.A.
Direct Submission
Submitted (17-APR-2002) Genome Sciences, University of Washington,
1705 NE Pacific, Seattle, WA 98195, USA
To cite this work please use: SeattleSNPs, NHLBI H66682 Program
for Genomic Applications, UW-FHCRC, Seattle, WA (URL:
http://pga.gs.washington.edu).
FEATURES
source
1. .29488
/organism="Homo sapiens"
/db_xref="taxon:9606"
152
/frequency="0.04"
/replace="c"
167
/frequency="0.01"
/replace="t"
370
/frequency="0.01"
/replace="a"
577
variation
variation
variation
variation
variation
variation

```

variation	/frequency="0.33" /replace="t"	variation	/frequency="0.04" /replace="a"
variation	671 /frequency="0.01" /replace="t"	variation	2527 /gene="F10" /frequency="0.12" /replace="c"
variation	713 /frequency="0.12" /replace="c"	variation	2757 /gene="F10" /frequency="0.04" /replace="g"
variation	851 /frequency="0.01" /replace="g"	misc_feature	2860..3410 /gene="F10"
variation	866 /frequency="0.02" /replace="a"	repeat_region	/note="region not scanned for variation"
variation	880 /frequency="0.05" /replace="c"	variation	3544..3975 /rpt_family="MALR" /rpt_type-dispersed
variation	1116 /frequency="0.79" /replace="a"	variation	3715 /gene="F10" /frequency="0.09" /replace="t"
variation	1169 /frequency="0.02" /replace="a"	variation	3740 /gene="F10" /frequency="0.39" /replace="g"
repeat_region	1189..1395 /rpt_family="MIR" /rpt_type-dispersed	variation	3977 /gene="F10" /frequency="0.01" /replace="c"
variation	1319..1324 /frequency="0.57" /replace="a"	variation	4100 /gene="F10" /frequency="0.01" /replace="t"
variation	1449 /frequency="0.48" /replace="c"	variation	4544 /gene="F10" /frequency="0.19" /replace="c"
variation	1451 /frequency="0.33" /replace="a"	repeat_region	4567..4967 /rpt_family="L2" /rpt_type-dispersed
variation	1612 /frequency="0.01" /replace="a"	variation	5128 /gene="F10" /frequency="0.01" /replace="g"
variation	1632 /frequency="0.01" /replace="t"	variation	5300 /gene="F10" /frequency="0.02" /replace="c"
gene	<1647..28346 /gene="F10"	variation	5413 /gene="F10" /frequency="0.13" /replace="c"
mRNA	join(<1647..1741,8269..8429,17274..17298,18174..18287,19736..19867,22668..22912,26198..26315,27735..28346) /gene="F10"	variation	5521 /gene="F10" /frequency="0.11" /replace="a"
CDS	/product="coagulation factor X" join(1672..1741,8269..8429,17274..17298,18174..18287,19736..19867,22668..22912,26198..26315,27735..28336) /gene="F10"	misc_feature	5540..5950 /gene="F10"
	/codon_start=1 /product="coagulation factor X" /protein_id="AAM19347.1" /db_xref="GI:20336663"	variation	5997 /note="region not scanned for variation"
	/translation="MGRIPIIVLISASIGLLGESLFIIRREANNIILAVIRANSF LEEMKGIHERCHEETSYEPAREVEDSDKTFENNKIKDDQETSFCQMGKCK DLGLGYCTCTCGEFGKNCLETPRKLSLWDGDCDCHERPNVSVCARGYTLADN DGLACIPTPGKQTLERRKRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDL DNGQNPQNLTRIVGQCKDGECPMQALLINENGFCGGTILSFYILTAH CLYQAKRRVRRGRDTEOERGEAVHE/EVYIKHNRTETQDFDIAYVRLTPTLE RNNVAPALCPEDNAESTLMTOKGIYS:RRTHEKRGOSTRLKMLEVPYVDRNSCL SSSFTITNMFRAGIDTKQEDACGDSG:PVYTFKDTYFTVTGI7SMGEGCARKKGYG IYTKVTAFLKWDKSMKTRGLPKAKSHA,EVITSSPLK"	variation	6098 /gene="F10" /frequency="0.03" /replace="a"
variation	1731 /gene="F10" /frequency="0.01" /replace="t"	variation	6110 /gene="F10" /frequency="0.01" /replace="c"
variation	2011 /gene="F10" /frequency="0.22" /replace="g"	variation	6445 /gene="F10" /frequency="0.06"
variation	2456 /gene="F10"		

variation /replace="c"  
6638. 6641  
/gene="F10"  
/frequency="0.99"  
repeat\_region /replace="a"  
6943. 7395  
/rpt\_family="ERV1"  
/rpt\_type="dispersed"  
repeat\_region /rpt\_family="Alu"  
7396. 7727  
/rpt\_type="dispersed"  
variation /rpt\_type="dispersed"  
7437  
/gene="F10"  
/frequency="0.01"  
/replace="a"  
repeat\_region /rpt\_family="ERV1"  
7728. 8145  
/rpt\_type="dispersed"  
variation /rpt\_type="dispersed"  
7742  
/gene="F10"  
/frequency="0.01"  
/replace="t"

Query Match 98.4%; Score 98.4; DB 9; Length 29488;  
Best Local Similarity 99.0%; Pred. No. 1.2e-23;  
Matches 99; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 GGTCTGCACAGGCGCCGTCATCATGAGAAAGAGGTTCTGTGTGAACATT 60  
DB 26186 GGTCTGCACAGGCGCCGTCATCATGAGAAAGAGGTTCTGTGTGAACATT 26245

OY 61 CTGAGCGAGTTCTACATCTTAACGCGAGCCCACTGTCTCT 100  
DB 26246 CTGAGCGAGTTCTACATCTTAACGCGAGCCCACTGTCTCT 26285

RESULT 4  
ARI21387  
LOCUS ARI21387 725 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 12 from patent US 6159722.  
ACCESSION ARI21387  
VERSION ARI21387.1 GI:14104963  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
FEATURES  
REFERENCE 1 (bases 1 to 725)  
AUTHORS Bode,W., Engh,R., Hopfner,K.-P., Huber,R. and Kopetzki,E.  
TITLE Chimeric serine proteases  
JOURNAL Patent: US 6159722-A 12 12-DEC-2000;  
LOCATION/Qualifiers  
source 1. 725  
BASE COUNT 172 a 198 c 216 g 139 t  
ORIGIN

Query Match 92.6%; Score 92.6; DB 6; Length 725;  
Best Local Similarity 96.0%; Pred. No. 1e-21;  
Matches 95; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 2 GTCGTGCACAGGCGCCGTCATCATGAGAAAGAGGTTCTGTGTGAACATT 61  
DB 65 GTCCTGCGAGGCGCCGTCATCATGAGAAAGAGGTTCTGTGTGAACATT 124

OY 62 TGAGCGAGTTCTACATCTTAACGCGAGCCCACTGTCTCT 100  
DB 125 TGAGCGAGTTCTACATCTTAACGCGAGCCCACTGTCTCT 163

RESULT 5  
ARI24119  
LOCUS ARI24119 725 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 12 from patent US 6171842.

ACCESSION ARI24119  
VERSION ARI24119.1 GI:1.109480  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 725)  
AUTHORS Bode,W., Engh,R., Hopfner,K.-P., Huber,R. and Kopetzki,E.  
TITLE Chimeric serine proteases  
JOURNAL Patent: US 6171842-A 12 09-JAN-2001;  
LOCATION/Qualifiers  
source 1. 725  
BASE COUNT 172 a 198 c 216 g 139 t  
ORIGIN

Query Match 92.5%; Score 92.6; DB 6; Length 725;  
Best Local Similarity 96.0%; Pred. No. 1e-21;  
Matches 95; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 2 GTCGTGCACAGGCGCCGTCATCATGAGAAAGAGGTTCTGTGTGAACATT 61  
DB 65 GTCCTGCGAGGCGCCGTCATCATGAGAAAGAGGTTCTGTGTGAACATT 124

OY 62 TGAGCGAGTTCTACATCTTAACGCGAGCCCACTGTCTCT 100  
DB 125 TGAGCGAGTTCTACATCTTAACGCGAGCCCACTGTCTCT 163

RESULT 7  
E36142  
LOCUS E36142 725 bp DNA linear PAT 18-JUN-2001  
DEFINITION Chimeric serine protease.  
ACCESSION E36142  
VERSION E36142.1 GI:13022520  
KEYWORDS JP 1999235173-A/12.  
SOURCE synthetic construct  
ORGANISM synthetic construct

REFERENCE 1 (bases 1 to 725)  
AUTHORS Bode,W., Engh,R., Kopetzki,E. and Hopfner,K.P.  
TITLE Chimeric serine proteases  
JOURNAL Patent: EP 0927764-A 12 07-JUL-1999;  
ROCHE DIAGNOSTICS GMBH (DE)  
LOCATION/Qualifiers  
source 1. 725  
BASE COUNT 172 a 198 c 216 g 139 t  
ORIGIN

Query Match 92.6%; Score 92.6; DB 6; Length 725;  
Best Local Similarity 96.0%; Pred. No. 1e-21;  
Matches 95; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 2 GTCGTGCACAGGCGCCGTCATCATGAGAAAGAGGTTCTGTGTGAACATT 61  
DB 65 GTCCTGCGAGGCGCCGTCATCATGAGAAAGAGGTTCTGTGTGAACATT 124

OY 62 TGAGCGAGTTCTACATCTTAACGCGAGCCCACTGTCTCT 100  
DB 125 TGAGCGAGTTCTACATCTTAACGCGAGCCCACTGTCTCT 163

REFERENCE 1 (bases 1 to 725)  
 AUTHORS Wolfran, B., Richard, E., Karl, P. H., Roler, H. and Erhard, K.  
 TITLE Chimeric serine protease  
 JOURNAL Patent: JP 1999235173-A 12 31-AUG-1999;  
 ROCHE DIAGNOSTICS GMBH

## COMMENT

OS Artificial Sequence  
 PN JP 1999235173-A/12  
 PD 31-AUG-1999  
 PE 03-DEC-1998 JP 1998343777  
 PR 03-DEC-1997 EP 97121232.9  
 PT WOLFRAN BODO, RICHARD ENGEL, KARL PATER HOFNER, ROBERT HYDRA, PI  
 ERHARD KOEPEL  
 PC C12N9/50, C12N1/21, C12N15/09, C12N9/50, C12N1/19, C12N1/21, PC  
 C12N1/19, PC  
 FH Key Location/Qualifiers  
 FT source 1..725  
 Location/Qualifiers

## FEATURES

1..725  
 Location/Qualifiers  
 /organism="synthetic construct"  
 /db\_xref="taxon:32630"

BASE COUNT 172 a 198 c 216 g 139 t  
 ORIGIN

Query Match 92.6%; Score 92.6; DB 6; Length 725;  
 Best Local Similarity 96.0%; Pred. No. 1e-21;  
 Matches 95; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2 GTCTGCACAGCCCTGCTCATCATGAGAAACAGAGGTTCTGTGTGAACCATTC 61  
 ||| |  
 DB 65 GTCCCTGGCAGGCCCTGCTCATCATGAGAAACAGAGGTTCTGTGTGAACCATTC 124

QY 62 TGAGCGAGTTCTACATCTAACGGCAGCCACTGTCTCT 100  
 ||| |  
 DB 125 TGAGCGAGTTCTACATCTAACGGCAGCCACTGTCTCT 163

RESULT 8  
 LOCUS AR095306 1126 bp DNA linear PAT 08-SEP-2000  
 DEFINITION Sequence 27 from patent US 6004555.  
 ACCESSION AR095306  
 VERSION AR095306.1 GI:10023064  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 1126)  
 AUTHORS Thorpe, P. E. and Edgington, T. S.  
 TITLE Methods for the specific coagulation of vasculature  
 JOURNAL Patent: US 6004555-A 27 21-DEC-1999;  
 FEATURES  
 source 1..1126  
 Location/Qualifiers  
 /organism="unknown"

BASE COUNT 269 a 341 c 342 g 174 t  
 ORIGIN

Query Match 92.6%; Score 92.6; DB 6; Length 1126;  
 Best Local Similarity 96.0%; Pred. No. 1e-21;  
 Matches 95; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2 GTCTGCACAGCCCTGCTCATCATGAGAAACAGAGGTTCTGTGTGAACCATTC 61  
 ||| |  
 DB 395 GTCCCTGGCAGGCCCTGCTCATCATGAGAAACAGAGGTTCTGTGTGAACCATTC 454

QY 62 TGAGCGAGTTCTACATCTAACGGCAGCCACTGTCTCT 100  
 ||| |  
 DB 455 TGAGCGAGTTCTACATCTAACGGCAGCCACTGTCTCT 493

RESULT 9

## AR103990

LOCUS AR103990 1126 bp DNA linear PAT 14-FEB-2001  
 DEFINITION Sequence 27 from patent US 6093399.  
 ACCESSION AR103990  
 VERSION AR103990.1 GI:12816698  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 1126)  
 AUTHORS Thorpe, P. E. and Edgington, T. S.  
 TITLE Methods and compositions for the specific coagulation of  
 vasculature  
 JOURNAL Patent: US 6093399-A 27 25-JUL-2000;  
 FEATURES  
 source 1..1126  
 Location/Qualifiers  
 /organism="unknown"

BASE COUNT 269 a 341 c 342 g 174 t  
 ORIGIN

Query Match 92.6%; Score 92.6; DB 6; Length 1126;  
 Best Local Similarity 96.0%; Pred. No. 1e-21;  
 Matches 95; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2 GTCTGCACAGCCCTGCTCATCATGAGAAACAGAGGTTCTGTGTGAACCATTC 61  
 ||| |  
 DB 395 GTCCCTGGCAGGCCCTGCTCATCATGAGAAACAGAGGTTCTGTGTGAACCATTC 454

QY 62 TGAGCGAGTTCTACATCTAACGGCAGCCACTGTCTCT 100  
 ||| |  
 DB 455 TGAGCGAGTTCTACATCTAACGGCAGCCACTGTCTCT 493

## RESULT 10

LOCUS HUMFX 1126 bp mRNA linear PRI 08-NOV-1994  
 DEFINITION Human factor X mRNA.  
 ACCESSION K01886  
 VERSION K01886.1 GI:182820  
 KEYWORDS  
 SOURCE Stuart factor; factor X; serine protease.  
 ORGANISM Human liver, cDNA, clone lambda-X-1137.  
 Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 1126)  
 AUTHORS Leytus, S. P., Chung, D. W., Kistiel, W., Kurachi, K. and Davis, E. W.  
 TITLE Characterization of a cDNA coding for human factor X  
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 81 (12), 3699-3702 (1984)  
 MEDLINE 84222026  
 PUBMED 6587384

COMMENT In processing, factor X (Stuart factor) is converted to Xa by  
 cleavage of a glycopeptide from the amino-terminal end of the heavy  
 chain. It then acts as a serine protease in converting prothrombin  
 to thrombin.

FEATURES  
 source 1..1126  
 Location/Qualifiers  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /map="13q34"  
 1..1126  
 /gene="F10"  
 <1..1126  
 /gene="F10"  
 /product="factor X mRNA"  
 <1..1116  
 /gene="F10"  
 /note="factor X precursor peptide"  
 /codon\_start=1  
 /protein\_id="AA52486.1"  
 /db\_xref="GI:182821"  
 /db\_xref="GDB:G00-119-890"  
 /translation="GFEKNCLEFLTRKLSLDNGDCDOFCEBONSVCSCARGYTLA  
 DNGRACIPGYPGKOTLERRRKRSVAQATSSSEAPDSITWPRYDAADDPENPFD

gene  
 mRNA

CDS

Human factor X mRNA, partial signal peptide and complete mature peptide. 1443 bp. PRI 08-NOV-1997



ORGANISM	REFERENCE
Homo sapiens	MacGillivray, R.T.A. (bases 1 to 2)
Eukaryota: Metazoa: Chordata: Craniata: Vertebrata: Euteleostomi: Mammalia: Eutheria: Primates: Catarrhini: Homnidae: Homo.	MacGillivray, R.T.A. (bases 3 to 1443)
REFERENCE	2 (bases 3 to 1443)
AUTHORS	Fung, M.R., Hay, C.W. and MacGillivray, R.T.
REFERENCE	Characterization of an almost full-length cDNA coding for human blood coagulation factor X
TITLE	Proc. Natl. Acad. Sci. U.S.A. 82 (11), 3591-3595 (1985)
JOURNAL	85156545
MEDLINE	2582420
PUBMED	During conversion of factor X to factor X-a, a glycopeptide of 5
COMMENT	

FEATURES	Location/Qualifiers
SOURCE	1. 1443

```

gene      1. .1443
          /gene="F10"
mRNA      <1. .1443
          /gene="F10"
          /product="X mRNA"
CDS       1. .1433

```

CDS

```

/note="factor X prepeptide"
/codon_start=3
/protein_id="AA52490.1"
/db_xref="GI:182841"
/db_xref="GDB:G00-119-890"
/translation="SIAGLILGSLFRRPQANNILARYTARNSPLEEMKGLERE
CMETCSYEEARVEFPEDSDKTNFENMRYK. GDQCEYSCUNQGCKRSDGLRYPTCLE
GFEEKNCLELFRKLCSLDNGCDQDFCHEQNSVSCARGTTLADNGKACIPGPYPC
KQPLERKRKSVQAQATSSSGEAPASITWKPDPADADLPETNPDLILPNOQPRGON
NLTVLQGOEBCKDCECPMOALLINEENGFCGAILSEFYLLTPAAHCLYQAKRKVRN
GDRNTEDEGEAEVAHEVEVVIKHNRFETETDPDIAVLRLLKPTLTERNNVADPLCP
DMASTLMTOKTGIVSGRGTRHEKGROSTRALKMLFVYPYDNSCKLSSFIITQNMCC
AGYPTKDEDCAGDGGSGPHVTRFKDTYFVTGIVSGECSCKARKTGITTKVATLMDI
DRSKTRLLPRKAKSHAPVITVTSPLK"
<1..86
/gene="F10"
/note="factor X signal peptide"
87..503
/gene="F10"
/product="factor X light chain"
513..1430
/gene="F10"
/product="factor X heavy chain"
1117
/gene="F10"
/note="a in pchX8; t in pchX5"
361 a 416 c 435 g 231 t
BASE COUNT 24 bp upstream of Avar1 site.
ORIGIN

```

Query Match	91.0%;	Score 91;	DB 9;	Length 1443;
Best Local Similarity	94.9%;	Pred. No. 3.9e-21;		
Matches	94;	Conservative	0;	Mismatches 5;
				Indels 0;
				Gaps 0;
QY	2	GTCTGTCAAGGCGCCCTGCATCATCATGAGAGAAAGAGGGTTCTGTGTGTGACCATTC	61	
DB	703	GTCCCTGCAGAGCCCTGCTCATCATGAGAGAAAGAGGGTTCTGTGTGACCATTC	762	
QY	62	TGAGGAGTTCTACATCTCTAACGCGACCCCATGTCTCT	100	
DB	763	TGAGCGAGTTCTACATCTCTAACGCGACCCCATGTCTCT	801	

	RESULT	14			
A86859	LOCUS	A86859	1467 bp	DNA	Linear
	DEFINITION	Sequence 43 from Patent WO9838318.			PAT 22-JAN-2000
	ACCESSION	A86859			
	VERSION	A86859.1	GI:6735650		
	KEYWORDS	.			
SOURCE	ORGANISM	unidentified.			
		unidentified			
		unclassified.			
REFERENCE		1 (bases 1 to 1467)			
	AUTHORS	Falkner, F. and Himmelspach, M.			
	TITLE	FACTOR X DELETION MUTANTS AND ANALOGUES THEREOF			
JOURNAL		Patent: WO 9838318-A 43 03-SEP-1998;			
		FALKNER WALO GUENTER (AT); HIMMELSPACH MICHELE (AT)			
FEATURES		Location/Qualifiers			
source		1..1467			
		/organism="unidentified"			
		/db_xref="taxon:32644"			
CDS		1..1467			

```

/note="unamed protein product"
/codon_start=1
/protein_id="CAB69367.1"
/db_xref="GI:6735651"
/translation="MGRPLHLVLLASLAGILLGSESLFIRREQANNILARVTRANSF
LEBKCKHLRECEMEETCSYEAREFVDSQRTFENPNKYKDGQCEFSPOANGKCE
GLDEYKCTCLGEPFGKNKCLFTPRKILCSLNDGDCDCEHONSVCSGARGYTLAND
GKACITPTGPPCGKQTLERKRKRYAOKATSSSGEAPDSITTKTPYAAADLPDENFDLL
DFNQTQPERGNDNLITRIVGGQEKDGEPCWALLINENBSFCGGLITSEYIILTAHAF
CLYAKRPERKXVAGDRNTEQEEGGEAVHVEVYIHNHFTETETYPFDIAVLNLTPIFEF
RMNAPACILPERMDAESTLMTOKTGIYSGFRTIEKRSQSLRMLLEVYPYDRNSCKRI
SSSLITQNMCECAGYDTRKODACOGDSCGSPVTRPKDTYFPTGIVMSGECARCKYTG
IYTVTAFLMKIDRSMTKGLPKAKSHAPVITYSPLK"
BASE COUNT      363 a      424 c      444 g      236 t
ORIGIN

```

Query Match	91.0%	Score 91	DB 6	Length 1467
Best Local Similarity	94.9%	Pred. No. 3.9e-21		
Matches	94	Conservative 0	Mismatches 5	Indels 0
			Gaps 0	
QY	2	GNCTGCACAGCCCTCGTCATCATCATGAGAGAAAGAGGGTTCTGTGTGGACCATTC	61	
DB	737	GTCCCTGGCAGGCCCTGGCTCATCAATGAGAGAAACGAGGTTCTGTGTGGACCATTC	796	
QY	62	TGAGCGAGTTCTACATCCCTAACGCGAGCCACCTGTCTCT	100	
DB	737	TGAGCGAGTTCTACATCCCTAACGCGAGCCACCTGTCTCT	835	

```

RESULT 15
AB6886 LOCUS 1467 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 26 from Patent WO9838317.
ACCESSION AB6886
VERSION AB6886.1 GI:6735677
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Himel|spach,M. and Eibl,J.
TITLE FACTOR X ANALOGUES WITH A MODIFIED PROTEASE CLEAVAGE SITE
JOURNAL Patent: WO 9838317-A 26 03-SEP-1998;
HIMEL|SPACH MICHELE (AT); EIBL JOHANN (AT)
FEATURES
source
1..1467 Location/Qualifiers
/organism="unidentified"
/db_xref="taxon:32644"
1..1467
/note="unnamed protein product"
/codon_start=1
/protein_id="CAB69368.1"

```

```

CDS
1..1467
/note="unnamed protein p
/codon_start=1
/protein_id="CAB69368.1


```

/db.xref="GI:6735678"  
 /translation="MGRPLHLVILSLASLALIGESLPIRROANNILARVTRANSF  
 LEEMKGHLERECEMEETCYEEAREVEFEDSKTNEFWNKIKDSDOCEISPCOQGRCK  
 DGLGEYTCLELGEFEGKNCLEFTRKLSLNDGCDQFCHEDONSVCSCARGYTLADN  
 GKACIPGPYPGCKQTLERKRKSVQAOTSSSGEAPDSITWKPYDADLDPTENPDL  
 DFNQTOBERGDNMLTRIVGQECCKDECPMALLINENEGFCGTLISEFYILTAH  
 CLYQAKRFKRVGDRNTBOEGGEAVHEVEVYIKHNRFKREYDPIAVIRLKTPTTF  
 RMNVAPACLPERDMABESTLMTOKTGIYSGRPTHEKROSTRILKMLEVPTVDNSCKL  
 SSSFIITQNNFCAGYDITKODACGDSGSGPHVTRFKDTIFVTGIVSMGESCARRGKYG  
 IYTKVTHFLMIDRSMKTRGLPRAKSHAPVITSSPLK"

BASE COUNT 363 a 424 c 444 g 236 t  
 ORIGIN

Query Match 91.0%; Score 91; DB 6; Length 1467;  
 Best Local Similarity 94.9%; Pred. No. 3.9e-21;  
 Matches 94; Conservative 0; Mismatches 5; Indels 0; Gaps 0;  
 OY 2 GTCGTGACAGGCCCTGCTCATCAATGAGGAAAGAGGGTTCTGTGTGAACCATTC 61  
 737 GTCCCTGGCAGGCCCTGCTCATCAATGAGGAAAGAGGGTTCTGTGTGAACCATTC 796  
 62 TGACGAGTCTCATCTAAGGACGCCACCTCTCT 100  
 Db 797 TGACGAGTCTCATCTAAGGACGCCACCTCTCT 835

Search completed: January 15, 2003, 20:35:36  
 Job time : 1354 secs



**ORIGINAL  
COPY**

GenCore version 5.1.3  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 15, 2003, 17:50:20 : Search time 151 Seconds

(without alignments)  
1491.390 Million cell updates/sec

Title: L00396\_COPY\_1\_100

Perfect score: 100

Sequence: 1 CGTCTGTACAGGCCCTGCT.....AACGACAGCCCACTGCTCT 100

Scoring table: IDENTITY NUC

Gapop 10.0, Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

N\_Geneseq\_101002.\*  
1: /SID2/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.\*  
2: /SID2/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.\*  
3: /SID2/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.\*  
4: /SID2/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.\*  
5: /SID2/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.\*  
6: /SID2/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.\*  
7: /SID2/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.\*  
8: /SID2/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.\*  
9: /SID2/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.\*  
10: /SID2/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.\*  
11: /SID2/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.\*  
12: /SID2/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.\*  
13: /SID2/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.\*  
14: /SID2/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.\*  
15: /SID2/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.\*  
16: /SID2/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.\*  
17: /SID2/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.\*  
18: /SID2/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.\*  
19: /SID2/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.\*  
20: /SID2/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.\*  
21: /SID2/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.\*  
22: /SID2/gcgdata/geneseq/geneseq-emb1/NA2001.DAT.\*  
23: /SID2/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.\*  
24: /SID2/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	100	100.0	236	21	AAC70863
2	99.6	99.6	236	21	AAC70866
3	92.6	92.6	725	20	AA78022
4	92.6	92.6	1126	20	AA15427
5	92.6	92.6	1126	21	AA89786
6	92.6	92.6	1126	21	AA12970
7	92.6	92.6	1126	21	AA56120
8	92.6	92.6	1404	19	AAV10462
9	92.6	92.6	1560	22	AA24735

10	92.6	92.6	1860	22	AA24738
11	91	91.0	1467	19	AAV56776
12	91	91.0	1467	19	AAV56821
13	91	91.0	1467	21	AA59409
14	91	91.0	1507	21	AA54031
15	91	91.0	1887	22	AA57469
16	75.2	75.2	591	22	AAK30368
17	63.4	63.4	1554	15	AAQ71243
18	36	36.0	1028	21	AAA61561
19	34.4	34.4	1250	23	ABL12391
20	34.4	34.4	3250	23	ABL13694
21	34.4	34.4	9594	23	ABL13694
22	34.2	34.2	689	18	AA779127
23	34.2	34.2	1189	22	AA602556
24	34.2	34.2	1305	22	AA602556
25	34.2	34.2	1479	22	AA602557
26	34.2	34.2	1795	22	AA626880
27	34.2	34.2	1854	22	AA899574
28	34.2	34.2	2038	20	AA871554
29	34.2	34.2	2063	21	AA870959
30	34.2	34.2	2063	22	AA870959
31	34.2	34.2	2063	22	AA870959
32	34.2	34.2	2063	22	AA870959
33	34.2	34.2	2063	22	AA870959
34	34.2	34.2	2063	22	AA870959
35	34.2	34.2	2063	22	AA870959
36	34.2	34.2	2063	22	AA870959
37	34.2	34.2	2063	22	AA870959
38	34.2	34.2	2063	22	AA870959
39	33.8	33.8	2864	23	ABL28901
40	32.8	32.8	180	21	AA89010
41	32.6	32.6	2137	22	AA89010
42	32	32.0	817	22	AA89010
43	32	32.0	866	23	AA89010
44	32	32.0	864	19	AA89010
45	32	32.0	864	19	AA89010

#### ALIGNMENTS

RESULT 1	
ID	AAC70863
AC	AAC70863
XX	09-FEB-2001 (first entry)
XX	Single nucleotide polymorphism containing sequence #231.
XX	Single nucleotide polymorphism; SNP; human; genetic disease;
XX	disease susceptibility; cardiovascular system; endocrine system;
XX	neurological system; forensic testing; paternity testing; ds.
XX	Homo sapiens.
XX	MO200058519-A2.
XX	05-CCT-2000.
XX	30-MAR-2000; 2000MO-US08440.
XX	31-MAR-1999; 99US-0127248.
XX	(WHED) WHITEHEAD INST BIOMEDICAL RES.
XX	(AFET-) AFFETRIX INC.
XX	Alshuler D, Cargill M, Daley GQ, Ireland JS, Lander ES;
XX	Lipshutz RJ, Patil N, Sklar P,
XX	WPI; 2000-611722/58.

Nucleotide sequenc  
Human Factor X gen  
Human Factor X gen  
Human factor X nuc  
Human factor X cod  
Human liver cell s  
Human G-protein-co  
Serine protease fo  
CDNA encoding mous  
Drosophila melanog  
Drosophila melanog  
Drosophila melanog  
Human serine prote  
Protease D-G catay  
Human seripancrin  
Human seripancrin  
Human CDNA encodin  
Human proteinase BUP  
Human Prol1570 (UNQ  
Human DNA encoding  
Human Prol1570 CDNA  
DNA encoding prote  
CDNA encoding tumo  
Human Transmembran  
CvA8 CDNA. Homo s  
Human serine prote  
Drosophila melanog  
Drosophila melanog  
Cavea sp. factor I  
Human membrane-tyr  
Drosophila melanog  
Drosophila melanog  
Flea serine proteas  
Flea serine proteas

PT Nucleic acid selected from one of 106 genes comprising single  
 PT nucleotide polymorphisms, allele-specific oligonucleotides to the genes  
 PT are useful for phenotypic correlations, forensics, paternity testing,  
 PT medicine and genetic analysis -  
 PS Claim 1; Fig 5; 214pp; English.

CC The present invention is concerned with a number of human single  
 CC nucleotide polymorphisms (SNPs) which the inventors identified in human  
 CC genes. These SNPs can be used in disease diagnosis and prediction of an  
 CC individual's susceptibility to disease, in forensic and paternity testing  
 CC and in genetic mapping. In particular, the SNPs of the invention can be  
 CC used to diagnose susceptibility to diseases of the cardiovascular,  
 CC endocrine and neurological systems, such as coronary artery disease,  
 CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's  
 CC diseases.  
 CC Note: The degenerate codon within the sequence represents the position  
 CC of an SNP, for example the letter S represents a polymorphism where the  
 CC nucleotide may be C or G.

Q Sequence 236 BP; 54 A; 66 C; 67 G; 47 T; 2 other;  
 Query Match 100.0%; Score 100; LB 21; Length 236;  
 Best Local Similarity 100.0%; Pred. No. 1.1e-25;  
 Matches 100; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGTCTGTCACAGGCCCTGCTCATCATGAGGAAACGAGGGTTCTGTGCGAACCATT 60  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 DB 54 CGTCTGTCACAGGCCCTGCTCATCATGAGGAAACGAGGGTTCTGTGCGAACCATT 113  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||

QY 61 CTGAGCGAGTTCTACATCTTAACGCGACGCCACCTGTCTCT 100  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 DB 114 CTGAGCGAGTTCTACATCTTAACGCGACGCCACCTGTCTCT 153  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||

RESULT 2  
 AAC70866  
 ID AAC70866 standard; DNA; 236 BP.  
 AC AAC70866;  
 XX  
 DT 09-FEB-2001 (first entry)  
 XX  
 DE Single nucleotide polymorphism containing sequence #232.  
 XX  
 KW Single nucleotide polymorphism; SNP; human; genetic disease;  
 KW disease susceptibility; cardiovascular system; endocrine system;  
 KW neurological system; forensic testing; paternity testing; ds.  
 XX  
 XX Homo sapiens.  
 A WO200058519-A2.  
 PN  
 XX  
 PD 05-OCT-2000.  
 XX  
 PF 30-MAR-2000; 2000WO-US08440.  
 XX  
 PR 31-MAR-1999; 99US-0127248.  
 XX  
 PA (WHEED) WHITEHEAD INST BIOMEDICAL RES.  
 PA (AFFY-) AFFYMETRIX INC.  
 XX  
 PI Altschuler D, Gargill M, Daley GO, Ireland JS, Lander ES,  
 PI Lipshutz RJ, Patil N, Sklar P;  
 XX  
 DR WPI; 2000-611722/58.  
 XX  
 PT Nucleic acid selected from one of 106 genes comprising single  
 PT nucleotide polymorphisms, allele-specific oligonucleotides to the genes  
 PT are useful for phenotypic correlations, forensics, paternity testing,  
 PT medicine and genetic analysis -  
 PS Claim 1; Fig 5; 214pp; English.

XX The present invention is concerned with a number of human single  
 CC nucleotide polymorphisms (SNPs) which the inventors identified in human  
 CC genes. These SNPs can be used in disease diagnosis and prediction of an  
 CC individual's susceptibility to disease, in forensic and paternity testing  
 CC and in genetic mapping. In particular, the SNPs of the invention can be  
 CC used to diagnose susceptibility to diseases of the cardiovascular,  
 CC endocrine and neurological systems, such as coronary artery disease,  
 CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's  
 CC diseases.  
 CC Note: The degenerate codon within the sequence represents the position  
 CC of an SNP, for example the letter S represents a polymorphism where the  
 CC nucleotide may be C or G.

SQ Sequence 236 BP; 54 A; 66 C; 67 G; 47 T; 2 other;  
 Query Match 99.6%; Score 99.6; DB 21; Length 236;  
 Best Local Similarity 99.0%; Pred. No. 1.6e-25;  
 Matches 99; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGTCTGTCACAGGCCCTGCTCATCATGAGGAAACGAGGGTTCTGTGCGAACCATT 60  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 DB 54 CGTCTGTCACAGGCCCTGCTCATCATGAGGAAACGAGGGTTCTGTGCGAACCATT 113  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||

QY 61 CTGAGCGAGTTCTACATCTTAACGCGACGCCACCTGTCTCT 100  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 DB 114 CTGAGCGAGTTCTACATCTTAACGCGACGCCACCTGTCTCT 153  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||

RESULT 3  
 AAX78022  
 ID AAX78022 standard; DNA; 725 BP.  
 AC AAX78022;  
 XX  
 DT 19-AUG-1999 (first entry)  
 XX  
 DE Chimeric serine protease FXT DNA.  
 XX  
 KW Serine protease; chim rlc; antithrombotic; modulator; drug design;  
 KW 3-D crystal structure; crystallization; hematopoietic cascade;  
 KW FXT; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN EP927764-A2.  
 XX  
 PD 07-JUL-1999.  
 XX  
 PF 27-NOV-1998; 98EP-0122481.  
 XX  
 PR 03-DEC-1997; 97EP-0121232.  
 XX  
 PA (HOFF) ROCHE DIAGNOSTICS GMBH.  
 XX  
 PI Bode W, Engh R, Hopfner K, Huber R, Kopetzki E;  
 XX  
 DR WPI; 1999-359878/31.  
 DR P-PSDB; AAY08894.  
 XX  
 PT Chimeric serine protease comprising Factor X and Trypsin catalytic  
 PT domains, useful for identifying thrombolytic agents  
 XX  
 PS Example 2; Fig 2; 23pp; German.

CC This invention describes a novel chimeric serine protease compound which  
 CC has antithrombotic activity and comprises two domains with a beta-sheet  
 CC structure. The first domain corresponds to the first domain of a first  
 CC serine protease and the second domain corresponds to the second domain  
 CC of a second serine protease. The products of the invention can be used  
 CC for identifying antithrombotic agents by determining whether an agent  
 CC modulates the activity of the serine protease. They can also be used to  
 CC identify agents through rational drug design using information based on

CC its 3-D crystal structure. The chimeric serine protease, is very good  
CC for crystallization and for determining structural data and is also  
CC useful for the identification of specific antithrombotic agents that  
CC unlike prior art agents are extremely specific for only one factor in a  
CC haemostatic cascade.

SO Sequence 725 BP; 172 A; 198 C; 216 G; 139 T; 0 other;

Query Match 92.6%; Score 92.6; DB 20; Length 725;  
Best Local Similarity 96.0%; Pred. No. 6.6e-23;  
Matches 95; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 2 GTCGTGCACAGCCCTGCTCATCATGAGAAAGAGGTTCTGTGTGAACCATTC 61

DB 65 GTCCCTGGCAGCCCTGCTCATCATGAGAAAGAGGTTCTGTGTGAACCATTC 124

OY 62 TGAGCGAGTTCTACATCCTTAACGCGAGCCCACTGTCTCT 100

DB 125 TGAGCGAGTTCTACATCCTTAACGCGAGCCCACTGTCTCT 163

RESULT 4  
AA15427  
ID AA15427 standard; DNA; 1126 BP.

AA15427;

05-MAY-1999 (first entry)

DNA encoding coagulation factor X/Xa.

Truncated tissue factor; tissue factor binding ligand; coagulation;  
disease-associated vasculature; tumour; benign prostatic hyperplasia;  
diabetic-retinopathy; vascular restenosis; arteriovenous malformation;  
AVM; meningioma; hemangioma; neovascular glaucoma; psoriasis; synovitis;  
dermatitis; endometriosis; angiodioma; rheumatoid arthritis;  
atherosclerotic plaque; corneal graft neovascularisation;  
haemophilic joint; hypertrophic scar; Osler-Weber syndrome;  
pyogenic granuloma; retrolental fibroplasia; scleroderma; trachoma;  
vascular adhesion; coagulation factor; factor X/Xa; ss.

OS Homo sapiens.

US5877289-A.

02-MAR-1999.

07-JUN-1995; 95US-0479733.

07-JUN-1995; 95US-0479733.

05-MAR-1992; 92US-0846349.

02-MAR-1994; 94US-0205330.

11-JUL-1994; 94US-0273567.

(SCRI) SCRIpps RES INST.

(TEXA) UNIV TEXAS SYSTEM.

Edgington TS, Thorpe PE;

WPI; 1999-189722/16.

Tissue factor binding ligands - comprising first binding region

which binds to vasculature, particularly of tumours, and tissue

factor construct

Example 9; Columns 129-132; 83pp; English.

CC hyperplasia, diabetic-retinopathy, vascular restenosis, arteriovenous  
CC malformations (AVM), meningioma, hemangioma, neovascular glaucoma,  
CC psoriasis, synovitis, dermatitis, endometriosis, angiodioma, rheumatoid  
CC arthritis, atherosclerotic plaques, corneal graft neovascularisation,  
CC haemophilic joints, hypertrophic scars, Osler-Weber syndrome, pyogenic  
CC granuloma retrolental fibroplasia, scleroderma, trachoma, or vascular  
CC adhesions. The products can also be used in binding assays.

SO Sequence 1126 BP; 269 A; 341 C; 342 G; 174 T; 0 other;

Query Match 92.6%; Score 92.6; DB 20; Length 1126;  
Best Local Similarity 96.0%; Pred. No. 7.5e-23;  
Matches 95; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 2 GTCGTGCACAGCCCTGCTCATCATGAGAAAGAGGTTCTGTGTGAACCATTC 61

DB 395 GTCCCTGGCAGCCCTGCTCATCATGAGAAAGAGGTTCTGTGTGAACCATTC 454

OY 62 TGAGCGAGTTCTACATCCTTAACGCGAGCCCACTGTCTCT 100

DB 455 TGAGCGAGTTCTACATCCTTAACGCGAGCCCACTGTCTCT 493

RESULT 5

AAA89786  
ID AAA89786 standard; DNA; 1126 BP.

AAA89786;

14-DEC-2000 (first entry)

DNA encoding coagulation factor X/Xa.

Tissue factor protein; truncated tissue factor; tTF; cytostatic;  
coagulant; diabetic retinopathy; arteriovenous malformation;  
meningioma; hemangioma; neovascular glaucoma; psoriasis; synovitis;  
endometriosis; hemophilic joint; hypertrophic scar; vascular adhesion;  
tumour; cancer; ligand; human; factor X; ds.

OS Homo sapiens.

US6093399-A.

25-JUL-2000.

07-JUN-1995; 95US-0482369.

05-MAR-1992; 92US-0846349.

02-MAR-1994; 94US-0205330.

11-JUL-1994; 94US-0273567.

(SCRI) SCRIpps RES INST.

(TEXA) UNIV TEXAS SYSTEM.

Edgington TS, Thorpe PE;

WPI; 2000-531471/48.

New immunological and growth factor-based bispecific binding ligands,

useful for stimulating coagulation in vasculature-associated diseases,

e.g. for treating both benign and malignant diseases (e.g. meningioma

or hemangioma)

Example 9; Column 129-130; 83pp; English.

CC The present invention relates to a binding ligand with a first binding  
CC region that is operatively linked to either a coagulation factor or a  
CC second binding region that binds to a coagulation factor. The first  
CC binding region binds to a component on the surface of a tumour. The  
CC second binding region is all or part of an antibody. An example of a  
CC coagulation factor for use in the invention is human truncated tissue  
CC factor. Truncated tissue factor (tTF) is the extracellular domain of the  
CC mature tissue factor protein (see AAB15019). The binding ligand of the

CC invention is useful for stimulating coagulation in vasculature  
 CC associated diseases. Particularly, the binding ligand is useful for  
 CC treating both benign and malignant diseases that have a vascular  
 CC component. These diseases include benign growths (e.g. BPH), diabetic  
 CC retinopathy, arteriovenous malformations, meningioma, hemangioma,  
 CC neovascular glaucoma, psoriasis, synovitis, endometriosis, hemophylia  
 CC joints, hypertrophic scars or vascular adhesions. The present binding  
 CC ligands offer the advantage that even limited damage to the tumour  
 CC vasculature could produce an avalanche of tumour cell death because  
 CC each capillary provides oxygen and nutrients for thousands of tumour  
 CC cells. The present sequence is DNA encoding coagulation factor  
 CC X/Xa. This factor was used in the invention.

SO Sequence 1126 BP; 269 A; 341 C; 342 G; 174 T; 0 other;

Query Match 92.6%; Score 92.6; DB 21; Length 1126;  
 Best Local Similarity 96.0%; Pred. No. 7.5e-23;  
 Matches 95; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 2 GTCGTGACAGGCCCTGCTCATCATGAGGAAACGAGGTTCTGTGTGAACCATTC 61  
 395 GTCCTGAGAGGCTGCTCATCATGAGGAAACGAGGTTCTGTGTGAACCATTC 454  
 OY 62 TGAGCGAGTTCTACATCTTAACGCGAGCCCACTGTCTCT 100  
 455 TGAGCGAGTTCTACATCTTAACGCGAGCCCACTGTCTCT 493

## RESULT 6

AAA12970  
 ID AAA12970 standard; DNA; 1126 BP.

AC AAA12970;

DF 18-JUL-2000 (first entry)

DE DNA encoding Factor X/Xa, SEQ ID NO:27.

XX Truncated tissue factor; tTF; human; blood coagulation;

KW Tumour vasculature; bispecific antibody; targeting; cancer;

KX Vascularised tumour; PCR primer; ss.

OS Homo sapiens.

PN US6036955-A.

PD 14-MAR-2000.

PF 07-JUN-1995; 95US-0479727.

PR 05-MAR-1992; 92US-0846349.

PR 02-MAR-1994; 94US-0205330.

PR 11-JUL-1994; 94US-0273567.

PA (TEXA ) UNIV TEXAS SYSTEM.

PA (SCTR ) SCRIPPS RES INST.

XX Edgington TS, Thorpe PE;

XX WPI; 2000-269871/23.

XX Kit for inducing coagulation in tumor vasculature, useful for treating

PT malignant or benign growths, contains ligand, linked to coagulation

PT agent, that targets tumor marker

XX Example 9; Columns 131-132; 86pp; English.

CC The invention relates to the induction of blood coagulation specifically

CC within tumour vasculature. This is achieved by the use of a bispecific

CC molecule, which comprises a region capable of binding to intratumoral

CC vascular or stromal cells linked to a coagulation factor or to a region

CC capable of binding to a coagulation factor. An example of such a

CC bispecific molecule is a bispecific antibody, where one arm binds a

CC tumour antigen, and the other arm binds a coagulation factor. The  
 CC expression of certain proteins (tumour antigens) is upregulated in  
 CC tumour vasculature, such proteins include vascular endothelial growth  
 CC factor (VEGF) and members of the fibroblast growth factor (FGF) family.  
 CC An antibody or antibody fragment against VEGF or basic FGF (bFGF) may be  
 CC incorporated into the bispecific molecule in order to target coagulation  
 CC to tumour vasculature. The coagulation factor-binding portion of the  
 CC bispecific molecule may be, for example, directed to tissue factor (TF).  
 CC A preferred form of TF used in the invention is a truncated form (tTF,  
 CC AAY81488) which lacks the cytoplasmic and transmembrane domains.  
 CC Although tTF can associate with Factor VIIa, the tTF/Factor VIIa complex  
 CC cannot alone initiate the coagulation cascade as the complex has to be  
 CC associated with a phospholipid surface for coagulation to occur.  
 CC However, binding of tTF to tumour vasculature via a tumour antigen/tTF  
 CC membrane to enable the initiation of coagulation. Kits for the induction  
 CC of tumour vasculature-specific coagulation may be used to treat malignant  
 CC or benign diseases associated with a vascular component, particularly  
 CC cancers, but also benign growths, prostatic hypertrophy, restenosis,  
 CC psoriasis, glaucoma, rheumatoid arthritis. Coagulation is induced  
 CC selectively in the tumour vasculature, minimising side effects. Such kits  
 CC are likely to be effective against many different types of cancer.  
 CC Sequences AAA12945-AAA12952, AAA12954-AAA12965 and AAA12971-AAA12972  
 CC represent PCR primers used in exemplifications of the present invention  
 CC to generate constructs encoding tTF, tTF variants or tTF dimers.

SO Sequence 1126 BP; 269 A; 341 C; 342 G; 174 T; 0 other;

Query Match 92.6%; Score 92.6; DB 21; Length 1126;  
 Best Local Similarity 96.0%; Pred. No. 7.5e-23;  
 Matches 95; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 2 GTCGTGACAGGCCCTGCTCATCATGAGGAAACGAGGTTCTGTGTGAACCATTC 61  
 395 GTCCTGAGAGGCTGCTCATCATGAGGAAACGAGGTTCTGTGTGAACCATTC 454  
 OY 62 TGAGCGAGTTCTACATCTTAACGCGAGCCCACTGTCTCT 100  
 455 TGAGCGAGTTCTACATCTTAACGCGAGCCCACTGTCTCT 493

## RESULT 7

AAZ56120  
 ID AAZ56120 standard; DNA; 1126 BP.

AC AAZ56120;

DF 27-MAR-2000 (first entry)

DE Vitamin-K-dependent coagulation factor X/Xa coding sequence.

KW Vitamin-K dependent coagulation factor; tumour associated vasculature;

KW carcinoma; benign prostatic hyperplasia; diabetic retinopathy;

KW vascular restenosis; arteriovenous malformation; meningioma; haemangioma;

KW neovascular glaucoma; psoriasis; cytoskeletal; antidiabetic; vasotropic;

KW ophthalmological; antipsoriatic; Factor X/Xa; ss.

OS Unspecified.

PN US6004555-A.

PD 21-DEC-1999.

PF 07-JUN-1995; 95US-0487427.

PR 05-MAR-1992; 92US-0846349.

PR 02-MAR-1994; 94US-0205330.

PR 11-JUL-1994; 94US-0273567.

PA (SCTR ) SCRIPPS RES INST.

PA (TEXA ) UNIV TEXAS SYSTEM.

XX Edgington TS, Thorpe PE;



XX WPI; 2000-072047/06.

XX Bispecific binding ligands for promoting blood coagulation in a tumour  
XX associated vasculature are useful for treating cancer.

XX Example 9: Column 131-132; 83pp; English.

XX This is the coding sequence for Factor X/Xa, a vitamin-K-dependent  
XX coagulation factor. This coagulation factor can be used in the formation  
XX of coagulants. Mutated versions of this sequence can be used in the  
XX method for delivering a coagulant to a tumour-associated vasculature  
XX using bispecific binding ligands which promote blood coagulation. The  
XX binding ligand consists of a binding region that binds to a  
XX surface-expressed, surface accessible or surface-localised component of a  
XX tumour cell, intratumoural vasculature or tumour associated stroma. The  
XX binding region is linked to a coagulating agent which is a coagulation  
XX factor (e.g. tissue factor). The second binding region comprises an  
XX antibody or an antigen binding region of an antibody. The method is used  
XX for delivering an exogenous or an endogenous coagulation factor to  
XX tumour-associated vasculature which is benign or malignant. The method  
XX can be used to treat cancer by promoting specific blood coagulation in  
XX the vasculature of the tumour relative to the vasculature in nontumour  
XX sites. Vascularised tumours are usually solid tumours, particularly  
XX carcinomas which require a vascular component to provide oxygen and  
XX nutrients. The ligands are suitable to treat benign and malignant  
XX hyperplasia, diabetic retinopathy, vascular restenosis, arteriovenous  
XX malformations, meningioma, haemangioma, neovascular glaucoma and  
XX portomas. The ligands can also be used in standard binding assays in  
XX vitro. Bispecific ligands can also be designed which are capable of binding to  
XX vascular endothelial cells and disease-associated agents are similar in  
XX activated platelets. Certain disease-associated agents are similar in  
XX different diseases and in different tumours, making it possible to treat  
XX numerous diseases and different types of cancer with one pharmaceutical,  
XX therefore an agent does not need to be tailored to each individual  
XX disease or specific tumour type.

XX Sequence 1126 BP; 269 A; 341 C; 342 G; 174 T; 0 other;

XX Query Match 92.6%; Score 92.6; DB 21; Length 1126;

XX Best Local Similarity 96.0%; Pred. No. 7.5e-23;

XX Matches 95; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2 GTCTGTACAGGCGCTCTCATATGAGGAGGAGGTTCTGTGTGGAACCATTC 61  
DB 395 GTCTGTACAGGCGCTCTCATATGAGGAGGAGGTTCTGTGTGGAACCATTC 454  
Y 62 TGAGCGAGTTCTACATCTTAACGCGAGCCACTGTCTCT 100  
DB 455 TGAGCGAGTTCTACATCTTAACGCGAGCCACTGTCTCT 493

RESULT 8  
AAV10462  
ID AAV10462 standard; DNA; 1404 BP.

XX AAV10462:

XX 16-JUN-1998 (first entry)

XX Human Factor X protease cDNA.

XX Factor X; factor IX; serine protease activity; catalytic domain; ZAD;  
XX zymogen-activating domain; epidermal growth factor-like domain; EGFL;  
XX BGF2; regulator; coagulation; fibrinolysis; homeostasis; X-ray structure;  
XX detection; drug modelling; restriction protease; ss.

XX Homo sapiens.

XX Key Location/Qualifiers  
FH 1.1404  
FT CDS /tag= a

FT /product= Factor X  
FT /note= "partial coding sequence"

XX MO9747737-AL.

XX 18-DEC-1997.

XX 11-JUN-1997; 97MO-EP03027.

XX 06-JUL-1996; 96EP-0110959.

XX 11-JUN-1996; 96EP-0109288.

XX 22-JUN-1996; 96EP-0110109.

XX (BOEF) BOEHRINGER MANNHEIM GMBH.

XX Hopfner K, Kopetzki E;

XX WPI; 1998-052304/05.

XX P-PSDB; AAM40283.

XX Non-glycosylated, truncated forms of factor IX family protein with  
XX serine protease activity - used to screen for specific modulators  
XX and to assay factor IXa

XX Disclosure; Fig 3; 49pp; German.

XX This sequence encodes a human factor X protease. This protein is used  
XX in the construction of a novel non-glycosylated protein and truncated  
XX and zymogen forms of this protein, which have serine protease activity.  
XX The protein is composed of various domains from a factor IX family  
XX protein, namely a catalytic domain (CD), N-terminally bound to a  
XX zymogen-activating domain (ZAD), N-terminally bound to an EGFL and/or  
XX are used to identify activators/inhibitors of factor IX family proteins  
XX (potentially useful as regulators of coagulation, fibrinolysis and  
XX homeostasis). The protein in zymogen form is also useful in assays for  
XX detecting factor IXa activity in aqueous solution (specifically in body  
XX fluids). The protein can be used to produce co-crystals with protease  
XX variants or inhibitors for X-ray structural analysis and drug modelling  
XX and as restriction proteases in biotechnology. These truncated proteins  
XX have the same specificity as factor IX family proteases and can be  
XX produced in prokaryotes in a form that allows production of active enzyme  
XX by conversion to native form and enzymatic cleavage.

XX Sequence 1404 BP; 356 A; 404 C; 423 G; 221 T; 0 other;

XX Query Match 92.6%; Score 92.6; DB 19; Length 1404;

XX Best Local Similarity 96.0%; Pred. No. 8.1e-23;

XX Matches 95; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2 GTCTGTACAGGCGCTCTCATATGAGGAGGAGGTTCTGTGTGGAACCATTC 61  
DB 683 GTCTGTACAGGCGCTCTCATATGAGGAGGAGGTTCTGTGTGGAACCATTC 742  
QY 62 TGAGCGAGTTCTACATCTTAACGCGAGCCACTGTCTCT 100  
DB 743 TGAGCGAGTTCTACATCTTAACGCGAGCCACTGTCTCT 781

RESULT 9  
AAF24735

XX AAF24735 standard; DNA; 1560 BP.

XX AAF24735:

XX 20-APR-2001 (first entry)

XX Nucleotide sequence of Sig/CBD cex/BR retaining peptide fusion.

XX Protein production; food processing; protein antibiotic; feed enzyme;

XX protein L; CBD cex protein; cell signal peptide; ss.

XX Synthetic.



DT 27-NOV-1998 (first entry)  
 XX Human Factor X genomic DNA.  
 DE  
 XX Factor X; analogue; activation cleavage site; protease; bleeding; human;  
 KM Factor IX; Factor VII; Factor VIII; haemophilia; gene therapy; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT CDS 1..1467  
 FT /\*tag= a  
 FT /product= "Factor X"  
 FT sig\_peptide 1..120  
 FT /\*tag= b  
 FT mat\_peptide 121..1464  
 FT /\*tag= c  
 FT  
 PN WO9838317-A1.  
 X 03-SEP-1998.  
 XX  
 PF 27-FEB-1998; 98WO-AT00045.  
 XX  
 PR 27-FEB-1997; 97AT-0000335.  
 XX  
 PA (IMMO ) IMMUNO AG.  
 XX  
 PI Dörner F, Eibl J, Fisch A, Himmelspach M, Schlokot U;  
 XX  
 DR WPI; 1998-481211/41.  
 DR P-PSDB; AAM76216.  
 XX  
 PT New factor X analogues with processing site for protease not active  
 PT on natural protein - and related DNA, is very stable and can be  
 PT activated in vitro or in vivo without using animal protease(s),  
 PT particularly for treating disorders of blood coagulation  
 XX  
 PS Claim 3; Fig 1; 86pp; German.  
 XX  
 CC This sequence encodes the human Factor X protein which is used in a  
 CC method resulting in the production of novel human Factor X (F10)  
 CC analogues. Such analogues have in the region of the natural F10a  
 CC activation cleavage site, a modification that creates a processing site  
 CC for a protease that does not naturally cleave F10 in this region. The  
 CC proteins are used to generate, in vivo or in vitro, F10a analogues that  
 CC can be used to control bleeding and for treating defects of factors IX,  
 CC VII or VIII, e.g. in haemophiliacs who have developed antibodies to  
 CC factors VIII and/or IX. The encoding nucleic acid can be used in gene  
 CC therapy of the same conditions. The analogues have high stability and can  
 CC be activated without use of animal enzymes such as trypsin. Only  
 CC activation is affected, their activity is the same as the natural factor.  
 CC The analogues can be isolated as a pure single-chain pro-protein (not  
 CC usually possible because of rapid processing of the native precursor) and  
 CC this converted to two-chain form by subsequent activation. Activated  
 CC analogues have good stability and structural integrity and are  
 CC practically free of inactive intermediates and autoprolytic  
 CC decomposition products.  
 XX  
 SQ Sequence 1467 BP; 363 A; 424 C; 444 G; 236 T; 0 other;  
 XX  
 QY Query Match 91.0%; Score 91; DB 19; Length 1467;  
 DB Best Local Similarity 94.9%; Pred. No. 3e-22;  
 DB Matches 94; Conservative 0; Mismatches 5; Indels 0; gaps 0;  
 QY 2 GTCTGTCACAGCCCTCTCATCATGAGGAAACGAGGCTTCTGTGTGAACCATTC 61  
 DB 737 GTCCCTGCGACGCGCTCTCATCATGAGGAAACGAGGCTTCTGTGTGAACCATTC 796  
 QY 62 TGAGCGAGTTCTACATCTAAGCGACGACCATCTCTCT 100  
 DB 797 TGAGCGAGTTCTACATCTAAGCGACGACCATCTCTCT 835

RESULT 12  
 ID AAV56821  
 XX AAV56821 standard; DNA; 1467 BP.  
 AC AAV56821;  
 XX  
 DT 27-NOV-1998 (first entry)  
 XX  
 DE human Factor X genomic DNA.  
 XX  
 KM Factor X; analogue; activation cleavage site; protease; bleeding; human;  
 KM Factor IX; Factor VII; Factor VIII; haemophilia; gene therapy; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT CDS 1..1467  
 FT /\*tag= a  
 FT /product= "Factor X"  
 FT sig\_peptide 1..120  
 FT /\*tag= b  
 FT mat\_peptide 121..1464  
 FT /\*tag= c  
 FT  
 PN WO9838318-A1.  
 X 03-SEP-1998.  
 XX  
 PF 27-FEB-1998; 98WO-AT00046.  
 XX  
 PR 27-FEB-1997; 97AT-0000336.  
 XX  
 PA (IMMO ) IMMUNO AG.  
 XX  
 PI Dörner F, Eibl J, Falkner F, Himmelspach M, Pfeleiderer M;  
 XX  
 DR WPI; 1998-481212/41.  
 DR P-PSDB; AAM76218.  
 XX  
 PT New factor 10 deletion mutants lacking the natural protease  
 PT processing site - but having a non-natural site inserted, and  
 PT related DNA, particularly for in vitro activation to products used  
 PT to treat blood coagulation disorders  
 XX  
 PS Claim 3; Fig 1; 82pp; German.  
 XX  
 CC This sequence encodes the human Factor X protein which is used in a  
 CC method resulting in the production of novel human Factor X (F10)  
 CC analogues. Such analogues have in the region of the natural F10a  
 CC activation cleavage site, a modification that creates a processing site  
 CC for a protease that does not naturally cleave F10 in this region. The  
 CC proteins are used to generate, in vivo or in vitro, F10a analogues that  
 CC can be used to control bleeding and for treating defects of factors IX,  
 CC VII or VIII, e.g. in haemophiliacs who have developed antibodies to  
 CC factors VIII and/or IX. The encoding nucleic acid can be used in gene  
 CC therapy of the same conditions. The analogues have high stability and can  
 CC be activated without use of animal enzymes such as trypsin. Only  
 CC activation is affected, their activity is the same as the natural factor.  
 CC The analogues can be isolated as a pure single-chain pro-protein (not  
 CC usually possible because of rapid processing of the native precursor) and  
 CC this converted to two-chain form by subsequent activation. Activated  
 CC analogues have good stability and structural integrity and are  
 CC practically free of inactive intermediates and autoprolytic  
 CC decomposition products.  
 XX  
 SQ Sequence 1467 BP; 363 A; 424 C; 444 G; 236 T; 0 other;  
 XX  
 QY Query Match 91.0%; Score 91; DB 19; Length 1467;  
 DB Best Local Similarity 94.9%; Pred. No. 3e-22;  
 DB Matches 94; Conservative 0; Mismatches 5; Indels 0; gaps 0;

OY 2 GTCTGTCACAGGCCCTCTCTATCAATGAGAAAAAGAGGTTTCTGTGTGGAACCATTC 61  
 DB 737 GTCCCTGGCAGGCCCTCTCTATCAATGAGAAAAAGAGGTTTCTGTGTGGAACCATTC 796  
 OY 62 TGAGCGAGTTCTACATCTTAACGAGCCGACCTGTCTCT 100  
 DB 797 TGAGCGAGTTCTACATCTTAACGAGCCGACCTGTCTCT 835

## RESULT 13

AAF59409  
 ID AAF59409 standard; cDNA; 1467 BP.

AC AAF59409;

DT 02-MAY-2001 (first entry)

DE Human factor X nucleotide sequence SEQ ID NO:1.

XX Human; factor X; mutant; haemostatic; gene therapy; haemophilia;

XX blood coagulation disorder; haemophilia; ss.

XX Homo sapiens.

XX MO200110896-A2.

XX 15-FEB-2001.

XX 07-AUG-2000; 2000MO-EP07631.

XX 10-AUG-1999; 99AT-0001377.

XX (BAXT) BAXTER AG.

XX Himmelspach M, Schlokot U;

XX WPI; 2001-191516/19.

XX P-PSDB; AAB70411.

XX Novel factor X analog useful for producing drug which is useful for

XX treatment of blood coagulation disorders, such as hemophilia, contains

XX modification between amino acids Glu226 and Ile235

XX Disclosure; Fig 1; 50pp; English.

XX The present invention describes a factor X analogue (I) which contains

XX amino acid sequence given in AAB70411. (I) has haemostatic activity and

XX can be used in gene therapy. (I) encoding polypeptide (II) can be

XX used to produce a drug, which is useful for treatment of patients with

XX blood coagulation disorders, such as patients suffering from haemophilia,

XX or haemophilias with inhibitory antibodies. Preparations containing a

XX polypeptide with factor X/Xa activity are more readily activated by

XX factor Xa or its derivative, which has high stability, without having

XX to use one of the proteases used in prior art to activate the natural

XX factor X, particularly one of animal origins, such as Russell's viper

XX venom (RVV) or trypsin. The present sequence encodes human factor X,

XX which is given in the exemplification of the present invention.

XX Sequence 1467 BP; 363 A; 424 C; 444 G; 236 T; 0 other;

XX Query Match 91.0%; Score 91; DB 22; Length 1467;

XX Best Local Similarity 94.9%; Pred. No. 3e-22;

XX Matches 94; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

RESULT 14  
 ID AAF54031  
 XX AAF54031 standard; DNA; 1507 BP.

XX AAF54031;

XX 08-FEB-2001 (first entry)

XX Human factor X coding sequence.

XX Vitamin K dependent protein; VKDP; gamma-carboxylation; chimeric

XX protein; fusion protein; coagulation factor; Factor X; Factor VII;

XX protein S; Factor IX; Protein C; prothrombin; blood clotting;

XX haemophilia; human; de

XX Homo sapiens.

XX WO200054787-A1.

XX 21-SEP-2000.

XX 16-MAR-2000; 2000MO-US06934.

XX 16-MAR-1999; 99US-0124609.

XX (CHIL-) CHILDRENS HOSPITAL, PHILADELPHIA.

XX (UYNC-) UNIV NORTH CAROLINA.

XX High KA, Camire RM, Larson PJ, Stafford DW;

XX WPI; 2000-638152/61.

XX Chimeric DNA for optimizing gamma carboxylation of vitamin K-dependent

XX protein useful for treating diseases associated with the protein, the

XX protein comprises sequence encoding propeptide fused to sequence encoding the

XX protein

XX Disclosure; Fig 6a; 60pp; English.

XX Efficient processing and release of mature two-chain factor X into

XX the circulation requires: removal of the signal sequence; formation

XX of disulfide bonds; modification of amino terminal glutamic acid

XX residues, to gamma-carboxyglutamic acid; modification of one

XX aspartic acid in the first epidermal growth factor (EGF) domain to

XX beta-hydroxyaspartic acid; addition of N- and O-linked

XX oligosaccharides to the activation peptide; removal of an internal

XX tripeptide to yield two-chain factor X and removal of the

XX propeptide just prior to secretion. While some of these modifications

XX do not appear essential for factor X function the removal of the

XX signal sequence, propeptide, internal tripeptide and full

XX gamma-carboxylation are all steps which are important requisites for

XX the production of biologically active factor X/FXa. Isolated chimeric

XX polynucleotides are described which encode a propeptide fused to a

XX nucleic acid sequence encoding a vitamin K-dependent protein (VKDP).

XX The fusion proteins encoded are vitamin K-dependent protein

XX gamma-carboxylation enhancers and are useful for optimising the

XX VKDP. The fusion proteins and recombinant cells expressing them are

XX useful for alleviating a VKDP associated disease. The fusion

XX constructs result in the production of fully gamma-carboxylated

XX mature VKDPs, which are biologically active. The invention

XX encompasses all combinations of propeptide sequences (modified or

XX not) and VKDP's. This sequence encodes the signal, propeptide and

XX mature protein sequence of human factor X.

XX Sequence 1507 BP; 394 A; 429 C; 446 G; 238 T; 0 other;

XX Query Match 91.0%; Score 91; DB 21; Length 1507;

XX Best Local Similarity 94.9%; Pred. No. 3e-22;

XX Matches 94; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

XX 2 GTCTGTCACAGGCCCTCTCTATCAATGAGAAAAAGAGGTTTCTGTGTGGAACCATTC 61

DB 737 GTCCCTGGCGCCCTCTATCATAGAGAAACGAGGGTTCTGTGGACATATTC 796  
QY 62 TGAGCGAGTTCTACATCTAACGCGACCCACTGTCTCT 100  
DB 797 TGAGCGAGTTCTACATCTAACGCGACCCACTGTCTCT 835

RESULT 15  
AAH57469

ID AAH57469 standard; cDNA; 1887 BP.

XX AAH57469;

DT 10-SEP-2001 (first entry)

DE Human liver cell specific cDNA sequence SEQ ID NO:309.

KW Human; tissue specific; diagnosis; brain; heart; skeletal muscle;

lung; liver; uterus; ovary; stomach; intestine; kidney; pancreas; ss;  
metabolic disease; developmental disease; cytostatic; immunomodulatory;  
neuroprotective; gene therapy; cancer; immunopathology; neuropathology.

OS Homo sapiens.

PN WO200132927-A2.

PD 10-MAY-2001.

PF 02-NOV-2000; 2000WO-US30396.

PR 04-NOV-1999; 99US-0163508.

XX (INCY-) INCYTE GENOMICS INC.

PI Sornasse T, Seilhamer JJ, Watson GA;

DR WPI; 2001-291057/30.

PT New cell and tissue specific polynucleotides useful for diagnosis,  
prognosis or monitoring of treatments for disorders where the gene is  
associated with a cancer, immunopathology or neuropathology -

PS Claim 1; Page 233; 327pp; English.

CC AAH57161 to AAH57576 represent cell and tissue specific polynucleotide  
sequences (I). (I) can have cytosolic, immunomodulatory and  
neuroprotective activities, and can be used in gene therapy. (I) and  
proteins (II) encoded by them are used in high throughput screening  
assays to select DNA molecules, RNA molecules, peptide nucleic acids,  
mimetics, peptides, proteins, agonists, antagonists, antibodies or  
their fragments, immunoglobulins, inhibitors, drug compounds and  
pharmaceutical agents. Expression of (I) in a sample indicates the  
differentiation of embryonic stem cells into a tissue selected from  
brain, heart, kidney, liver, lung, skeletal muscle or pancreatic  
tissues. (I) and (II) are used to produce an expression profile that  
defines a metabolic or developmental process, treatment, condition,  
disease or disorder. The gene profile can be used for diagnosis,  
prognosis or monitoring of treatments and for investigating a  
predisposition to a disorder where the gene is associated with a  
cancer, immunopathology or neuropathology.

CC Sequence 1887 BP; 467 A; 549 C; 544 G; 327 T; 0 other;

Query Match 91.0%; Score 91; DB 22; Length 1887;

Best Local Similarity 94.9%; Pred No. 3.3e-22;

Matches 94; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 2 GTCTGTACAGGCCCTGTCTATCATAGAGAAACGAGGGTTCTGTGTGACCATATTC 61

DB 792 GTCCCTGGCGCCCTCTATCATAGAGAAACGAGGGTTCTGTGTGACCATATTC 851

QY 62 TGAGCGAGTTCTACATCTAACGCGACCCACTGTCTCT 100

DB 852 TGAGCGAGTTCTACATCTAACGCGACCCACTGTCTCT 890

Search completed: January 15, 2003, 19:50:17  
Job time: 153 secs

1	92.6	92.6	725	3	US-09-197-801-12	Sequence 12, App1
2	92.6	92.6	725	4	US-09-551-028-12	Sequence 12, App1
3	92.6	92.6	1126	2	US-08-479-733A-27	Sequence 27, App1
4	92.6	92.6	1126	3	US-08-487-427-27	Sequence 27, App1
5	92.6	92.6	1126	3	US-08-479-727A-27	Sequence 27, App1
6	92.6	92.6	1126	3	US-08-482-369A-27	Sequence 27, App1
7	92.6	92.6	1126	5	PCT-US95-07439-27	Sequence 27, App1
8	92.6	92.6	1404	4	US-09-202-101-15	Sequence 15, App1
9	91	91.0	1500	1	US-08-487-037-4	Sequence 4, App1
10	75.2	75.2	591	4	US-09-280-116-138	Sequence 138, App1
11	63.4	63.4	1554	1	US-08-469-486-1	Sequence 1, App1
12	63.4	63.4	1554	2	US-08-469-658-1	Sequence 1, App1
13	34.2	34.2	2038	4	US-09-008-271A-18	Sequence 18, App1
14	34.2	34.2	2079	4	US-09-656-002-1	Sequence 1, App1
15	32	32.0	864	3	US-08-906-769-138	Sequence 138, App1
16	32	32.0	864	3	US-08-906-616-138	Sequence 138, App1
17	32	32.0	864	3	US-08-639-075A-138	Sequence 138, App1
18	32	32.0	864	4	US-09-012-431-138	Sequence 138, App1
19	32	32.0	864	4	US-09-012-692-138	Sequence 138, App1
20	32	32.0	864	4	US-08-906-613-138	Sequence 138, App1
21	30.8	30.8	855	3	US-08-906-769-130	Sequence 130, App1
22	30.8	30.8	855	3	US-08-906-616-130	Sequence 130, App1
23	30.8	30.8	855	3	US-08-639-075A-130	Sequence 130, App1
24	30.8	30.8	855	4	US-09-012-431-130	Sequence 130, App1
25	30.8	30.8	855	4	US-09-012-692-130	Sequence 130, App1
26	30.8	30.8	855	4	US-08-906-613-130	Sequence 130, App1
27	29.4	29.4	758	3	US-08-906-769-126	Sequence 126, App1

45	28	28.0	1389	4	US-09-202-101-16	Sequence 16, App
44	28.8	28.8	258	5	PCT-US05-14442A-52	Sequence 52, App
43	28.8	28.8	258	4	US-08-906-613-52	Sequence 52, App
42	28.8	28.8	258	4	US-09-012-692-52	Sequence 52, App
41	28.8	28.8	258	4	US-09-012-431-52	Sequence 52, App
40	28.8	28.8	258	3	US-08-639-075A-52	Sequence 52, App
39	28.8	28.8	258	3	US-08-485-443B-52	Sequence 52, App
38	28.8	28.8	258	3	US-08-817-795-52	Sequence 52, App
37	28.8	28.8	258	3	US-08-906-615-52	Sequence 52, App
36	28.8	28.8	258	2	US-08-906-765-52	Sequence 52, App
35	28.8	28.8	258	2	US-08-484-211C-52	Sequence 52, App
34	28.8	28.8	258	2	US-08-482-139C-52	Sequence 52, App
33	28.8	28.8	258	1	US-08-485-445D-52	Sequence 52, App
32	29.4	29.4	758	4	US-08-906-613-126	Sequence 126, App
31	29.4	29.4	758	4	US-09-012-692-126	Sequence 126, App
30	29.4	29.4	758	4	US-09-012-431-126	Sequence 126, App
29	29.4	29.4	758	3	US-08-639-075A-126	Sequence 126, App
28	29.4	29.4	758	3	US-08-906-616-126	Sequence 126, App

## ALIGNMENTS

RESULT 1  
US-09-197-801-12

Sequence 12, Application US/09197801E  
Patent No. 6159722

**GENERAL INFORMATION**

APPLICANT: Hopfner, Karl-Peter

APPLICANT: Bode, Wolfram  
APPLICANT: Huber, Robert

FILE REFERENCE: 20119

CURRENT FILING DATE: 1998-11-23

```

; NUMBER OF SEQ ID NOS: 15
SOFTWARE: PatentIn ver. 2.0

```

```

; SEQ ID NO 12
;
; LENGTH: 725

```

ORGANISM: *Homo sapiens*

US-09-197-801-12

**Query Match**

Best Local Similarity 96.0%; Pred. No. 4e-25;  
Matches 95; Conserved 0; Mismatch 4; Indels 0; Cans 0

2 GATCTGTCACAGGCCTCATTCAATCAATCAAGCAAAACCGCTTCTTCGTAACAACATAA 67

Db 65 GTCCCTGGCAGGCCTCTCATCATGAGGAAACGAGGTTCTGTGTGGAAACCATTC 124

62 TGAGCGAGTTCATACATCCTAACGGCAGCCCACTGTCTCT 100

Db 125 TGAGCGAGTCTACATCCTAACGGCAGCCCACTGTCTCT 163

US-09-551-028-12

; Patent NO. 6171842

APPLICANT: Kopetzki, Erhard

APPLICANT: Engh, Richard

APPLICANT: Huber, Robert  
TITLE OF INVENTION: Chemicals Containing Proteins

FILE REFERENCE: 20119  
CURRENT APPLICATION NUMBER: NS/09/551 028

PRIOR APPLICATION NUMBER: US/09/197.801

OY 2 GTCTGTACAGAGGCCCTGCTCATTCATGAGAAAACGAGGGTTTCTGTGTGGAACCATTC 61  
||| | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||

```

: Sequence#7, Application US/08479/27A
: Patent No. 6036955
:
: GENERAL INFORMATION:
:
: APPLICANT: Thorpe, Philip E.
: TITLE OF INVENTION: Methods and Compositions for the
: TITLE OF INVENTION: Specific Coagulation of Vascuature

```

```

1 FILING DATE: 07-JUN-1995
2 CLASSIFICATION: 424
3 PRIOR APPLICATION DATA:
4 APPLICATION NUMBER: US 08/273,567
5 FILING DATE: 11-JUL-1994
6 ATTORNEY/AGENT INFORMATION:
7 NAME: Parker, David L.
8 REGISTRATION NUMBER: 32,165
9 REFERENCE/DOCKET NUMBER: UTSD:433/PAR
10 TELECOMMUNICATION INFORMATION:
11 TELEPHONE: 512/418-3000
12 TELEFAX: 512/474-7577
13 TELEX: N/A
14 INFORMATION FOR SEQ ID NO: 27:
15 SEQUENCE CHARACTERISTICS:
16 LENGTH: 1126 base pairs
17 TYPE: nucleic acid
18 STRANDEDNESS: single
19 TOPOLOGY: linear
20 US-08-482-369A-27
21
22 Query Match
23 Best Local Similarity 92.6%; Score 92.6; DB 3; Length 1126;
24 Matches 95; Conservative 0; Mismatches 4; Indels 0; Gaps 0
25
26 QY 2 GTCCTCAGACAGCCCGTCATCATGAGAAAGAGGCTTCGTGTGAACCATTC 61
27 ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
28 DB 395 GTCCTGAGAGCCCTGTCATCATGAGAAAGAGGCTTCGTGTGAACCATTC 454
29 ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
30 QY 62 TGAGCGAGTTCTACATCTTACGCGACGCCACTGTCTCT 100
31 ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
32 DB 455 TGAGCGAGTTCTACATCTTACGCGACGCCACTGTCTCT 493
33 ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
34
35 RESULT 7
36 PCT-US95-07439-27
37 Sequence 27, Application PC/TUS9507439
38 GENERAL INFORMATION:
39 APPLICANT:
40 APPLICANT: NAME: BOARD OF REGENTS, THE UNIVERSITY OF
41 APPLICANT: TEXAS SYSTEM
42 APPLICANT: STREET: 201 West 7th Street
43 APPLICANT: CITY: Austin
44 APPLICANT: STATE: Texas
45 APPLICANT: COUNTRY: United States of America
46 APPLICANT: POSTAL CODE: 78701
47 APPLICANT: TELEPHONE NO: (512)499-4462
48 APPLICANT: TELEFAX: (512)499-4523
49 APPLICANT: NAME: THE SCRIPPS RESEARCH INSTITUTE
50 APPLICANT: STREET: 10666 North Torrey Pines Road
51 APPLICANT: CITY: LaJolla
52 APPLICANT: STATE: California
53 APPLICANT: COUNTRY: United States of America
54 APPLICANT: POSTAL CODE: 92037
55 TITLE OF INVENTION: METHODS AND COMPOSITIONS
56 TITLE OF INVENTION: FOR THE SPECIFIC
57 NUMBER OF SEQUENCES: 27
58 CORRESPONDENCE ADDRESSES:
59 ADDRESSEE: Arnold, White & Durkee
60 STREET: P. O. Box 4433
61 CITY: Houston
62 STATE: Texas
63 COUNTRY: USA
64 ZIP: 77210
65
66 COMPUTER READABLE FORM:
67 MEDIUM TYPE: Floppy disk
68 COMPUTER: IBM PC compatible
69 OPERATING SYSTEM: PC-DOS/MS-DOS, ASCII
70 CURRENT APPLICATION DATA:
71 APPLICATION NUMBER: PCT/US95/07439
72 FILING DATE: Concurrently herewith
73 CLASSIFICATION:

```



## PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/273,567  
FILING DATE: 11-JUN-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: PARKER, DAVID L.  
REGISTRATION NUMBER: 32,165  
REFERENCE/DOCKET NUMBER: UTFDA33P--  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (512) 418-3000  
TELEFAX: (713) 789-2679  
TELEX: 79-0924  
INFORMATION FOR SEQ ID NO: 27:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1126 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
PCT-US95-07439-27

Query Match 92.6%; Score 92.6; DB 5; Length 1126;  
Best Local Similarity 96.0%; Pred. No. 4.7e-25;

Matches 95; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2 GTCTGTACAGAGCCCTGCTCATCAATGAGAAAGAGGTTTCTGTGTGGAACCATTC 61

DB 395 GTCCCTGGCAGGCCCTGCTCATCAATGAGAAAGAGGTTTCTGTGTGGAACCATTC 454

QY 62 TGAGCAGATTCTACATCCTTAACGGAGCCCACTGTCTCT 100

DB 455 TGAGCAGATTCTACATCCTTAACGGAGCCCACTGTCTCT 493

## RESULT 8

US-09-202-101-15  
Sequence 15, Application US/09202101  
Patent No. 6277618

## GENERAL INFORMATION:

APPLICANT:  
TITLE OF INVENTION: Recombinant blood-coagulation proteases  
NUMBER OF SEQUENCES: 17  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
OPERATING SYSTEM: IBM PC compatible  
SOFTWARE: Patent Release #1.0, Version #1.30B (BPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/202,101  
FILING DATE:  
INFORMATION FOR SEQ ID NO: 15:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1404 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
US-09-202-101-15

Query Match 92.6%; Score 92.6; DB 4; Length 1404;  
Best Local Similarity 96.0%; Pred. No. 5.1e-25;  
Matches 95; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2 GTCTGTACAGAGCCCTGCTCATCAATGAGAAAGAGGTTTCTGTGTGGAACCATTC 61

DB 683 GTCCCTGGCAGGCCCTGCTCATCAATGAGAAAGAGGTTTCTGTGTGGAACCATTC 742

QY 62 TGAGCAGATTCTACATCCTTAACGGAGCCCACTGTCTCT 100

DB 743 TGAGCAGATTCTACATCCTTAACGGAGCCCACTGTCTCT 781

## RESULT 9

US-08-487-037-4  
Sequence 4, Application US/08487037

Patent No. 5795863

## GENERAL INFORMATION:

APPLICANT: Wolf, David L.  
TITLE OF INVENTION: RECOMBINANT AGENTS AFFECTING THROMBOSIS  
NUMBER OF SEQUENCES: 11  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: MORRISON & FOERSTER  
STREET: 2000 Pennsylvania Avenue, NW  
CITY: Washington  
STATE: DC  
COUNTRY: USA  
ZIP: 20006-1812  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/487,037  
FILING DATE: 07-JUN-1995  
CLASSIFICATION: 514  
ATTORNEY/AGENT INFORMATION:  
NAME: Adler, Reid G.  
REGISTRATION NUMBER: 30,988  
REFERENCE/DOCKET NUMBER: 2803-0002.02  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 887-1500  
TELEFAX: (202) 887-0763  
TELEX: 90-4030

## SEQUENCE CHARACTERISTICS:

LENGTH: 1500 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-487-037-4

## Query Match

Best Local Siml. arity 94.9%; Score 91; DB 1; Length 1500;  
Matches 94; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 2 GTCTGTACAGAGCCCTGCTCATCAATGAGAAAGAGGTTTCTGTGTGGAACCATTC 61

DB 769 GTCCCTGGCAGGCCCTGCTCATCAATGAGAAAGAGGTTTCTGTGTGGAACCATTC 828

QY 62 TGAGCAGATTCTACATCCTTAACGGAGCCCACTGTCTCT 100

DB 829 TGAGCAGATTCTACATCCTTAACGGAGCCCACTGTCTCT 867

## RESULT 10

US-09-280-116-138/C  
Sequence 138, Application US/09280116A  
Patent No. 6331427

## GENERAL INFORMATION:

APPLICANT: Robison, Keith E.  
TITLE OF INVENTION: Nucleic Acid Molecules Encoding Human Protease Homologs  
FILE REFERENCE: 5800-24, 05800/176965  
CURRENT APPLICATION NUMBER: US/09/280,116A  
CURRENT FILING DATE: 1999-03-26  
NUMBER OF SEQ ID NOS: 268  
SOFTWARE: Patent Ver. 2.0  
SEQ ID NO 138  
LENGTH: 591

## TYPE: DNA

ORGANISM: Homo sapiens

## FEATURE:

OTHER INFORMATION: trypsin-like serine proteases

NAME/KEY: misc feature

LOCATION: (1)-(591)  
OTHER INFORMATION: n = a, t, c or g

US-09-280-116-138

Query Match 75.2%; Score 75.2; DB 4; Length 591;  
Best Local Similarity 95.7%; Pred. No. 1.1e-18;  
Matches 88; Conservative 0; Mismatches 3; Indels 1; Gaps 1;

QY 6 GTACAGAGCCGCTCATCAATGAGAAACG-AGGCTTCTGCTGGAACCATCTCA 64  
DB 499 GTACAGAGCCGCTCATCAATGAGAAACGAGGCTTCTGCTGGAACCATCTCA 440

QY 65 GCGAGTTCTACATCCTAACGCGCCACTGT 96  
DB 439 GCGAGTTCTACATCCTAACGCGCCACTGT 408

RESULT 11  
US-08-469-486-1

; Sequence 1, Application US/08469486  
; Patent No. 5739281

; GENERAL INFORMATION:

APPLICANT: Thøgersen, Hans Christian

APPLICANT: Hollet, Thor Ias

APPLICANT: Elzerodt, Michael

TITLE OF INVENTION: Improved method for the refolding of

NUMBER OF SEQUENCES: 58

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish & Richardson

STREET: 225 Franklin Street

CITY: Boston

STATE: Massachusetts

COUNTRY: USA

ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version

SOFTWARE: #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/469,486

FILING DATE:

CLASSIFICATION: 530

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/192,060

FILING DATE: February 4, 1994

ATTORNEY/AGENT INFORMATION:

NAME: Paul T. Clark

REGISTRATION NUMBER: 30,162

REFERENCE/DOCKET NUMBER: 06363/002001

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617 542 5070

TELEFAX: 617 542 8906

TELEX: 200154

INFORMATION FOR SEQ ID NO: 1:

SEQUENCE CHARACTERISTICS:

LENGTH: 1554 base pairs

TYPE: nucleic acid

STRANDEDNESS: double

TOPOLOGY: linear

MOLECULE TYPE: CDNA

HYPOTHETICAL: YES

ANTI-SENSE: NO

ORIGINAL SOURCE:

ORGANISM: Bos taurus

FEATURE:

NAME/KEY: CDS

LOCATION: 76..1551

US-08-469-486-1

QY 10 CAGGCCCTGCTCATCAATGAGAAACGAGGCTTCTGCTGGAACCATCTGACGAG 69  
DB 817 CAGGCCCTGCTGCTCATCAATGAGAAACGAGGCTTCTGCTGGAACCATCTGACGAG 876

QY 70 TTCTACATCCTAACGCGCCACTGTCT 98  
DB 877 TTCTACATCCTAACGCGCCACTGTCT 905

RESULT 12  
US-08-469-658-1

; Sequence 1, Application US/08469658  
; Patent No. 5917018

; GENERAL INFORMATION:

APPLICANT: Thøgersen, Hans Christian

APPLICANT: Hollet, Thor Ias

APPLICANT: Elzerodt, Michael

TITLE OF INVENTION: IMPROVED METHOD FOR THE REPODLING OF

NUMBER OF SEQUENCES: 58

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish & Richardson P.C.

STREET: 225 Franklin Street

CITY: Boston

STATE: Massachusetts

COUNTRY: USA

ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version

SOFTWARE: #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/469,658

FILING DATE: June 5, 1995

CLASSIFICATION: 530

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/192,060

FILING DATE: February 4, 1994

ATTORNEY/AGENT INFORMATION:

NAME: Paul T. Clark

REGISTRATION NUMBER: 30,162

REFERENCE/DOCKET NUMBER: 06363/002002

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617 542 5070

TELEFAX: 617 542 8906

TELEX: 200154

INFORMATION FOR SEQ ID NO: 1:

SEQUENCE CHARACTERISTICS:

LENGTH: 1554 base pairs

TYPE: nucleic acid

STRANDEDNESS: double

TOPOLOGY: linear

MOLECULE TYPE: CDNA

HYPOTHETICAL: YES

ANTI-SENSE: NO

ORIGINAL SOURCE:

ORGANISM: Bos taurus

FEATURE:

NAME/KEY: CDS

LOCATION: 76..1551

US-08-469-658-1

Query Match 63.4%; Score 63.4; DB 2; Length 1554;  
Best Local Similarity 82.0%; Pred. No. 3.6e-14;  
Matches 73; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 10 CAGGCCCTGCTCATCAATGAGAAACGAGGCTTCTGCTGGAACCATCTGACGAG 69  
DB 817 CAGGCCCTGCTGCTCATCAATGAGAAACGAGGCTTCTGCTGGAACCATCTGACGAG 876



REFERENCE/DOCKET NUMBER: 2618-25-C2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (303) 863-9700  
TELEFAX: (303) 863-0223  
INFORMATION FOR SEQ ID NO: 138:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 864 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 2..781  
OTHER INFORMATION: /note="At pos. bp 456, change G to  
OTHER INFORMATION: K; at pos. bp 504, change A to R. At pos. aa 152 and 168,  
OTHER INFORMATION: substitute Xaa."  
US-08-906-769-138

Query Match 32.0%; Score 32; DB 3; Length 864;  
Best Local Similarity 58.3%; Pred. No. 0.013;  
Matches 56; Conservative 0; Mismatches 40; Indels 0; Gaps 0;  
QY 3 TCTGTACAGAGCCCTGCTCATCATGAGAAAGAGAGGTTTCTGTGTGGAACCATTC 62  
DB 145 TCCGTATCAGATTGCACTGAGAAATCGGACCTAGACCATTTCTGTGTGCTCCATCTT 204  
QY 63 GAGCGAGTTCTACATCCTTAAGCGAGCCCACTGTCT 98  
DB 205 AACCAACGTTGATTTGTGTGACGCGCTGCACATTTGCTT 240

Search completed: January 15, 2003, 20:51:15  
Job time: 33 secs